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Abstract
The recruitment of lymphocytes to areas of inflammation and angiogenesis involves
specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on
lymphocytes and the vascular endothelium. The adhesion process follows a multi-step
cascade which has been shown both in vitro and in vivo to involve intercellular adhesion
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial
leukocyte adhesion molecule-i (E-selectin) expressed on enidothelial cells. The expression
of these CAMs on endothelial cells is modulated by the local concentration of cytokines and
growth factors released by resident tissue cells, infiltrating leukocytes, and/or cancer cells.
The regulatory mechanisms of adhesion molecule expression by angiogenic factors in
tumor and the resulting leukocyte-endothelial interaction are poorly understood.
The objectives of this thesis were to determine: a) the binding kinetics of each non-
activated and IL-2 activated lymphocyte subpopulation (CD4+, CD8+, and CD56+ cells),
to human umbilical vein endothelial cells (HUVECs) through the use of a parallel-plate
flow chamber; b) the expression levels of various cell adhesion molecules on intact
HUVEC monolayers treated with tumor interstitial fluid (TIF) and various angiogenic
factors, such as VEGF, bFGF, TNFa, and TGFP, using targeted sampling fluorometry
(TSF) and flow cytometry; c) the molecular mechanisms used by bFGF in regulating
TNFa-mediated cell adhesion molecule (CAM) expression and function; and d) integration
of the mechanisms into a framework for lymphocyte-endothelial interaction in disease and
health.
These studies demonstrated that both IL-2 activated and non-activated lymphocytes
vary in their ability to adhere to activated vascular endothelial cells over a wide-range of
physiological flow rates. Also, activated lymphocytes are able to bind with increased levels
of efficiency over the non-activated populations, and that variability in lymphocyte subset
binding kinetics is dependent on the level of counter-ligand expression and the state of
activation. Additional studies demonstrated that IL-2 activated natural killer cells (CD56+)
principally utilize an integrin-dependent (P1 and P2), selectin-independent adhesion process
in binding to activated vascular endothelium.
The expression studies revealed that fluid extracted from the tumor interstitium
upregulates specific CAMs on endothelial cells in vitro, which promotes lymphocyte
binding. These results correlated with in vivo findings and validated the use of the tumor
fluid as a model for the tumor microenvironment. Analysis of the individual angiogenic
factors showed that TNFa and VEGF are able to upregulate specific cell surface CAMs in a
dose-dependent manner with similar temporal kinetics. In contrast, bFGF produced a
biphasic effect on ICAM-1 regulation, and failed to exhibit an observable effect on the
expression of other CAMs. TGF3 demonstrated no significant differences in CAM
expression. Treatment regimens combining bFGF with TNFa or VEGF showed a
reduction in the levels of induced CAM expression in a time-dependent process,
independent of prior exposure to activating cytokines. This inhibitory effect of bFGF was
the result of transcriptional regulation of the inducible CAM genes. Additionally, the early
signaling events mediating bFGF action involve the regulation of its receptor tyrosine
kinase activity, followed by activation of phospholipase C-y, phospholipase D, and protein
kinase C.
The findings from these studies suggest that cytokines and growth factors
differentially effect lymphocyte subset binding to activated vascular endothelium by altering
cell adhesion molecule expression. Thus, valuable insight is provided into the
accumulation of lymphocytes in normal and pathological conditions, such as in tumor and
inflammation, and the role of angiogenic factors in regulating the host responsiveness at
these sites.
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Chapter 1
Introduction
1.1 Motivation and Background
Each year in the United States, over 1.2 million individuals are diagnosed with
cancer for the first time. According to the American Cancer Society, cancer took the lives
of over 560,000 Americans in 1997, representing 23% of all mortality and the second
leading cause of death, as defined by 1994 statistics [Vital Statistics of the United States,
1994]. More than 85% of these cancers are solid tumors, and approximately one-half of
the patients with these tumors die of their disease. A most sobering and troublesome
reality.
Solid tumors, derived from normal host cells which have gone awry, have a
fundamental characteristic in being dependent on blood supply for oxygen, nutrients and
waste removal beyond a size of 1-2 mm in diameter [Folkman, 1990]. The development of
new blood vessels from pre-existing vessels is termed angiogenesis, and occurs in a range
of pathologies in addition to cancer (tumor angiogenesis), including atherosclerosis
(hyperproliferation of the vasa vasorum within atherosclerotic plaques), endometriosis, and
diabetic retinopathy.
Cancer cells, as well as surrounding and infiltrating host cells, produce multiple
polypeptide cytokines that are essential for promoting the process of angiogenesis, and are
appropriately termed angiogenic growth factors. Among the most well-documented are
vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF),
transforming growth factor-P (TGFP), and tumor necrosis factor-a (TNFa). These
factors, in addition to other cellular products produced by the neoplastic and non-neoplastic
cells, influence the tumor microenvironment by establishing temporal and spatial
heterogeneities in blood flow, altering expression of cell adhesion molecules on
parenchymal, stromal, and vascular cells, and modifying physiological and metabolic
properties. The changes in the microenvironment produce effective barriers against the
delivery of cells and molecular therapeutics to tumors.
The mounting and delivery of an effective immunogenic response to tumors by the
host immune system involves a progressive sequence of steps, each of which is potentially
modified by the tumor microenvironment. The steps include: a) entering the tumor
vasculature from host sites, b) interacting with the vascular compartment and forming
stable cell:cell adhesion to the vessel wall, c) transporting across the microvascular wall
into the interstitium, d) transporting through the interstitial compartment to reach the cancer
cells, and then e) actively attacking or supporting the killing of the cancer cells.
The mechanisms of lymphocyte interaction with the vascular endothelial cells serves
as a particular point of interest for its importance in the initial steps of the immune response
and potentially subserving specific cell populations. The capture and adhesive interactions
are influenced by the local hemodynamic forces, determined by the vessel diameter,
viscosity, and fluid velocity, and by the adhesive forces, determined by the spatial
arrangement and level, affinity, and kinetics of bond formation between receptor-ligand
pairs. A working hypothesis is that the specific microenvironment present in regions of
angiogenesis, specifically the biological influence of growth factors on the vascular
endothelium, is necessary for the interactive process.
The same or closely related adhesion molecules used in angiogenesis to promote
cell migration and proliferation also mediate immune cell adhesion to the vasculature. This
seemingly paradoxical influence is further complicated by the fact that immune cells
themselves are able to produce significant levels of angiogenic factors to either facilitate
additional immune cell infiltration or promote tumor vessel formation. An increased
understanding of the temporal regulation of the adhesion molecules and angiogenic factors
expressed in tumors, as well as the particular molecular mechanisms used by lymphocyte
subpopulations, is needed to further elucidate this interactive process.
The influence of angiogenesis and the growth factors and cytokines involved in the
interaction of blood leukocytes with the vascular endothelium extends beyond the
pathophysiology of tumors. Other diseases with fundamentally similar angiogenic
processes involved include atherosclerosis, vasculitis, allograft rejection, graft vs. host
disease, and chronic inflammation. It is also vital to several normal physiological
processes as well, such as acute inflammation, tissue repair, and embryogenesis.
1.2 Hypotheses and Specific Aims
In formulating the thesis, a set of hypotheses were initially postulated which
provided a framework on which the specific objectives were derived. The original
hypotheses were as follows:
Tumor interstitial fluid and purified angiogenic factors can
modulate cell adhesion molecules (CAMs) on the endothelium.
Diversity among angiogenic factors can result in the differential
regulation of CAMs.
Endothelial CAMs induced by angiogenic factors can be
recognized differentially by lymphocyte sub-populations,
namely T lymphocytes and natural killer cells.
Differences in the intracellular signaling pathways used by the
angiogenic factors can result in differential CAM modulation.
The specific goals of this thesis were to test these hypotheses by performing the
following experimental studies:
Measure the binding kinetics of each specific non-activated
and IL-2 activated lymphocyte subpopulation, namely CD4+,
CD8+, and natural killer cells (CD56+), through the use of
parallel-plate flow chamber studies.
Quantify the expression of various cell adhesion molecules on
intact HUVEC monolayers treated with tumor interstitial fluid
and various angiogenic factors, such as VEGF, bFGF,
TNFa, and TGF, using targeted sampling fluorometry (TSF)
and flow cytometry.
Determine the molecular mechanisms used by bFGF in
regulating TNFao-mediated cell adhesion molecule (CAM)
expression and function.
Integrate the mechanisms into a framework for lymphocyte-
endothelial interaction in disease and health
1.3 Significance
Current therapies, which include chemotherapy, radiation, and surgery, can cure
about half of the diagnosed cancers. While encouraging, it still leaves a large population of
individuals that cannot be treated successfully. New therapies are continuously being
explored, including combined treatment protocols. Of particular interest are gene-based
therapy [Goldspiel, et al., 1993], and adoptive immunotherapy, whereby TIL (tumor-
infiltrating lymphocyte) or LAK (lymphokine-activated killer) cells are delivered to cancer
patients in the hope that the body's natural immune cells will resolve the tumor [Rosenberg,
1990]. However, both have had only obtained limited success, but have helped raise
questions about the fundamental mechanisms by which the immune system acts.
The studies proposed in this thesis can provide increased understanding to several
physiological and pathophysiological processes. The binding kinetics and molecular
mechanisms used by the individual lymphocyte subpopulations in interacting with the
vasculature, both in tumor, inflammation, and wound healing, are essential for determining
mechanisms used by the immune system in localizing to areas requiring active
immunological response. In addition, improvements can be made to current modeling
schemes which attempt to predict the biodistribution of effector cell populations in the
human.
The effects of angiogenic factors on cell adhesion can provide necessary insight into
the regulatory and protective mechanisms potentially found in tumors, as well as in
inflammation and wound healing. It may also contribute to a better understanding of
metastasis and the role of cytokines and growth factors in the process.
Finally, defining the signaling mechanisms used by specific growth factors, may
contribute to a better understanding of the molecular mechanisms used by the growth
factors to modify cell adhesion molecule expression, and its relation to the other
physiological functions which it produces. Also, it gives insight into the angiogenic
process and the kinetic responses elicited by specific growth factors in the
microenvironment.
Clearly, a better understanding of these processes may provide new insights into
the mechanisms of tumor evasion, immune response and neovascular growth, which may
be used for developing alternative or modified modalities of therapies against cancer and
other diseases.
1.4 Organization of Thesis
The thesis is organized into the following chapters, and is outlined in Figure 1-1:
Chapter 1 gives the motivation and significance of the work, as well as the
hypotheses and specific aims addressed in the thesis.
Chapter 2 provides a summary of the background essential for the studies
conducted in this investigation on lymphocyte-endothelial interactions and cell signaling.
Chapter 3 discusses the materials and methods used in this research. Included is
a description of the lymphocyte and endothelial preparations, as well as the protein,
mRNA, and functional adhesion assays performed.
Chapter 4 provides results and discussion on the experiments performed
examining the lymphocyte binding kinetics for both non-activated and activated lymphocyte
subpopulations.
Chapter 5 presents results and discussion on the analysis of cell surface adhesion
molecule expression induced by the angiogenic factors TNFoa, VEGF, bFGF, and TGF3,
as well as the tumor interstitial fluid.
Chapter 6 describes the results and provides discussion on the studies performed
analyzing the molecular mechanisms used by bFGF in modulating CAM expression.
Chapter 7 provides a summary of the studies conducted in the thesis, and
discusses future directions for the research, along with its clinical significance.
The work presented in this thesis has at least partially contributed to four published
manuscripts [Munn, et al., 1995; Melder, et al., 1996; Melder, et al., 1996; Jain, et al.,
1996], and two in preparation involving the findings presented in Chapters 4 and 6. In
addition, a patent is pending with the U.S. Patent Office, based on the inhibitory
mechanisms of basic fibroblast growth factor (bFGF) and includes as co-inventors: R.K.
Jain, R.J. Melder, and L.L. Munn.
IVEGFCAM Modulation *bFGF
b *TGF S
Chapter 4 Chapter 6
Lymphocyte Binding olecular Mechanis
Kinetics of bFGF Signaling
on- activated CD4+,CD8+,CD6+ * functional effects
n- activated CD4+,CD8+,CD56+ Chapter 3 * mRNA effects
.-2 activated CD4+,CD8+,CD56+
Methods,.,
Chapter 7
Summary
Conclusions
Figure 1-1. Schematic outline of the thesis.
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Chapter 2
Background
2.1 Introduction
The active recruitment of circulating lymphocytes to sites of inflammation, wound
repair, and tumor is an integral event in mounting an effective immune response. Adhesive
forces resulting from the spatial arrangement, quantity, affinity and kinetics of bond
formation between receptor-ligand pairs of cell adhesion molecules (CAMs) must overcome
the hemodynamic forces present in the blood vessels. The expression of these CAMs on
the endothelium is modulated by the local concentration of inflammatory cytokines and
angiogenic factors, see Table 2-1 [Osborn, 1990; Jain, et al., 1996]. The majority of
studies involving the growth factors have focused on the specific angiogenic responses.
Only recently has there been increased interest in defining the role of these factors in cell
adhesion molecule induction and modulation. Growing interest has been placed on the
specific signaling transduction pathways used by these cytokines and growth factors in
regulating cellular responses in the hopes of developing new therapies for several
pathological conditions, such as cancer and heart diseases.
This chapter is designed to serve as a basic reference of the literature related to the
understanding of lymphocyte capture mechanisms, the function and signaling pathways
used by several cytokine and growth factors, and the fluid mechanics of the in vitro vessel
model used in this thesis. With this background, it is hoped that the reader will have a
better fundamental understanding of the studies conducted in this thesis, and be able to
follow the general findings and appreciate the significance of this work.
Table 2-1. Regulation of adhesion molecules by cytokines and angiogenic factors.
Adapted from [Jain, et al., 1996].
Cytokine Cell Type ICAM-1 VCAM-1 E-Selectin P-Selectin
bFGF HUVEC -, L -, , - -
HDMEC 1 _ _ NM
IFNY HUVEC <> <> NM
HDMEC NM <) NM NM
MME. NM NM
RME NM T NM NM
IL-1 HUVEC 1 1 NM
HDMEC T - NM
MME 1" NM NM
IL-4 HUVEC 1, I _ ", NM
HDMEC NM - NM NM
MME NM + NM NM
BDEC , T NM
TGFP HUVEC <4 <_ , NM
MME +, + NM NM
TNFa HUVEC T T T T
HDMEC NM 1T NM NM
MME - NM NM
BDEC " T NM
BCE NM NM T NM
VEGF HUVEC T T T
IL-1 + IL-4 HUVEC , I NM
IL-1 + bFGF HUVEC 1 <.> NM
IL-1 +IFN HUVEC T NM T NM
IL-1 + TGF3 HUVEC NM NM ,I NM
TNFa + IL-4 HUVEC 4 " NM
HDMEC NM < NM NM
BDEC + (. -, < NM
TNFa + IFNy HUVEC t NM 1 NM
TNFa + bFGF HUVEC - , NM
TNFa + TGFp HUVEC 4 _ , NM
TGFP + IL-8 HUVEC NM NM NM
bFGF + VEGF HUVEC _ NM NM NM
IFNy + IL-4 HUVEC 1 .. NM NM
IL-4 + TGF3 HUVEC NM 'NM I - NM
1 = upregulation, <-4 = no effect, 1 = downregulation, NM = not measured. Effect of combined treatments are
relative to the individual treatments, whereby: 1TT = synergistic upregulation, 1 = additive effect, <-* = no
difference from responsive individual treatment, 1 = negative combined effect. HUVEC - Human Umbilical Vein
Endothelial Cell (EC), HDMEC = Human Dermal Microvascular EC, MME = Murine Microvascular Endothelium,
RME = Rat Microvascular Endothelium, BDEC = Baboon Dermal EC (in vivo), BCE = Bovine Capillary EC.
2.2 Cell Adhesion Molecules
There are basically two families of CAMs involved in producing the adhesive forces
between leukocytes and endothelial cells: 1) the selectins (e.g. E-, L-, and P-selectin) and
2) the immunoglobulin (Ig) superfamily members (ICAM-1 and VCAM-1) on endothelial
cells and the corresponding integrin receptors on the leukocytes (02 and 13 ) [Springer,
1995; Collins, 1995].
2.1.1 Selectins
Selectins consist of an N-terminal lectin domain, one epidermal growth factor-like
module, and from two to nine short consensus repeats [Lawrence and Springer, 1991]. To
date, they have only been shown to exist on circulating cells and the endothelium, unlike
integrins and Ig superfamily members. The three members of this group of CAMs are: a)
E-selectin (ELAM-1, CD62E), b) P-selectin (PADGEM, CD62P), and c) L-selectin
(LECAM-1, CD62L). E-selectin is synthesized by endothelial cells in response to
inflammatory agents and promotes attachment of monocytes, neutrophils, and certain
lymphocytes by combining with the ligand sialyl-Lewis X [Bevilacqua, et al., 1989]. P-
selectin is expressed in Weibel-Palade bodies of endothelial cells and in a granules of
platelets, becoming mobilized to the cell membrane upon inflammatory activation and
promoting adhesion to monocytes and neutrophils [Larsen, et al., 1989]. L-selectin is
expressed on leukocytes, promoting lymphocyte adhesion in peripheral lymph nodes and in
neutrophils, monocytes, and lymphocyte emigration at inflammatory locales [Spertini, et
al., 1991]. The structure of the selectins and their corresponding carbohydrate ligands
allow for a high on-rate to complex formation resulting in efficient interactions of rapidly
flowing cells with the endothelium, and along with a high off-rate, permit active rolling to
occur. Thereby, the selectins are considered to primarily mediate leukocyte capture and
rolling.
2.1.2 Integrins and Immunoglobulin Superfamily
Integrins consist of a oap heterodimer, with the a subunits (120-180 kD) covalently
associated with a p subunit (90-110 kD) [Hynes, 1992]. Most integrins are expressed on a
wide variety of cells and are major receptors for cell attachment to extracellular matrices and
in mediating cell-cell adhesion events. There consists a large, yet restrictive, diversity of
integrins with currently 8 known 0 units and 15 known a subunits (see Table 2-2) [Hynes,
1992; Rouslahti, 1991]. The a and P subunit combination determines the ligand
specificity. While the majority of these integrins are recognized by extracellular matrix
proteins involved in cell-substratum adhesion, there are some which recognize integral
membrane proteins of the immunoglobulin superfamily and mediate direct firm cell-cell
adhesion.
The Ig superfamily consists of a group of proteins with one or more Ig domains,
regions of 70 to 110 amino residues homologous to either Ig variable (V) or constant (C)
domains. Most members of this superfamily are integral plasma membrane proteins with
Ig domains in the extracellular portions, transmembrane domains composed of
hydrophobic amino acids, and widely divergent cytoplasmic tails with no homology to one
another. The most common of these which are associated with leukocyte adhesion to
vascular endothelium are ICAM-1 (intercellular adhesion molecule-i), ICAM-2, and
VCAM-1 (vascular cell adhesion molecule-1) [Rothlein, et al., 1986; Stauton, et al., 1989;
Osborn, et al., 1989]. ICAM-1 (CD54) and ICAM-2 (CD102), a constitutively expressed
adhesion molecule, on the endothelium bind to LFA-1 (P2 integrin) on the leukocytes, and
VCAM-1 (CD106) on the endothelium binds to VLA-4 (P1 integrin) on the leukocytes
[Marlin and Springer, 1987; Elices, et al., 1990; Hemler, 1990].
Table 2-2. Known ap integrin complexes.
01 [CD29] - al (CD49a), a2 (CD49b), a3 (CD49c),
a4 (CD49d), a5 (CD49e), a 6 (CD49f),
a7, a8, a9, Cv (CD51)
P2 [CD18] - caL (CDla), xM (CDllb), aX (CDllc)
P3 [CD61] --> alib , xv
04 [CD104] cx6
06 -4 av
37 --> x4, aIEL
P8 av
2.3 Leukocyte-Endothelial Interaction
As for functional studies involving cell adhesion, many investigators have analyzed
leukocyte adhesion to cytokine activated endothelial cell monolayers in vitro [Bevilacqua, et
al., 1985; Schleimer and Rutledge, 1987; Cavender, et al., 1987; Cotran and Pober, 1990].
Early studies were performed using static conditions and showed that basal adhesion of
blood monocytes was significantly greater than that of neutrophils and lymphocytes
[Bevilacqua, et al., 1985; Luscinskas and Lawler, 1994]. On activated endothelium, i.e.
TNFa, IL-1, or LPS treatment, increases of 2- to 5-fold were seen in monocyte and
lymphocyte adhesion and a 10- to 15-fold increase in neutrophil adhesion [Bevilacqua, et
al., 1985; Lo, et al., 1989; Pober, et al., 1987]. Multiple adhesion molecules and
leukocyte chemoattractants, e.g. ICAM-1, VCAM-1, E-selectin, P-selectin, L-selectin,
MCP-1 and PAF, were proven to be essential in the process and were suggestive of
redundant or overlapping function [Springer, 1994]. More recent studies using defined
laminar flow conditions have revealed a more complex process in which sequential and
overlapping functions exist for the multiple receptor-ligand pairs [Lawrence and Springer,
1991; Springer, 1994; Luscinskas, et al., 1994; Butcher, 1991]. The general model
commonly accepted now involves a multi-step cascade consisting of four events (phases 1-
4): (i) leukocyte capture and rolling mediated by L-selectin, E-selectin, and P-selectin, (ii)
leukocyte arrest dependent on 1 integrins/VCAM-1 with (iii) leukocyte firm adhesion and
spreading mediated by P2 integrins/ICAM-1, and (iv) in conjunction with CD31, P2
mediated leukocyte diapedesis, with some overlap in the functions of the adhesion
molecules.
Studies have been carried out defining the specific adhesive interactions between T
lymphocytes and vascular endothelium. Previous in vitro studies have demonstrated the
roles of LFA-1/ICAM-1, VLA-4/VCAM-1, and sialyl-Lewis X/E-selectin in resting CD4+
cell adhesion to activated endothelial cells under static conditions [Shimizu, et al., 1991;
Dustin and Springer, 1988; Bierer and Burakoff, 1988]. More recent in vitro studies have
determined the cellular processes and molecular events involved in resting CD4+ and CD3+
T cells to TNFa-activated HUVEC monolayers and murine-transfected cell lines
[Luscinskas, et al., 1995; Melder, et al., 1995]. Results using resting CD4+ T cells
showed that a) P-selectin, but not E- or L-selectin, mediated the initial capture and rolling,
b) VLA-4 (13 integrin) participated in rolling and was predominant in stable arrest, and c)
LFA-1 (P2 integrin) contributed to stable arrest and predominated cell spreading and
transmigration [Luscinskas, et al., 1995]. Resting CD3+ T cells displayed similar
characteristics in terms of VLA-4/VCAM-1 and LFA-1/ICAM-1 contributions to rolling,
stable arrest, and cell spreading [Melder, et al., 1995]. Interestingly, the contributions of
E- and L-selectin were shown to be essential in mediating the initial interaction process,
being limited to the range of 1-3 dyn/cm 2 [Melder, et al., 1995; Yago, et al., 1995]. It has
also been observed that the number of rolling CD45RA- T cells on E-selectin-transfected
cells was much higher than those of CD45RA+ T cells, emphasizing a potential molecular
difference between naive and memory T cells [Yago, et al., 1995].
When compared to other leukocytes, T cells exhibit some inherent differences in
their adhesive characteristics. Rolling velocities for CD4+ T cells were reported to be
approximately half that of neutrophils under similar flow conditions [Abassi, et al., 1993],
preferential cell attachment downstream of adhered cells was shown to be characteristic of
monocytes and not of CD4+ T cells, and that P-selectin mediated a significant role in CD4+
T cell initial contact and not L-selectin, as was observed in monocyte adhesion
[Luscinskas, et al., 1994].
Recent studies have shown the localization of lymphocytes in the microvasculature
of growing tumors [Sasaki, et al., 1991; Melder, et al., 1995], as well as along the
invasive margin [Suzuki, et al., 1995]. Evidence suggests that the localization of these
lymphocytes is due primarily to the adhesive characteristics of the endothelium [Butcher,
1991; Basse, et al., 1991], whereby a variable set of cell adhesion molecules are expressed
[Luscinskas and Lawler, 1994], and the effective level of receptor expression and affinity
for the particular expressed ligand. The alteration in endothelial cell phenotype is likely a
result of the tumor microenvironment, particularly the angiogenic factors present [Folkman,
1995]. The effects of the individual factors alone, or in combination with each other, in
terms of CAM modulation have only been explored to a limited extent, and are summarized
in Table 2-1 [Melder, et al., 1996; Kitayama, et al., 1994; Gamble and Khew-Goodall,
1993].
2.4 Cell Signaling
The ability of the cell to sense and respond to its environment is essential for its
survival and proper function. Extracellular molecules, such as cytokines, polypeptide
hormones, neurotransmitters, and antigens bind to cell surface receptors and generate
intracellular signals that are transmitted to different systems of the cell. These signaling
systems involve interactions between various components of a single pathway, as well as
complex interactions between mediators of other pathways and common factors involved in
different processes.
A growing interest has accumulated towards determining the specific signal
transduction pathways used by the various cytokines and growth factors in elucidating the
mechanisms of cell proliferation and differentiation, angiogenesis, apoptosis, cell adhesion
molecule regulation, as well as to enhance the use of novel chemotherapy, immunotherapy,
and gene therapy [Levitzki, 1994].
Several pathways are shared among the different cytokines and growth factors, and
provide a means of cross-talk between different signaling pathways. Among the
intracellular signaling molecules commonly utilized are the second messengers cyclic
adenosine monophosphate (cAMP), inositol-1,4,5-triphosphate (Ins 1,4,5P 3 ), and calcium
ions (Ca 2+). Elevated levels of these compounds can directly activate some metabolic
pathways, as well as stimulate the activity of certain protein kinases. The protein kinases
can consequently activate other enzymes, eventually leading to the modulation of gene
expression.
Receptors for several activating agents are linked to the enzyme, adenylyl cyclase,
through a G-protein. Activation of adenylyl cyclase results in the conversion of adenosine
trisphosphate (ATP) into adenosine 3',5'-monophosphate, or cyclic AMP. A variety of
enzymes within the cell, including a number of protein kinases (PKA), interact with cAMP
to modulate specific metabolic pathways.
Another set of specific receptors on endothelial cells regulates the second-
messenger system involving the stimulation of phosphoinositide hydrolysis. Often through
a G-protein, but not always the case, the receptors stimulate the activity of a phospholipase
C (PLC) that specifically hydrolyzes phosphatidylinositol-4,5-bisphosphate (PIP2) and
phosphatidylcholine, two of four major phospholipids found in the plasma membrane.
PtdInsP 2 activates two second messengers, diacylglycerol (I)AG) and inositol-1,4,5-
trisphosphate (IP3),which lead to further downstream release of cytoplasmic Ca 2+ stores
and the activation of protein kinase C (PKC), which has multiple functions within cells.
The receptors for most of the growth factors are transmembrane tyrosine-specific
protein kinases (PTK) [Carpenter, 1987]. PTK can be classified as (a) receptor tyrosine
kinases (RTK), which directly receive signals through the growth factor-bound
extracellular domain, and (b) cellular tyrosine kinases (CTK), which are signal transducers.
The family of receptor tyrosine kinases can be divided into a number of structural
subfamilies, in which all signal cells through tyrosine phosphorylation reactions. The
signaling begins with the dimerization of the receptor upon ligand binding and the
subsequent trans-autophosphorylation, or cross-phosphorylation of the dimer [Yu, et al.,
1985; Sternberg and Gullick, 1990; Ullrich and Schlessinger, 1990]. The activated
receptor then phosphorylates exogenous substrates and recruits adapter molecules and
enzymes through its autophosphorylated domains via SH2 domains [Sierke and Koland,
1993]. These events lead to the signal propagating through a number of pathways within
the cytoplasm, with the specific pathway dependent on the given cell type. Ultimately, the
signals lead to nuclear activation of gene regulatory proteins and stimulation of specific
gene transcription (early- and delayed-response).
RTK signaling can be inhibited for study by blocking ligand binding, receptor
dimerization, RTK activity or recruitment of signaling molecules. Inhibition of growth
factor ligand binding has been performed using growth factor antagonists (i.e., suramin),
growth factor toxins (i.e., chimeras between the growth factors and a bacterial or plant
toxin), antibodies and antibody-toxin chimeras. Inhibition of the tyrosine-kinase activity
has been carried out using: (a) tyrphostins, a family of synthetic benzyldiaminonitrile
compounds, and (b) genistein, methyl 2,5-dihydroxycinnamate, lavendustin A, and 2,5-
dihydroxybenzyl-aminobenzoic acid [Levitzki, 1992; Hawker and Granger, 1994]. The
inhibition of PLC-y and phospholipase D (PLD) has been done using 1-O-octadecyl-2-O-
methyl-lac-glycerol-3-phosphocholine or 2-nitro-4-carboxyphenyl N,N-diphenylcarbamate
(NCDC), and propranolol, respectively. The blocking of signaling transducers further
downstream has involved inhibition of RAS activation by interrupting the Sos exchanger,
Raf-1 Ser/Thr kinase, and post-translational modification by farnesylation. Blocking of
Ca2+ activity has been demonstrated using carboxamide amino-imidazole (CAI), which had
no effect on cAMP production or inositol phosphate. Lastly, high doses of phorbol esters
and moderate doses of bisindolylmaleimide, calphostin C, and sphingosine have been used
to inhibit the protein kinase C isozymes [Levitzki, 1994].
The protein kinase C family has been a particular source of interest for its diverse
physicochemical and regulatory properties in mammalian cells, as well as its differential
tissue expression with specific intracellular localization. Ten isoforms or subspecies of
PKC have been identified which are all dependent on phosphatidylserine, but exhibit
different requirements of phospholipid metabolites and Ca 2+ [Nishizuka, 1992; Asaoka, et
al., 1992]. The isozymes may be tentatively divided into three groups based on their
dependent processes: cPKC (ca,I/P3I,y), nPKC (8,e,r,O), and aPKC (S,X). Those PKC
isozymes which have been shown to be specific for human endothelial cells are: cPKC-
xa,3, nPKC-8,rj,0, and aPKC- , with nPKC-c being specifically absent [Kent, et al.,
1995]. Differences have also been found in the cellular distribution of PKC-X,E with the
number of endothelial cell passages (1 vs. 3) [Haller, et al., 1996].
Most of the individual signaling pathways which have been elucidated are derived
from studies involving epidermal growth factor (EGF) and platelet-derived growth factor
(PDGF) [Cadena and Gill, 1992; Jaye, et al., 1992]. A limited number of studies have
defined the pathways explicitly relevant to bFGF, VEGF, TNFa, and TGF3 [Hawker and
Granger, 1994; Jaye, et al., 1992]. While the receptors for bFGF and VEGF have been
proven to be protein tyrosine kinases [Jaye, et al., 1992; DeVries, et al., 1992], the
receptors for the TGFP superfamily have been identified as serine/threonine protein kinases
[Segarini, 1993]. TNFa has been shown to influence the behavior of vascular endothelial
cells by inducing granulocyte-macrophage colony-stimulating factor [Broudy, et al., 1986],
with its receptor being a protein tyrosine kinase, transient expression of surface antigen
correlated with enhanced leukocyte binding to the endothelium [Pober, et al., 1986], and
increasing the sensitivity of cells to undergo apoptosis through the sphingomyelin signal
transduction pathway [Kolesnick, et al., 1994].
Transcription of cell adhesion molecules and the role of individual cytokines and
angiogenic growth factors in the process have provided a direct linkage to the integration of
angiogenesis, adhesion, and metastasis, three areas previously considered to be distinct
[Jain, et al., 1996; Friesel and Maciag, 1995]. Positive regulatory domains required for
cytokine induction (TNFa, IL-1I) have been determined in the promoter regions of E-
selectin, ICAM-1, and VCAM-1 [Collins, et al., 1995]. The endothelial cell NF-KB/IKB
system and a limited set of other transcriptional activators (e.g. ATF-2, IRF, and HMG
I(Y)) are essential in the assembly of unique transcriptional factor complexes that activate
multiple endothelial genes.
The following section provides a more detailed description of the signaling
pathways used -by bFGF, VEGF, TNFa, and TGFp, and, where possible, emphasis on
signaling within endothelial cells and the regulation of cell adhesion molecule expression by
these factors.
2.4.1 Basic FGF Signaling
Basic fibroblast growth factor (bFGF or FGF-2) is the prototypical member of the
FGF gene family, which is comprised of a total of seventeen members (FGF-1 to 17)
which share a partial amino acid sequence homology [Friesel and Maciag, 1995;
Hoshikawa, et al., 1998]. FGFs are potent mitogens for mesenchymal and
neuroectoderm-derived cells, including vascular endothelial cells, and elicit diverse
biological activities on a large number of different cell types. Basic FGF, along with the
other FGFs, have been implicated in several physiological and pathological processes,
including embryonic development, angiogenesis, wound healing, tissue repair,
differentiation, neuronal outgrowth and function, migration, and cell survival [Christofori,
1997]. Additionally, bFGF is known to be the only cytokine that can trigger all the
phenomena associated with angiogenesis, including EC proliferation, migration, increase
plasminogen activities, collagenase production, and decrease plasminogen activator
inhibitors [Kumar, et al., 1998].
The biological effects of bFGF on endothelial cells, as well as numerous other
tissues and cell types, are mediated through four high-affinity, transmembrane tyrosine
kinase receptors: FGFR-1 (flg, cek 1), FGFR-2 (bek, cek 3), FGFR-3 (cek 2), and
FGFR-4. These receptors belong to the superfamily of RTKs and possess high diversity
with variable ligand specificity and affinity. Basic FGF also binds to heparan sulfate
polysaccharides (low-affinity receptors) and heparin, which act to form a ternary complex
with bFGF and its high-affinity receptor to potentially increase signaling efficiency and
bioactivity [Jaye, et al., 1992; Yayon, et al., 1991].
Binding of bFGF induces conformational changes to its high-affinity receptors,
followed by dimerization and transphosphorylation of its tyrosine residues [Ullrich and
Schlessinger, 1990]. The autophosphorylated intracellular tyrosine kinase domains
become targets for SH2, SH3, and phosphotyrosine-binding domain-containing molecules.
Intracellular mediators interacting via such a process are phospholipase C-yl (PLC-yl)
[Roth, 1994], cortactin [Zhan, et al., 1994], Shc [Spivak-Kroizman, et al., 1994] and
phosphatidyl-inositol 3' kinase [Varticovski, et al., 1994]. Activated PLC-yl catalyzes the
breakdown of the membrane phospholipid, phosphatidylinositol bisphosphate, to generate
inositol 1,4,5-triphosphate and diacylglycerol [Ullrich and Schlessinger, 1990]. Inostitol
triphosphate subsequently mobilizes Ca2+ from intracellular stores, which combines with
DAG to activate protein kinase C. PKC can, in turn, activate phospholipase D to catalyze
the hydrolysis of phosphatidylcholine (PC) to form phosphatidic acid (PA), a precursor of
DAG [Billah and Anthes, 1990; Exton, 1990]. PC-PLD may also be activated via an
independent pathway from PKC activation, and thus may serve as a regulator of long-term
activation of PKC [Ahmed, et al., 1994]. The secondary messengers generated in this
cascade may activate Raf kinase, mitogen-activated protein (MAP) kinase, extracellular
signal-regulated kinase (ERK), and NF-icB, and have been implicated in controlling many
of the physiological responses produced by bFGF, namely cell proliferation,
differentiation, migration and angiogenesis [Friesel and Maciag, 1995]. However, the
specific role of each messenger in mediating the cellular functions of bFGF are strongly
cell-type and function-dependent [Jaye, et al., 1992; Peters, et al., 1992; Mohammadi, et
al., 1992]. A schematic of the bFGF-mediated signaling pathways is shown in Figure 2-4-
1 for reference.
Studies involving the elucidation of the second messengers activated by bFGF
using several of the aforementioned inhibitors have been controversial. In fibroblast cell
lines, it has been shown that bFGF activates the enzyme phospholipase Cyl, yet it has not
been shown to correlate with increased FGF mitogenicity [Peters, et al., 1992; Coughlin, et
al., 1988]. Additionally, neither Ca2+ nor phosphotidylinositol hydrolysis appears to play
a role in FGF mitogenic activity [Peters, et al., 1992; Mohammadi, et al., 1992]. In
endothelial cells, there have also been conflicting results with emphasis on the role of PKC
in the mitogenic signaling mechanism. PKC has been shown to inhibit bFGF-dependent
DNA synthesis in capillary endothelial cells [Doctrow and Folkman, 1987], yet be essential
for bFGF mitogenic activity in normal and transformed fetal bovine aortic endothelial cells
[Presta, et al., 1989]. Additionally, studies have demonstrated increased bFGF-activated
PKC-xo, 8, F, 0, rI, and immunoreactivity in human umbilical vein endothelial cells
[Kent, et al., 1995; Haller, et al., 1996], and that endothelial proliferation may be mediated
by a Ca2+-independent PKC isozyme activated by bFGF [Kent, et al., 1995].
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Figure 2-4-1. Schematic of the potential signaling pathways used by bFGF.
2.4.2 VEGF Signaling
Vascular endothelial growth factor (VEGF), also known as vascular permeability
factor (VPF), is a homodimeric, heparin-binding glycoprotein with potent angiogenic,
mitogenic, chemotactic, and vascular permeability-promoting activities specific for
endothelial cells. The VEGF gene encodes four different proteins (VEGF 12 1, VEGF1 65 ,
VEGF 1 89 , and VEGF 206 ) as a result of alternative splicing [Tisher, et al., 1991].
VEGF 12 1 and VEGF1 65 are diffusible proteins that are readily secreted, while VEGF1 89
and VEGF20 6 have high affinity for heparin and principally remain bound to heparin-
containing proteoglycans in the extracellular matrix [Ferrara, et al., 1992]. VEGF has been
implicated in inflammation and in normal and pathological angiogenesis associated with
wound healing, embryonic development, growth and metastasis of solid tumors.
The biological effects of VEGF on endothelial cells are mediated through two
receptor tyrosine kinases, Flt-1 (fins-like tyrosine kinase-1) and KDR (kinase-insert-
domain-containing receptor; or the mouse homologue, Flk-1, fetal liver kinase-1). Binding
of VEGF induces conformational changes in KDR and Fit-1, followed by dimerization and
autophosphorylation on tyrosine residues [Heldin, 1995]. Activation of the low-affinity,
high-capacity KDR mediates actin reorganization, membrane ruffling, chemotaxis, and
mitogenicity [Waltenberger, et al., 1994]. The functions and mechanisms of action of the
high-affinity, low-capacity Flt-i are less clearly understood, but appear to mediate
chemotactic activity in monocytes and stimulate tissue factor expression in monocytes and
endothelial cells [Clauss, et al., 1996].
In molecular terms, VEGF is able to act through KDR and at least partly through
Fit-i to increase the tyrosine phosphorylation of phospholipase Cy, phosphatidylinositol 3-
kinase, and GTPase-activating protein in endothelial cells [Waltenberger, et al., 1994; Guo,
et al., 1995]. The activation of these early signal transduction events by VEGF, as for
bFGF, leads to the phosphorylation of protein kinase C via phospholipase Cy and the
hydrolysis of phosphatidylinositol-4,5 bisphosphate, and MAP kinases via the Ras
pathway. PKC isoforms a and PII have been found to be translocated in VEGF-stimulated
endothelial cells, while PKC-5 and -E are not, and that the stimulated cell growth is largely
mediated by the PKC-P isoform [Xia, et al., 1996]. Additionally, VEGF-activated PKC
has been shown to stimulate PLD in HUVECs, which is unlikely to be directly involved in
the control of DNA synthesis, but rather in regulating cytoskeleton-dependent effects such
as cell migration [Seymour, et al., 1996]. A schematic of VEGF cell signaling is shown in
Figure 2-4-2.
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Figure 2-4-2. Schematic of the signaling pathways used by VEGF.
2.4.3 TNFa Signaling
Tumor necrosis factor-a (TNF(), or cachectin, is a pleiotropic polypeptide that is
member of a broader, TNF ligand superfamily consisting of nine different proteins. It is
capable of producing a wide variety of effects on a large number of cells by activating
multiple signal transduction pathways, inducing or suppressing a vast number of genes,
and using ubiquitous receptors. As a consequence of this diversity, TNFa has been
recognized in many physiological and pathological processes, including normal host
resistance to infection, angiogenesis, cachexia, septic shock, autoimmune disorders, and
meningococcal septicemia.
HEG
With respect to endothelial cells, TNFa has been shown to induce the expression of
adhesion molecules, thromboplastin, tissue-type plasminogen activator, plasminogen
activator inhibitor type 1, prostacyclin, neutral metalloproteinases, class I MHC, NF-kB,
and IL-6, IL-8 and basic fibroblast growth factor [Fajardo L.-G. and Allison, 1997]. It is
also able to induce cell growth in cultured endothelial cells in a biphasic, dose-dependent
manner.
TNFa exerts its biological effect by interacting with two distinct cell surface
receptors, TR55 (TNFR-I) and TR75 (TNFR-II), which are expressed in most cell lines,
but in different densities [Hohmann, et al., 1989]. Both receptors are transmembrane
glycoproteins with molecular weights of 55 kDa and 75 kDa, respectively. The
intracellular domains of the two receptors are apparently unrelated and distinct
immunologically, suggesting they employ different signal transduction pathways.
Moreover, while TR55 has been shown to be an essential component for TNFa signal
transduction [Schtitze, et al., 1992; Wiegmann, et al., 1992], TR75 has been shown to
function as a TNFa antagonist by neutralizing TNFa, as well as a TNF(o agonist by
facilitating TNFa:TR55 complex formation [Peschon, et al., 1998; Pinckard, et al., 1997].
Two major and independent pathways for TNFx signaling have been identified and
found to occur in endothelial cells. One involves TNF-mediated phospholipase A2 (PLA2 )
activation, resulting in the production of arachidonic acid [Clark, et al., 1988]. The second
major pathway involves specific C-type phospholipases and protein kinases. The
TNFa:TR55 complex triggers intracellular signaling of a specific phospholipase C that
hydrolyzes phosphatidylcholine to produce the second messenger diacylglycerol [Schiitze,
et al., 1991]. DAG then activates two enzymes, protein kinase C (PKC) and an acidic
sphingomyelinase (SMase) that hydrolyzes sphingomyelin (SM) to produce ceramide
[Schiitze, et al., 1992]. While PKC can induce the pleiotropic transcription factor, NF-KB,
it has been demonstrated that PKC is not required for NF-icB activation by TNFa.
However, the TNFa-responsive PC-PLC system, acting through the second messenger-
like molecule ceramide, is able to induce NF-B and permit the expression of a variety of
genes, including E-selectin, VCAM-1, and ICAM-1. Interestingly, the induction of
VCAM-1 expression on endothelial cells by TNFx appears to be highly PKC-dependent,
as well requiring NF-KB-like binding activity for transcription [Deisher, et al., 1993; Read,
et al., 1996]. A schematic of TNFx cell signaling is included for reference and is shown in
Figure 2-4-3.
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Figure 2-4-3. Schematic of the signaling pathways used by TNFct.
2.4.4 TGFP Signaling
Transforming growth factor-3 (TGFI) is a pleiotrophic polypeptide and the
prototype for a superfamily (TGFi superfamily) of growth-regulatory polypeptides that
also include activins, inhibins, bone morphogenetic proteins (BMPs), and decapentaplegic
(Dpp). One subset of this superfamily is the TGFI family, which includes three
mammalian isoforms, TGFI1, 2,3 [Hartsough and Mulder, 1997]. Members of the TGFi
family exert wide ranging effects on several different cell types. Among the most common
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biological effects are regulation of cell growth, apoptosis, differentiation, adhesion and
extracellular matrix production [Heldin, et al., 1997]. With such a plethora of effects on
cells, it is not suprising that TGF3 has been implicated in many physiological processes,
including embryogenesis, inflammation, wound repair, and immunosuppression.
TGF3 elicits its cellular action by initially binding to a specific set of receptors,
classified as TGFP receptor Type I (RI), Type II (R11), Type III (RIII), and endoglin
[Segarini, 1993; Yamashita, et al., 1994]. Each member of the TGF3 superfamily binds to
a characteristic combination of receptor Type I and Type II, both of which are needed for
proper signaling and have intrinsic serine/threonine kinase activity. TGFII initially binds
to the type II receptor (TPR-II), which then sequentially recruits the type I receptor (TPR-I)
and forms a complex. TIR-II phosphorylates TiR-I, which consequently determines the
specificity of the intracellular signals [Carcamo, et al., 1994].
Currently, six distinct types of signaling components have been described for the
cytoplasmic signal transduction cascade of TGFI. These include protein kinase C,
phopholipase C, protein phosphatase 1, Ras, mothers against decapentaplegic (MAD)
superfamily members, and several mitogen-activated protein kinase superfamily members,
such as TAK-1 and stress-activated protein kinase/Jun-N-terminal kinase (JNK). A
schematic of the potential TGF3-mediated signaling pathways is shown in Figure 2-4-4.
TGF3 RI receptor interaction with the a-subunit of farnesyl-protein transferase
(aFTP) may be the upstream mechanism for the activation of Ras, and the subsequent
activation of the MAPK cascade and cell cycle components downstream. This particular
pathway may mediate TGF3 production, AP-1 or ATF-dependent gene transcription,
growth inhibition, control of extracellular matrix production, and/or apoptosis.
TGF3 RI receptor activation may also stimulate the phosphorylation, nuclear
translocation and transcriptional activation of several SMAD proteins (vertebrate
homologues of MAD). This may also lead to gene transcription, growth inhibition, and
control of ECM.
The functions of TGFP-activated PKC and PLC have been implicated in the
prevention of c-jun-dependent transcription and augmentation of fibronectin and
plasminogen activator inhibitor-1 (PAI-1) mRNA expression [Halstead, et al., 1995].
Protein phosphatase 1 activation by TGFI was associated with growth-arrest in
keratinocytes, and it is unknown if the activity is cell-type specific or a general consequence
of TGF3 treatment [Gruppuso, et al., 1991].
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Figure 2-4-4. Schematic of the potential signaling pathways used by TGF3.
2.5 Fluid Dynamics
The dynamic flow experiments performed by the various studies mentioned above,
which provide in vitro simulation of the in vivo biomechanical environment, have been
carried out using one of two basic systems: 1) a parallel-plate flow chamber [van Kooten,
et al., 1992], or 2) a modified cone-plate viscometer [Bussolari, et al., 1982]. The latter
involves the generation of fluid shear stresses between a stationary base plate and a rotating
cone. The system used in this thesis is the parallel-plate flow chamber. It consists of a
polycarbonate block, a silastic gasket and a transparent microscope slide, on which a
confluent endothelial monolayer presides, all of which is held together by a vacuum pump
(see Figure 3-3). A syringe pump is able to generate a well-defined, unidirectional laminar
flow across the chamber, and the wall shear stress can be calculated using the Navier-
Stokes equations for fluid mechanics. Beginning with the equations of continuity and
conservation of momentum:
ap (1)
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where p is the fluid density, t is the time variable, V is the local fluid velocity, P is
the pressure, and g is the dynamic viscosity of the fluid.
Assuming a parallel, fully-developed flow of an incompressible Newtonian fluid of
constant viscosity in a rectangular duct of uniform cross-section, equations (1) and (2) can
be simplified and the axial fluid velocity u resolved to the following:
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where u is the axial fluid velocity, and x, y, z are the Cartesian space coordinates of
the flow chamber, with z being the axial coordinate.
The momentum equation (4) can further be simplified by assuming steady-state
flow conditions, and the following boundary conditions:
Ul+a,y = 0 and ulx,+b = 0 (5)
where a and b represent the distance from the center of the flow chamber to the
corresponding sides. Integrating equations (3) and (4) with the set boundary conditions (5)
and performing some algebraic re-arrangement, an analytical solution can found for the
steady-state condition [Savino and Siegel, 1964]:
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where the dimensionless coordinates X=x/a and Y=y/b and the dimensionless axial
fluid velocity U=u/u, have been introduced, and um represents the mean fluid velocity
defined as um=Q/4ab, where Q is the volumetric flow rate.
The wall shear stress z acting on the cell monolayer can be determined with
respect to the velocity profile in the chamber by the following equation:
au Um aU (7)
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Using the dimensionless velocity profile derived in equation (6), the wall shear
stress can be equated from equation (7) to form:
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The resulting equation for the wall shear stress rw is plotted in Figure 2-5-1 as a
function of the dimensionless width of the channel X for a volume flow rate of 0.085
ml/min, a commonly used flow rate to simulate physiological flow conditions.
Additionally, the values of the viscosity y = 0.015 poise, chamber height a = 40 gm, and
chamber width b = 0.625 cm are utilized.
Due to the significantly small aspect ratio of the chamber, y= 0.006 << 1, and the
relatively uniform wall shear stress distribution across the channel over which the
measurements are to be taken, it can be assumed that the chamber represents channel flow
and u = u(y) only. Using equations (4) and (7), with the boundary conditions specified in
equation (5), an exact solution for the wall shear stress can be derived in the form:
-32Q (9)
4a2 b
This equations demonstrates a linear relationship between the wall shear stress and
the volumetric flow rate and is valid to within a 2% error for a wide range of flow rates.
Consequently, equation (9) was used to calculate Tw in the functional adhesion studies
performed in the thesis.
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Figure 2-5-1. Wall shear stress as a function of the transverse coordinate in
the parallel-plate flow chamber for a volumetric flow rate of Q=0.085
ml/min. The shaded region designates the range over which all
measurements were taken in the functional experiments.
The calculated wall shear stresses induced by multiple flow rates can be
incorporated with a normalization routine which provides a more accurate method for
interpreting binding data for cell capture and efficiency using the parallel-plate flow
chamber [Munn, et al., 1994]. The routine provides an estimate of the cell flux near the
surface based on the sedimentation rate and velocity profile in the chamber. Thus, a more
detailed analysis on the interactions and kinetics of receptor-ligand binding can be
performed.
For the functional analysis experiments using a multiple series of flow rates, the
time to reach steady state for each flow rate is defined by equalizing the total number of
cells, Gi, passing at each step change in flow rate and is governed by the following
equation:
Cx ui- 2vx vxx (10)Gi = - +- +1 +Cu i 1+ twi u2 ui  uih uih u
where Gi = total number of cells passing at each flow rate, i = flow rate index, C =
bulk concentration, ui = average flow velocity at flow index i, v = settling velocity, h = 13
gm layer of fluid at the bottom of the flow chamber, twi = time period at given flow rate i
(including sampling time), and x = direction of axial flow.
Having this normalization of cell flux allows for the efficiency of cell capture to be
calculated, which is a function of the detachment force generated by flow-induced shear
stress. Efficiency, E, is specifically defined as the number of cells that bind, Nb, at a given
shear stress divided by the total number of cells, Nt, that pass over the surface.
Cumulative cell binding curves can then be fitted to the equation [Melder, et al., 1995]:
NbE= N b = Eoe  (11)Nt
where S is the shear stress, and Eo' and Kt are fitted parameters. The efficiency at
zero shear stress, Eo, provides a measure of the stability of the adhesion complex following
initial capture and can be derived from equation (11) to be of the form:
E0 =E(1e-ec) (12)
where AS is the difference in shear stress between successive flow rates. The
capture coefficient, k, also provides a useful measure by reflecting the relative sensitivity of
the cells to initial capture leading potentially to rolling and firm adhesion.
The receptor-ligand mediated adhesion of cells in a fluid stream to specific cell
surfaces is a complex process. A number of physical mechanisms have been shown to be
involved in the process, which include: the kinetics of receptor-ligand binding, receptor-
ligand affinities, forces and torques acting on the cell, and the delivery rate of cells to the
surface. Additional complexities are apparent when one considers that more than one
receptor-ligand pair mediates cell adhesion and that each system has its own distinctive
kinetics. The routines described above provide a useful means for giving further insight
into these processes and comparing the relative net adhesive forces between different cell
populations and receptor-ligand interactions.
Chapter 3
Materials and Methods
3.1 Introduction
One of the goals of this thesis was to characterize the in vitro molecular and cellular
interactions between resting and IL-2-activated human CD4+, CD8+, and CD56+ (NK)
lymphocyte populations and vascular endothelial cells activated by various angiogenic
factors. This involved quantifying the individual contributions of the cell adhesion
molecule receptors on the lymphocytes essential for capture and stable adhesion, and
correlating the adhesive characteristics of the cells with the levels of receptor and ligand
expression and binding kinetics.
The level of CAM expression on HUVEC monolayers treated with tumor interstitial
fluid and various angiogenic growth factors, namely TNFa, VEGF, bFGF, TGF3, was
also determined to further characterize the endothelial response and correlating with specific
ligand-receptor interactions involved in cell adhesion to the endothelium.
Additionally, the essential signal transduction pathways used by bFGF in
modulating the CAM expression was determined in providing a framework for the
molecular mechanisms of adhesion regulation.
To obtain this information, several techniques were utilized: a) parallel-plate flow
chamber for the functional studies involving lymphocyte binding kinetics, efficiencies, and
receptor-ligand pairings, b) targeted sampling fluorometry, flow cytometry, and a
fluorescence immunoassay for the expression studies involving endothelial cell
monolayers, and c) Northern blot for the transcriptional studies.
3.2 Lymphocyte Preparation
3.2.1 Lymphocyte Isolation
Human lymphocyte populations were isolated from Leukopack preparations
(Massachusetts General Hospital Blood Bank) or from peripheral blood donors and diluted
1:1 with RPMI-1640 + 10% FCS (Gibco, Grand Island, NY) and centrifuged over a
Ficoll-Hypaque gradient (Lymphoprep; Nycomel, Oslo, Norway). The lymphocyte layer
collected from the interface of the gradient was washed twice with DPBS and depleted of
monocytes by the plastic adherence method for 45 min and, in the case of Leukopack
preparations, was then incubation with L-phenylalanine methyl ester (PME; Fluka
Chemical, Buchs, Switzerland) for approximately 15 min in a Hanks' Balanced Salt
Solution (HBSS, with Ca 2+ + Mg 2+) [Leung, 1989]. The cells were subsequently
centrifuged and resuspended in RPMI-1640 + 10% FCS.
The resting lymphocyte subpopulations, namely unactivated CD4+, CD8+, and
CD56+, were isolated using a magnet bead separation technique (MACS; Miltenyi Biotech,
GmbH, Gladbach, Germany) in conjunction with targeted antibodies [Miltenyi, et al.,
1990]. The technique involved using a two-step, indirect staining process. The cells were
first washed with a solution of DPBS + Ca2+ + Mg2+ + 1% BSA + 5 mM EDTA + 0.01%
sodium azide (DPBS*) and incubated with an excess of primary antibody, 10 RLg
antibody/15 x 106 cells, in 0.1 ml of DPBS* at 4'C for 30 min. The cells were washed
three times with DPBS* and 10 gg of goat-anti-mouse IgG MicroBeads (Miltenyi Biotech)
was applied to a 0.1 ml cell suspension for 30 min at 4'C. The cells were then washed
three times, resuspend in 0.5 ml of DPBS*, and loaded on to magnetic separation columns
for selection following the manufacturer's instructions.
For use in the adhesion assays, the cells were positively selected for their respective
antigens, namely anti-CD4, anti-CD8 and anti-CD56 mAb were used as the primary
antibody. For flow cytometric analysis, the cells were negatively selected to prevent cross-
reactive binding of the antibodies to the fluorescein isothiocyanate (FITC) conjugate.
Therefore, CD4+ cells were obtained by positively selecting for CD8 (specific T cell
antigen), CD15 (monocyte antigen), CD 19 (B cell antigen), and CD56 (NK cell antigen);
CD8+ cells by selecting for CD4 (specific T cell antigen), CD15 (monocyte antigen), CD19
(B cell antigen), and CD56 (NK cell antigen); and CD56+ cells by selecting for CD4
(specific T cell antigen), CD8 (specific T cell antigen), CD15 (monocyte antigen), and
CD19 (B cell antigen). Extracted cell populations were shown to be greater than 90%
selective for their respective populations, as determined by flow cytometric analysis. The
isolated non-activated lymphocytes were then maintained in RPMI + 10% FCS + 0.1%
sodium azide at 4°C, reversibly limiting respiration and energy production, prior to
experimentation.
The activated lymphocyte subpopulations were prepared by initially incubating the
peripheral blood lymphocytes at a concentration of 2 x 106 cells/ml in a tissue culture
medium consisting of RPMI-1640 supplemented with 2 mM L-glutamine, 10% FCS, 5%
human serum, 100 U/ml penicillin, 100 g/ml streptomycin, and 1000 U/ml of
recombinant interleukin-2 (rIL-2) (Cetus/Chiron, Emeryville, CA), and placed in 25 cm 2
plastic culture flasks (Corning, Corning, NY) for 24 hr in a 37°C humidified incubator
containing 5% CO 2 . The non-adherent cells were removed, centrifuged to a pellet,
resuspended in tissue culture medium, placed in new, vertically aligned 25 cm 2 plastic
flasks and cultured for 1.5 to 4 weeks. Fresh tissue culture medium with 1000 U/ml of
rIL-2 was added regularly to maintain cell concentrations below 2 x 106 cells/ml. This
produced cultures of activated-lymphocytes with relatively significant populations of CD8+
(-25%) and CD4+ (-20%) cells, as determined by MACS technique and hemocytometer
counting. The activated lymphocyte subpopulations, namely CD4+ and CD8+ were
isolated using the magnet bead separation technique in conjunction with targeted antibodies,
as per the protocol previously described.
The plastic-adherent cells from the original 24 hr incubation were gently washed
four times with RPMI + 10% FCS. The supernatant from the non-adherent cells was
added the adherent cells and cultured for 1-4 weeks in 25 cm 2 plastic flasks aligned
horizontally to produce cultures of activated-natural killer cells, as described previously
[Pober and Cotran, 1990]. Fresh tissue culture medium with 1000 U/ml of rIL-2 was
added regularly to maintain cell concentrations below 2 x 106 cells/ml. Expanded cell
populations were shown to be 90-98% CD56+/CD3 - and <5% CD3 + cells by flow
cytometric analysis.
3.2.2 Lymphocyte Labeling
The lymphocytes were labeled with a cytosolic fluorescent dye, calcein-AM (calcein
acetoxymethyl ester, Molecular Probes, Eugene, OR), for better visualization of the
flowing, rolling, and adhered cells against the endothelial cell monolayer. The dye causes
no distinguishable physical changes to the adhesion receptors or other related properties of
the cell [Weston and Parish, 1990]. The cells were prepared using a calcein-AM
concentration of 0.01 mM in PBS and applied for 15 min at room temperature, washed and
resuspended in HBSS to a concentration of 1 x 106 cells/ml prior to the flow experiments.
3.2.3 Lymphocyte CAM Receptors
IL-2 activated and non-activated CD4+, CD8+, and CD56+ cells were labeled with
antibody to the following receptors: CD18, VLA-4, L-selectin, or sLeX, with IgGI and
IgG2a isotype antibodies as controls. Using a two-step, indirect staining process, the cells
were first washed with a solution of DPBS + Ca 2+ + Mg 2+ + 1% BSA + 5 mM EDTA +
0.01% sodium azide (DPBS*) and incubated with an excess of antibody, 10 jtg
antibody/15 x 106 cells, in 0.1 ml of DPBS* at 40C for 30 min. The cells were then
washed three times with DPBS* and 5 gg of a goat-anti-mouse F(ab')2 flourescein
conjugate (Tago, Burlingame, CA) was applied to a 0.1 ml cell suspension for 30 min at
40C. The cells were again washed three times and then fixed with 0.5 ml of 1%
paraformaldehyde. Flow cytometry analysis (FACScan; Becton Dickinson, San Jose, CA)
was utilized to determine the relative fluorescence data for the various labeled molecules
and provided an estimate of the level of adhesion receptor expression.
3.3 Endothelial Cell Preparation
3.3.1 Endothelial Cell Culture
Human umbilical vein endothelial cell (HUVEC) cultures1 were obtained from
single cord harvests and maintained in growth medium (EGM; Clonetics, San Diego, CA)
supplemented with 10% FCS and 1% penicillin/streptomycin in fibronectin (Sigma
Chemical, St. Louis, MO)-coated 75 cm2 tissue culture flasks (Corning Glass Works,
Corning, NY) in a 37C humidified incubator containing 5% CO 2. Additional studies
involving human dermal microvascular endothelial cell (HDMEC) cultures2 were used and
maintained under identical conditions. The use of the commercially available growth
medium EGM provided insurance towards the standardization and reproducibility of the
results [Watson, et al., 1995].
The endothelial cells used in the experiments of this thesis were of passage level 2
to 5. To maintain cultures for these extended periods, the endothelial cells were passaged
by enzymatic detachment using trypsin/ethylenediaminetetraacetic acid (EDTA) and
redistributed in a 1:3 proportion. The culture medium was changed every second day.
1 The HUVEC cultures used for these experiments are a generous gift from Dr. Michael Gimbrone, Jr. of
the Brigham and Women's Hospital [Gimbrone, et al., 1974].
2 The HDMEC cultures used for these experiments are a generous gift from Dr. Michael Detmar of the
Massachusetts General Hospital [Imcke, et al., 1991].
3.3.2 Endothelial Cell Monolayer Preparation
Preparation of the endothelial cell monolayers varied slightly depending on the
application intended, i.e. expression assay or functional assay. For endothelial cells used
in the functional adhesion assay, monolayers were grown on 3" x 1.5" sterile glass
microscope slides (Fisherbrand, Fisher Scientific, Pittsburgh, PA) with plastic wells at a
seeding concentration of 3 x 104/well and using EGM + 10% FCS. The monolayers were
greater than 90% confluent and ready to use within 24 hours. The slides utilized were pre-
treated with a siliconizing agent (Aquasil; Pierce Co., Rockford, IL) and coated with
fibronectin (6 gg/cm2 ) for 30 minutes at 37C. The plastic wells were maintained on the
slides by a 2% agarose preparation, permitting confinement of the monolayer and an
accurate means for determining cytokine concentration (see Figure 3-1). The growth
medium was subsequently replaced with serum-free RPMI and either cytokine, growth
factor, and/or inhibitor was added for prescribed periods. Prior to use, the agarose was
removed from the slides by using straight-edge extraction and the monolayer gently rinsed
with HBSS before attaching to the flow chamber.
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Figure 3-1. Slide preparation for monolayers to be used in the adhesion assay.
For endothelial cells used in the expression assays, HUVEC seeding varied
depending on whether a well-plate or chamber slide was utilized. In either case, the
substrate was pre-coated with 6 gg/cm2 of fibronectin, and the monolayer grown to greater
than 90% confluency in EGM medium over 24 hrs. Subsequently, the medium was
replaced with serum-free RPMI and either cytokine, growth factor, and/or inhibitor was
added. Complete descriptions of the preparations for each of the expression assays are
described in their respective sections below.
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3.4 Reagents
3.4.1 Cytokines and Growth Factors
The cytokines and growth factors used in the thesis were as follows: TNFc
(Cetus, Emeryville, CA), IL-10 (R&D Systems), bFGF (Gibco BRL, Grand Island, NY),
aFGF (R&D Systems), VEGF (Peprotech, Rocky Hill, NJ), and TGFO (Genzyme,
Cambridge, MA). The phorbol ester, phorbol 12-myristate, 13-acetate (PMA; Sigma
Chemical, St. Louis, MO), was also utilized.
3.4.2 TIF Collection
Preparations of tumor interstitial fluid (TIF) were obtained from LS 174T colon
adenocarcinoma tumors (ATCC, Rockville, MD) grown in severe combined
immunodeficient (SCID) mice by using the Gullino chamber, a semipermeable chamber
[Gullino, 1970; Jain, et al., 1979; Melder, et al., 1996]. Essentially, a wafer-like chamber
encased by a semipermeable membrane (0.45 gm mean pore size and typical porosity of
79%; type HA, Millipore, Bedford, MA) was inoculated with LS 174T cells and implanted
subcutaneously into SCID mice (see Figure 3-2). Following sufficient tumor growth, fluid
accumulation within the internal cavity was sampled at 7, 10, and 14 days post-
implantation and pooled from 3 mice, and was immediately stored at -70°C. Various
dilutions of this fluid were used in both the expression and functional adhesion assays.
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Figure 3-2. Schematic of the Gullino chamber used for the collection
of tumor interstitial fluid.
3.4.3 Monoclonal Antibodies
Monoclonal antibodies used in the thesis were as follows: anti-ICAM-1 (CD54,
clone LB-2; Becton Dickinson, San Jose, CA), anti-VCAM-1 (CD106, clone 1G11;
1R11-~Lil ~
AMAC, Westbrook, ME), anti-E selectin (CD62E, clone H 18/7; Becton Dickinson), anti-P
selectin (CD62P, clone GA6; Becton Dickinson), anti-ICAM-2 (CD102, clone CBR-IC2/2;
Endogen, Cambridge, MA), anti-sialyl Lewis X (clone CSLEX1, Becton Dickinson), anti-
LECAM-1 (CD62L, clone SKl l1, Becton Dickinson), anti-CD15 (clone MMA, Becton
Dickinson), anti-CD19 (Leu-12, clone 4G7, Becton Dickinson), IgG 1 and IgG2a isotype
control antibodies (clones X40 and X39; Becton Dickinson), anti-CD56 (Leul9, clone
MY31, Becton Dickinson), anti-CD4 (clone IOT4a, Immunotech, Westbrook, ME), anti-
CD8 (clone IOT8a, Immunotech), and anti-bFGF (R&D Systems, Minneapolis, MN).
3.4.4 Signaling Inhibitors
Sources for inhibitors to signaling molecules and transcription used in the thesis
were as follows: methyl 2,5-dihydroxycinnamate (MDHC; Sigma Chemical), sodium
orthovanadate (Na3V04; Sigma Chemical), 2-nitro-4-carboxyphenyl N,N-
diphenylcarbamate (NCDC; Sigma Chemical), propranolol DL (Sigma Chemical),
calphostin C (Research Biochemicals International, Natick, MA), GF109203X
(bisindolylmaleimide, Research Biochemicals International), and actinomycin D (Sigma
Chemical).
3.5 Functional Adhesion Assay
In vitro adhesion characteristics between a suspension of lymphocytes (CD4+,
CD8+, or CD56+) and endothelial cell monolayers were studied using a parallel-plate flow
chamber [Munn, et al., 1994]. The flow chamber allows for the study of the kinetics of
cellular binding in well-defined shear fields [Doroszewski, et al., 1979]. It consisted of a
polycarbonate block, a silastic gasket and a transparent microscope slide, on which a
confluent endothelial cell monolayer presided, all of which was held together by suction via
a vacuum pump (see Figure 3-3).
A computer-driven (IBM PC; International Business Machines, Boca Raton, FL)
variable speed syringe pump (Harvard Apparatus, South Natick, MA) drove the
lymphocyte cell suspension from a reservoir through the chamber, which was stationed on
an inverted microscope x, y stage (Nikon Diaphot TMD; Nikon, Garden City, NY)
equipped with a 10x objective. Attached to the microscope was an I-CCD camera (Cohu
5000 Series, San Diego, CA) connected to a time code generator (Panasonic WJ-810,
Secaucus, NJ), video cassette recorder (Sony SVO-9500MD, Park Ridge, NJ) and monitor
(Ikegami PM205A, Maywood, NJ). Also directly connected to the microscope was an
ultraviolent lamp (Nikon, Garden City, NY) for excitation of the fluorescently-labelled
lymphocytes. The system allowed for the simultaneous real-time visualization and
recording of the flowing suspension and capture process of the lymphocytes, as well as the
morphology and integrity of the endothelial cell monolayer. A schematic of the overall
experimental set-up is presented in Figure 3-4.
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Figure 3-3. Parallel-plate flow chamber in a) an orthogonal representation,
and b) a dimensional view point.
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Figure 3-4. Schematic of the in vitro adhesion assay set-up.
The pump and chamber system allowed for a well-defined, unidirectional laminar
flow to occur at single flow rates, typically 0.085 ml/min (corresponding to 1.0 dyne/cm 2
wall shear stress) applied for 6-8 minutes, or at multiple flow rates, ranging from 0.30
ml/min (3.51 dyne/cm 2 ) to 0.05 ml/min (0.59 dyne/cm 2) in steps of 0.05 ml/min. At each
specific flow rate, steady-state was obtained, the corresponding run time adjusted to
maintain equivalent cell flux [Munn, et al., 1994], and the stage was positioned to obtain 5-
8 sample fields/flow rate. Each field was approximately 680 Rm x 500 im in size.
Off-line analysis using the video recordings was performed to determine the
number of cells firmly bound per field, i.e. those cells which have not moved during the
sampling period. In the case of multiple flow rates, a cumulative bound cell density was
determined at each level of shear stress.
Antibody blocking experiments were also conducted with the lymphocyte
subpopulation or the HUVEC monolayer being treated with an excess of antibody to
determine the role of each receptor-ligand pairing in cell adhesion. Activated and non-
activated lymphocytes were suspended in 0.2 ml of HBSS and incubated with mAbs
against CD18, VLA-4, sLeX, and IgG isotype control for 30 minutes at 4"C and
resuspended in 1 ml immediately prior to experimentation. HUVEC monolayers were
incubated in 0.2 ml medium with mAbs against ICAM-1, ICAM-2, VCAM-1, E-selectin,
P-selectin, and IgG isotype control for 30 minutes at 37C. The antibodies were used
separately and in combination to assess the essential functional roles of the CAMs.
3.6 Protein Expression Assays
Four essential assays were used in this thesis to determine the level of protein
expression. Three of the techniques involved cell surface protein expression of cell
adhesion molecules on endothelial cells, namely targeted sampling fluorometry (TSF), flow
cytometry, and fluorescence immunoassay. Each elicited their own advantages and
disadvantages and were chosen based on these properties.
The fourth technique involved using enzyme-linked immunosorbent assays to
quantify the levels of specific cytokines and growth factors in tumor interstitial fluid which
may be essential in its modulatory characteristics of cell adhesion molecule expression.
3.6.1 Targeted Sampling Fluorometry
Targeted sampling fluorometry was specifically developed in the Steele Laboratory
during this thesis to analyze the level and spatial profile of cell adhesion molecule
expression on intact endothelial cell monolayers [Munn, et al., 1995]. The method utilizes
standard immunostaining, fluorescence microscopy, and digital image analysis (see Figure
3-5).
In using TSF to measure cell adhesion molecule expression on the cell surface,
HUVECs were grown in 8-chamber wells (Labtek; Nalge Nunc, Naperville, IL) on
fibronectin-coated glass slides with a seeding density of 3 x 104 cells/well. The
monolayers were greater than 90% confluent and ready to use within 24 hrs. At which
time, the cells were washed 3 times with a serum-free solution of RPMI-1640
supplemented with 100 U/ml penicillin and 100 gg/ml streptomycin, and treated with a
given cytokine and/or growth factor(s). After a selected incubation period, the cell
monolayers were washed 3 times with PBS + Ca2+ + Mg2+, fixed with paraformaldehyde
(1 mg/ml in PBS) for 15 min, washed 4 times and then immunostained with a primary
antibody directed against the given adhesion molecule (ICAM-1, ICAM-2, VCAM-1, E-
selectin, P-selectin), followed by a secondary FITC-conjugated goat-anti-mouse antibody.
Both primary and secondary antibodies were added in excess, 10 glg primary antibody and
5 glg secondary antibody in 0.1 ml of PBS + 0.1% BSA, and incubated for 30 min. After
the second incubation, the monolayers were washed 4 times and incubated with 1 mg/ml
propidium iodide (PI) to stain for the cell nuclei. After a 15 minute period at 27°C, the
monolayers were washed and then mounted for microscopic observation using a buffer
consisting of glycerol:PBS (2:8) with 1 mg/ml paraphenylenediamine (Aldrich Chemical,
Milwaukee, WI) to inhibit photobleaching.
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Figure 3-5. Targeted sampling fluorometry. Upper left image is that of the
PI-stained nuclei and at right of center is the immunostained image. Bottom
left image represents the sampled ROIs overlayed on the immunostained
image and the corresponding histogram showing the distribution of intensity
over the cell population.
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Images of the stained monolayers were obtained using an epifluorescence
microscope (Zeiss Axioplan, Oberkochen, Germany) with an I-CCD camera (Model
C2400; Hamamatsu, Middlesex, NJ). Connected to this system was a frame grabber
(DataTranslation, Marlboro, MA) installed on a Compaq® ProLinea 4/50 computer
(Compaq Co., Houston, TX) for digitization and storage of images. A 20x, 0.40 N.A.
objective was used which provided a field size of approximately 200-300 cells. Three
fields were recorded per well, with each field providing two images: one image recorded in
the 488/530 fluorescein channel and the other in the 488/600 channel (PI staining). No
overlap was evident of the PI fluorescence in the fluorescein channel.
The images were processed and analyzed using a Macintosh® Quadra 650 (Apple
Computer, Cupertino, CA) or a PowerWave 120 (Power Computing, Austin, TX)
computer. The images representing the cell nuclei (PI staining) 'were initially.recorded to
determine the relative field coordinates of the cells. An algorithm had been written for the
NIH Image 1.55 software (available through anonymous FTP at zippy.nih.nimh.gov)
which segmented the gray-scale images into rectangular regions using a 20 x 20 grid and
converted them into binary versions by pseudo-autothresholding (see Appendix B). This
procedure effectively eliminated any problems due to shading and provided an accurate
binary representation of the cell monolayer nuclei. The immunostained images were
corrected for light intensity variations and shading effects by pixel-by-pixel division using
an averaged background fluorescence image. The recorded x, y coordinates of the cell
nuclei were then used by the algorithm to determine regions of interest (ROIs), which were
representative of the area covered by each cell. These ROIs were adjusted to account for
cell density variations on the monolayer to minimize sampling overlap. The mean gray
level intensity for each ROI was then determined from the processed immunostained
images, and histograms were formulated for the entire cell population. The method
effectively provided the level of cell adhesion molecule expression on a per cell basis.
3.6.2 Flow Cytometry (FACS)
Confluent endothelial monolayers were formed on fibronectin-coated 3.5 cm culture
dishes and incubated with treatments of growth factor and/or cytokine for prescribed
periods of time. The monolayers were then trypsinized with trypsin-EDTA (Sigma
Chemical), centrifuged, washed with a solution of DPBS + Ca2+ + Mg 2+ + 1% BSA + 5
mM EDTA + 0.01% sodium azide (DPBS*), and resuspended in 0.1 ml of DPBS* with an
excess of antibody, 10 Vtg antibody/15 x 106 cells, at 4°C for 30 min. The monoclonal
antibodies used stained for the following receptors on the cells: ICAM- 1, ICAM-2, VCAM-
1, E-selectin, P-selectin, and IgGI and IgG2a isotype controls. The cells were then washed
three times with DPBS* and 5 jgg of a goat-anti-mouse F(ab') 2 flourescein conjugate
(Tago, Burlingame, CA) was applied to a 0.1 ml cell suspension for 30 min at 4"C. The
cells were again washed three times and then fixed with 0.5 ml of 1% paraformaldehyde.
Flow cytometry analysis (FACScan) was utilized to determine the relative fluorescence data
for the various labeled molecules and provided an estimate of the level of adhesion receptor
expression.
3.6.3 Fluorescence Immunoassay (FIA)
The fluorescence immunoassay method was utilized for those studies involving the
signaling pathway inhibitors. It provided a rapid and sensitive approach to measure the
mean fluorescence, which directly correlated with the mean cell surface protein expression
of a given CAM [Gerszten, et al., 1996].
In using FIA, HUVECs were seeded in 96-well, flat-bottom plates (Falcon; Becton
Dickinson, Franklin Lakes, NJ) at concentrations of 2.25 x 104 cells/well in EGM medium
at 37C. Within 24 hrs, the monolayers were greater than 90% confluent and the cells were
subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with
100 U/ml penicillin and 100 glg/ml streptomycin, and treated with a given cytokine and/or
growth factor(s). After a selected incubation period, the cell monolayers were washed 3
times with PBS + Ca 2+ + Mg2+, fixed with paraformaldehyde (1 mg/ml in PBS) for 15
min, washed 3 times and then immunostained with a primary antibody directed against the
given adhesion molecule in 0.1 ml of RPMI + 1% FCS at 10 mg/ml for 45 min. The cells
were then washed 3 times with RPMI + 1% FCS and incubated with an FITC-conjugated
goat-anti-mouse antibody diluted 1:50 in DPBS at 4"C. After 45 minutes, the cells were
washed twice with DPBS + 20% FCS and twice more with serum-free DPBS. The cells
were then lysed with 0.01% NaOH in 0.1% sodium dodecyl sulfate (SDS) and transferred
to 96-well, round-bottom plates (Corning) for optical clarity. A CytoFluor 2350
(PerSeptive Biosystems, Framingham, MA) fluorescent plate reader set at 485/535 was
used to quantify the mean fluorescence from each well and provide the level of CAM
expression on the cell surface.
3.6.4 Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA kits (Quantikine, R&D Systems) were used to quantify the levels of TNFa,
VEGF, and bFGF existing in several tumor interstitial fluid samples. This information was
utilized in conjunction with the results obtained from the studies involving the individual
angiogenic factor treatments to postulate the effects of these factors within the tumor on cell
adhesion molecule expression and lymphocyte adhesion.
The immunoassays used employed the quantitative sandwich enzyme immunoassay
technique. The procedure followed began by first adding 50 pl of assay diluent, a buffered
protein base, to the 96-well polystyrene microplates pre-coated with monoclonal antibody
specific for the cytokine. A series of dilution standards and triplicate samples at a total
volume of 200 pl were added and incubated for 2 hr at room temperature. The wells were
then washed 3 times with wash buffer and 200 Cl of conjugate was added. After 2 hrs of
incubation at room temperature, the wells were washed 3 times with wash buffer and 200
l of substrate solution, stabilized hydrogen peroxide and tetramethylbenzidine, was added
to each well and incubated for 20 min at room temperature. A stop solution of 2N sulfuric
acid was then added and the optical densities of each well was read at 450 nm using a
microplate reader (Emax, Molecular Devices, Sunnyvale, CA).
3.7 Northern Blot Analysis
3.7.1 Blot Preparation and Hybridization
HUVEC were grown to confluency on 3.5 cm culture dishes (Corning) incubated
with prescribed treatments of growth factor and/or cytokine in the presence or absence of a
transcription blocker. Total RNA was isolated using TRIZOL reagent (Life Technologies,
Grand Island, NY), a mono-phasic solution of phenol and guanidine isothiocyanate, and
following the manufacture's instructions. RNA content and purity was quantified by
measuring the optical densities at 260 X and 280 X using an UV spectrophotometer (Perkin-
Elmer, Oak Brook, IL), and the isolated RNA was assured to have an A2 60/2 80 ratio greater
than 1.6.
For Northern transfer analysis, 15 gg of RNA was separated by electrophoresis on
a 1% agarose formaldehyde denaturing gel containing 40 mM MOPS, 2 mM EDTA (pH
7.5), 5 mM Iodoacetamide, and 0.5 gg/ml ethidium bromide. After running for
approximately 3 - 4 hrs at 100 V, the gel was soaked in 1 L of 50 mM NaOH and after 30
min, 75 mM of HOAc and 400 mM of NaCl was added and the gel was allowed to soak for
another 30 min. RNA was then transferred to a nitrocellulose membrane by capillary
transfer, and the blots were crosslinked by ultraviolet irradiation (FB-UVXL-1000, Fisher
Scientific, Springfield, NY).
The membrane was then pre-hybridized in a hybridization cylinder with 6.5 ml of
0.77 M NaPO4 + 1 mM EDTA preboiled and 3.5 ml of 20% SDS and 40 pl of 0.5 M
Iodoacetamide for 1 hr at 65 C. Labelled probe was added to the solution and allowed to
hybridize at 65 "C for 18 - 24 hrs. Following hybridization, the blot was washed 3 times
with 2X saline-sodium phosphate-EDTA (SSPE) + 1% SDS for 30 min each at 37 "C, and
once with 0.2X SSPE + 1% SDS for 30 min at 65 "C (IX solution of SSPE consists of
150 mM NaC1, 10 mM NaH2PO4 and 1 mM EDTA). The blot was patted dry, placed in an
autoradiography cassette (Fisher Scientific, Pittsburgh, PA), and exposed to a film
(Eastman Kodak, Rochester, NY) for several hours, depending on the probe utilized.
RNA levels were quantified by densitometry using NIH Image 1.55 and normalized with
respect to the p-actin levels.
3.7.2 cDNA Probe Preparation
The cDNA constructs used in the Northern blot analysis were generously provided
by the following individuals: a) ICAM-1 and E-selectin cDNA by Dr. Brian Seed,
Department of Molecular Biology, Massachusetts General Hospital; b) P-actin cDNA by
Dr. Toshihiro Shioda, Laboratory of Tumor Biology, Massachusetts General Hospital, c)
VCAM- 1 cDNA by Dr. Tucker Collins, Department of Pathology, Brigham and Women's
Hospital, and d) ICAM-2 cDNA by Dr. Timothy Springer, Center for Blood Research,
Harvard Medical School. The clones were all suitable for hybridization analysis of gene
expression.
Extraction of the cDNA from the plasmid was performed using restriction enzymes
appropriate for the given construct. More specifically, the cDNA of ICAM- I1 and E-selectin
were extracted from plasmid 7tH3M by incubating 1 p1 of Hind III and Not I restriction
enzymes, 3 L1 of Buffer II, 20 pl of H20 and 1.5 gLg of construct for 1 hr at 37 "C. The
product was then loaded in a low melting gel and the probe fragment cut at the specified
molecular weight. Similarly, the cDNA of VCAM-1 was extracted from plasmid pBS
M13+ using 1 pl of Kpn I and Sph I restriction enzymes, and the cDNA of ICAM-2 was
extracted from plasmid CDM8 using 2 pl of Xba I restriction enzyme. The P-actin cDNA
product was generated using reverse transcriptase-polymerase chain reaction (RT-PCR)
and required no additional preparation.
Labelled probe was prepared from human ICAM-1, ICAM-2, VCAM-1, E-selectin,
and p-actin cDNA with the Megaprime DNA labelling kit (Amersham Life Science,
Buckinghamshire, England). Initially, 5 pl of template cDNA was added to 5 pl of primer
and 23 gl of H2 0 and denatured by heating to 100 "C for 5 min. Following a brief spin in
a microcentrifuge, 10 pl of labelling buffer (dATP, dGTP, and dTTP in Tris/HCl (pH
7.5), 2-mercaptoethanol and MgCl2), 2 l of 1 U/pl DNA polymerase I Klenow fragment,
and 5 pl of 32 P-dCTP was added and the solution was incubated for 30 min at 37 "C. The
reaction was subsequently stopped by the addition of 5 g1 of 0.2M EDTA. The labelled
DNA was then denatured by heating to 100 "C for 5 min, followed by placement on ice
until hybridization with the membrane.
3.8 Signal Transduction Analysis
Studies were undertaken to determine essential signaling pathways used by the
growth factor bFGF and cytokine TNFa in modifying CAM expression. The fluorescence
immunoassay (FIA) method was used to determine the modulation of CAM expression on
endothelial cells, and the adhesion assay was used to assess the functional correlation with
signaling blockade.
In eliciting an effective blockade of the intracellular signaling pathways, the
following drugs were placed 2 hr prior to and remained confinuous with cytokine or
growth factor treatment to deplete the cell of the signaling molecule's action: a) the FGF
receptor tyrosine kinase inhibitor, MDHC, b) the phosphotyrosine phosphatase inhibitor,
sodium orthovanadate, c) the phospholipase C inhibitor, NCDC, d) the phospholipase D
inhibitor, propranolol DL, and e) the protein kinase C inhibitors, calphostin C and
GF109203X.
Blockage of the high-affinity receptor-ligand interaction of bFGF:FGFR was
obtained by initially adding 1 gg/ml of bFGF neutralizing antibody to a 10 ng/ml solution
of bFGF, incubating for 1 hr at 37C, and then applying the solution to the endothelial
cells.
The influence of heparin, a low-affinity proteoglycan, was assessed by the
supplemental addition of heparin (Elkins-Sinn, Cherry Hill, NJ) to the growth medium
upon the application of cytokine or growth factor.
3.9 Statistical Analysis
Statistical comparison of means was performed by two-tailed unpaired Student's t
test or Mann-Whitney test. The null hypothesis was considered rejected at P < 0.05.
Chapter 4
Lymphocyte Binding Kinetics
4.1 Introduction
The recruitment of lymphocytes, and more generally leukocytes, from the
peripheral circulation is an essential process for the induction and maintenance of an
effective immune and inflammatory response. Recruitment is mediated by specific
receptor-ligand interactions between the leukocytes and vascular endothelium. Current
models suggest a multi-step cascade involving members of the selectin, integrin, and
immunoglobulin (Ig) gene families in the sequential process of initial attachment (capture
and rolling), stable adhesion (arrest), cell spreading and diapedesis [Butcher, 1991; Carlos,
et al., 1990; Springer, 1994; Cotran and Pober, 1990]. Interactions of molecules of the
selectin family (E-, P-, L-selectin) with carbohydrate ligands (sialyl-Lewis X) mediate the
initial step of leukocyte capture and rolling, while the subsequent firm adhesion and
diapedesis requires activation-dependent engagement of integrins (LFA-1, VLA-4) with
their endothelial ligands (ICAM-1, VCAM-1) [Lawrence and Springer, 1991; Luscinskas,
et al., 1994].
Leukocyte populations have been shown to vary in their surface expression of cell
adhesion receptors, and consequently differ in the specific molecular mechanisms they use
in binding to the endothelium. For instance, polymorphonuclear (PMN) cells lack the P1-
integrin VLA-4, which is commonly expressed on T lymphocytes and monocytes, and thus
do not recognize the counter-receptor VCAM-1 on endothelial cells. When compared to
other leukocytes and in detailed, independent adhesion studies, T lymphocytes exhibited
inherent differences in their adhesive characteristics [Abassi, et al., 1993; Luscinskas and
Lawler, 1994; Melder, et al., 1995], as described in section 2.1.
While these studies have provided a better understanding of the molecular
mechanisms used by T cells in binding to the vascular endothelium, evidence has lacked as
to a direct comparison of the adhesive binding kinetics among the individual lymphocyte
subpopulations, namely CD4+, CD8+, and CD56+/CD3- cells. CD4+ cells, or helper T
cells, mediate specific cell-mediated immune response that recognizes foreign antigen via
major histocompatibility complex (MHC) class II complexes, and serve to secrete cytokines
and provide stimuli for B cell differentiation. CD8+ cells, or cytotoxic T cells, constitute
the specific immune effector response that recognizes foreign peptides via MHC class I
complexes. In addition, the CD8+ cells act to lyse virus-infected cells, tumor cells, and
allografts, as well as secrete various cytokines. CD56+ cells, or natural killer (NK) cells,
participate in the innate immune response and act to lyse virus-inf6cted cells and tumor cells
by recognizing cells lacking MHC class I. Considering that the specificity of the cellular
immune response varies for each subpopulation, adhesion receptor expression and their
binding characteristics and efficiencies are also likely to vary.
Additionally, initial immunological responses are typically carried out by circulating
lymphocytes in the resting or non-activated state. Only upon antigen recognition or
extended cytokine exposure do the cells become activated, transform from the
CD45RA+/CD45RO- to the CD45RA-/CD45RO+ phenotype, and produce stronger, more
specified responses. The activation state is also known to alter the adhesive characteristics
of lymphocytes by increasing integrin expression and the viscoelastic properties by
decreasing cell deformability [Roth, 1994; Melder and Jain, 1992]. In vivo
experimentation has shown an increased localization of IL-2 activated NK cells in normal
and tumor tissues, and an increased accumulation of endogenous lymphocytes to tumor
vessels following systemic IL-2 treatment [Melder, et al., 1993; Ohkubo, et al., 1991;
Aronson, et al., 1988]. However, a detailed comparison analyzing the specific binding
characteristics of IL-2 activated and non-activated lymphocyte subpopulations under
physiological flow conditions has not been previously addressed.
Moreover, while CD3+ T lymphocyte molecular binding properties have been
studied to a limited extent, the specific biophysical and molecular mechanisms of IL-2
activated CD56+ (NK) cells have not been defined under dynamic conditions. Under static
conditions, IL-2 activated CD56+ cell adhesion to endothelial cells has been shown to
involve the 31 and P2 integrins and their corresponding counter-receptor pairs, ICAM-1
and VCAM-1, but E-selectin-mediated interaction was found to be of no consequence
[Allavena, et al., 1991]. However, static adhesion assays are limited in the their ability to
discriminate between differences in bond strengths or rate-limited binding events, which
are characteristic of specific CAMs [Kojima, et al., 1992].
In this chapter, results are presented from experiments using the parallel-plate flow
chamber which were designed to address the following essential issues: a) what
differences are evident in the binding kinetics and efficiences to activated endothelial cells
by the lymphocyte subpopulations CD4+, CD8+, and CD56+; b) what differences are
present in the binding characteristics between IL-2 activated and non-activated lymphocyte
subpopulations; and c) what are the molecular and biophysical mechanisms of IL-2
activated NK cell adhesion to activated endothelial cells? The findings from these studies
provide additional insight to the immunological response of lymphocytes in normal and
pathological conditions, such as tumor, inflammation and allograft rejection.
4.2 Non-Activated Lymphocyte Binding
To determine the binding characteristics of the individual subpopulations of resting
lymphocytes, cumulative cell binding densities and capture efficiencies were obtained for
each population of cells using the parallel-plate flow chamber under shear stress conditions
ranging from 0.56 to 3.5 dyn/cm2 . The flow rates and shear stresses were representative
of those found in physiological settings [Melder, et al., 1995]. Non-activated HUVEC
monolayers were used to obtain basal adhesion characteristics. Monolayers activated with
TNF(x (50 ng/ml), a positive CAM modulator, bFGF (10 ng/ml), a negative CAM
modulator (see Section 5.2), and a combination of the two factors were used to obtain in
vitro binding profiles representative of those potentially found in tumors and inflammation.
The data obtained using the functional adhesion assay was plotted as the number of
bound cells/mm2 of monolayer area vs. the wall shear stress produced by the flow system
(dynes/cm 2). This was used to describe the binding kinetics of the flowing lymphocytes
over an intact endothelial cell monolayer. Additionally, capture efficiency plots were
generated to provide further comparitive analysis between the subset of lymphocytes.
The initial set of experiments performed involved using non-activated endothelial
cells to obtain basal adhesion kinetics. The cummulative bound cell densities of each
lymphocyte subpopulation over the range of shear stresses are plotted in Figure 4-2-1. The
results show a low, but significant accumulation of cells occuring only at the lowest shear
stress employed, 0.56 dyn/cm2 . Higher wall shear stresses were not conducive for
binding of any of the non-activated lymphocytes.
In comparing the lymphocyte sub-types, a significant difference was found in the
number of bound CD56+ cells relative to both CD4+ and CD8+ cells at the lowest shear
While relatively few in number, these cells are
representative of a significant baseline adhesion to resting endothelium.
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Figure 4-2-1. Cumulative binding curves of non-activated CD4+, CD8+,
and CD56+ cells on non-activated HUVEC monolayers. Mean numbers +
SD of bound cells for five adjacent fields are shown for 1 of 3 representative
flow experiments. * p < 0.05.
Table 4-2-1. Comparison of cell binding densities of non-activated CD4+, CD8+,
and CD56+ cells on non-activated HUVEC monolayers. Mean values ± SD are
shown for n = 3 flow experiments.
Shear stress CD4+ CD8+ CD56+
(dyn/cm 2 ) (bound cells/mm 2) (bound cells/mm2 ) (bound cells/mm 2)
3.51 0.00 + 0.00 0.00 ± 0.00 0.00 ± 0.00
2.93 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
2.34 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
1.76 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
1.17 0.00 + 0.00 0.00 ± 0.00 0.00 ± 0.00
0.56 0.29 ± 0.93 0.59 ± 1.24 2.65 ± 2.17 t,
t Significant difference
n Significant difference
compared to CD4+ cells, p < 0.05.
compared to CD8+ cells, p < 0.05.
To provide a monolayer which was more conducive to cell binding, TNFc
treatment was applied to the HUVEC monolayers for 24 hrs, allowing for sufficient ICAM-
1 and VCAM-1 expression, while still maintaining an appreciable level of E-selectin. The
cumulative binding curves for each of the lymphocyte subpopulations are shown in Figure
---4--- CD4+
- [ -CD8+
-.- ACD56+
, *
stress (p < 0.05) (see Table 4-2-1).
4-2-2. A significant increase in the level of binding above baseline was observed for each
cell subtype for all flow rates considered (p < 0.05) (see Table 4.2.2). The number of
bound cells on the TNFca-activated monolayer under the lowest shear stress, 0.56
dyn/cm 2, was approximately 50-fold higher for resting CD56+ cells, 150-fold higher for
resting CD8+ cells, and 275-fold higher for resting CD4+ cells. The disproportionate
increase in cell binding produced by the latter two cell subtypes may have been the result of
the excessively low values found at baseline relative to the CD56+ cells, and therefore, are
artifactual.
As another possibility for the disproportionate binding between cell subtypes, the
TNFa-induced increase in CAM expression on the endothelial cells may have provided a
critical level for the adhesion receptors on the CD4+ and CD8+ cells to interact and
effectively bind.
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Figure 4-2-2. Cumulative binding curves of non-activated CD4+, CD8+,
and CD56+ cells on TNFa-activated HUVEC monolayers. Mean numbers +
SD of bound cells for five adjacent fields are shown for 1 of 3 representative
flow experiments. * significant difference between CD4+ and CD56+ cells,
p < 0.05, and $ significant difference between CD8+ and CD56+ cells, p <
0.05.
In comparing the cell binding densities between the lymphocyte subpopulations,
there was no statistically significant differences between the non-activated CD4+ and CD8+
cells for the complete range of flow rates. However, a greater number of CD56+ cells
consistantly bound to the activated monolayers relative to both CD4+ and CD8+ cells for
shear stresses ranging from 1.76 to 0.56 dyn/cm2 (p < 0.05). At the lowest shear stress,
the level of CD56+ cell binding was approximately 30% greater than the levels obtained by
both CD4+ and CD8+ cells. Considering the greater influence of integrin-mediated events
contributing to the cell binding process at these low shear stresses, the results are consistent
with the finding of differences in the P2 integrin surface density on lymphocyte subsets
[Pardi, et al., 1989]. Additionally, CD56+ cells are known to express significant levels of
CD 18 expression on their villi and podosomes, providing these cells with a topological
advantage to binding [Burridge, et al., 1988; Marchisio, et al., 1988; Melder, et al., 1990].
Table 4-2-2. Comparison of cell binding densities of non-activated CD4+, CD8+,
and CD56+ cells on HUVECs treated with TNFa for 24 hrs. Mean values ± SD are
shown for n = 3 flow experiments.
Shear stress CD4+ CD8+ CD56+
(dyn/cm 2) (bound cells/mm2 ) (bound cells/mm 2) (bound cells/mm2 )
3.51 1.76 ± 1.86 * 1.37 ± 1.88 * 1.76 ± 1.86 *
2.93 5.88 ± 3.52 * 6.86 ± 4.26 * 7.84 ± 3.46 *
2.34 13.53 ± 3.10 * 16.86 ± 4.65 * 20.78 ± 6.33 *,"
1.76 28.63 ± 7.24 * 32.35 ± 6.48 * 44.12 ± 6.39 *
1.17 55.69 ± 7.74 * 57.45 + 10.77 * 80.20 ± 11.89 *,,t
0.56 80.59 ± 9.55 * 86.47 ± 7.19 * 120.59 + 10.01 *,:,"
* Significant difference from baseline of the respective cell type, p < 0.05.
: Significant difference compared to CD4+ cells, p < 0.05.
rt Significant difference compared to CD8+ cells, p < 0.05.
To provide further insight into the different binding characteristics between the
lymphocyte subtypes, capture efficiency plots for each of the cell types were generated and
are shown in Figure 4-2-3. Changes in bound cell density with changing shear stress is
directly related to the capture efficiency as a function of the force generated by the flow
system. Fits of the bound cell density data were made to the function: E = Eoe - i , where E
is the capture efficiency at shear stress S. Additional parameters are: E0 , the efficiency at
zero shear, and rc, the capture coefficient. Eo reflects the overall drag forces which
promote cell arrest over a range of shear stress levels (integrin-mediated interactions), while
c is correlated with the change in capture rate with increasing shear stress (selectin-
mediated process) [Melder, et al., 1995].
Binding efficiency plots derived from the cell accumulation curves reproducibly
showed a reduction in binding efficiency that was uniform across the range of shear
stresses examined for each of the lymphocyte subpopulations (see Figure 4-2-3). No
statistical difference in the capture coefficient, rc, was evident between the three non-
activated lymphocyte subsets, and is plotted in Figure 4-2-4a. This finding indicates the
non-activated lymphocyte subsets produce relatively similar adhesive forces at the time of
initial contact with the endothelium.
A comparison of the fitted parameter E, showed a statistically significant difference
between CD56+ cells (0.879 ± 0.075 ) and CD4+ cells (0.597 ± 0.137), as well as CD8+
cells (0.601 ± 0.034) (p < 0.05), and is plotted in Figure 4-2-4b. No statistical difference
was evident between the CD4+ and CD8+ cells. These findings indicate that the efficiency
of the adhesion process after initial capture is greater for CD56+ cells, which is a direct
function of their ligand-receptor affinity and integrin concentration.
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Figure 4-2-4. Comparison of the fitted parameters: a) IK, capture coefficient,
and b) Eo, efficiency at zero shear generated from the capture efficiency plots
of non-activated lymphocytes on TNFa-activated monolayers. R2 greater
than 0.96 in all cases. * p < 0.05.
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As a source for providing a negative modulation of CAM expression on endothelial
cells, in opposition to the positive modulation by TNFa, the binding characteristics of the
non-activated lymphocyte populations were also studied on bFGF and TNFuo + bFGF
treated HUVEC monolayers. As will be discussed in further detail in Chapter 5, bFGF
was found to inhibit the level of CAM expression on endothelial cells with optimal
inhibitory kinetics around 24 hrs.
A representative set of binding curves of the lymphocyte subpopulations on bFGF
(10 ng/ml)-activated HUVEC monolayers are shown in Figure 4-2-5. For the entire range
of shear stresses imposed, lymphocyte binding of all three subsets was completely absent.
A small, but statistically significant decrease in the level of CD56+ binding was found
when compared to baseline levels from non-treated monolayers at the lowest shear stress (p
< 0.05) (see Table 4-2-3). This suggests that a reduction of basal CAM expression by
bFGF reduced the threshold of adhesive interaction below that which is necessary for
stable adhesion under dynamic flow conditions.
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Figure 4-2-5. Cumulative binding curves of non-activated CD4+, CD8+,
and CD56+ cells on bFGF activated HUVEC monolayers. Mean numbers +
SD of bound cells for five adjacent fields are shown for 1 of 3 representative
flow experiments.
To further examine the effects of the negative modulation of CAM expression on
lymphocyte subpopulation binding kinetics, additional experiments were performed
combining TNFct and bFGF. These experiments were based upon previous work
[Melder, et al., 1996] demonstrating reduced binding of activated lymphocytes to bFGF-
treated endothelium. The following studies were designed to determine if the paradigm of
bFGF-modulated adhesion could be extended to normal circulating (non-activated)
lymphocyte populations. These experiments further elucidated differences in the molecular
binding kinetics of distinct lymphocyte subpopulations. The experiments also represented
a system in which to study the binding of circulating lymphocytes to vessels in or near
tumor or inflammatory sites where several growth factors and cytokines simultaneously
influence the microenvironment [Cotran and Pober, 1990; Blood and Zetter, 1990].
Table 4-2-3. Comparison of cell binding densities of non-activated CD4+, CD8+,
and CD56+ cells on HUVECs treated with bFGF for 24 hrs. Mean values ± SD are
shown for n = 3 flow experiments.
Shear stress CD4+ CD8+ CD56+
(dyn/cm 2) (bound cells/mm2 ) (bound cells/mm2 ) (bound cells/mm2 )
3.51 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
2.93 0.00 + 0.00 0.00 ± 0.00 0.00 ± 0.00
2.34 0.00 + 0.00 0.00 ± 0.00 0.00 ± 0.00
1.76 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
1.17 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0.56 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 *
* Significant difference from baseline of the respective cell type, p < 0.05.
The binding kinetics of non-activated lymphocytes to HUVEC monolayers activated
with TNFa + bFGF are shown in Figure 4-2-6. Significant increases in lymphocyte
binding above baseline levels were found for all cell subtypes for the range of shear
stresses between 2.34 to 0.56 dyn/cm2 (p < 0.05). Comparison of the cell binding
densities between the subpopulations revealed significant differences and are shown in
Table 4-2-4. Non-activated CD56+ cells consistantly showed binding levels above that of
CD4+ and CD8+ cells for the imposed shear stresses between 1.17 to 0.56 dyn/cm2 and
1.76 to 0.56 dyn/cm2 , respectively. At the lowest shear stress level, CD56+ cells bound to
the activated endothelium on average 37% greater than both CD4+ and CD8+ cells.
Differences between CD4+ and CD8+ cells were also observed, but were limited to the
shear stresses ranging from 2.34 to 1.17 dyn/cm 2. Interestingly, no significant difference
was found between these two cell subtypes at the lowest shear stress, possibly implying a
critical range over which a particular molecular species, such as VLA-4, on the cell surface
may vary between the cells. VLA-4, a P1 integrin, has been shown to have a potential
overlapping role in the initial capture process and in stable adhesion [Melder, et al., 1995].
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Figure 4-2-6. Cumulative binding curves of non-activated CD4+, CD8+,
and CD56+ cells on TNFx + bFGF activated HUVEC monolayers. Mean
numbers ± SD of bound cells for five adjacent fields are shown for 1 of 3
representative flow experiments. * significant difference between CD4+ and
CD56+ cells, p < 0.05, T significant difference between CD8+ and CD56+
cells, p < 0.05, and 1 significant difference between CD4+ and CD8+ cells,
p < 0.05.
Table 4-2-4. Comparison of cell binding densities of non-activated CD4+, CD8+,
and CD56+ cells on HUVECs treated with TNFa+bFGF for 24 hrs. Mean values +
SD are shown for n = 3 flow experiments.
Shear stress CD4+ CD8+ CD56+
(dyn/cm2 ) (bound cells/mm 2 ) (bound cells/mm 2) (bound cells/mm 2)
3.51 0.00 ± 0.00 * 0.00 + 0.00 * 0.00 ± 0.00 *
2.93 0.59 ± 1.22 * 0.00 ± 0.00 * 0.00 ± 0.00 *
2.34 3.53 + 1.99 "," 1.76 ± 2.44 * 3.53 ± 2.98 *
1.76 12.16 + 3.12 , 6.08 ± 3.23 * 14.90 ± 4.37 *
1.17 31.57 + 7.07 *, 21.18 + 7.88 * 43.14 + 7.91 *,
0.56 50.20 ± 7.50 * 50.20 + 11.42 * 79.22 + 10.34 *,$,
* Significant difference from TNFa-activated monolayers of the respective cell type, p < 0.05.
$ Significant difference compared to CD4+ cells, p < 0.05.
n Significant difference compared to CD8+ cells, p < 0.05.
In comparing the results obtained with TNFa-activated monolayers, several
differences were found. First, for all shear stresses imposed and all cells tested, there was
a significant reduction in the number of bound lymphocytes on the TNFa + bFGF treated
monolayers (p < 0.05). Secondly, while CD56+ cells consistantly bound at higher levels
compared to CD4+ and CD8+ for shear stresses between 1.76 to 0.56 dyn/cm 2, CD4+
cells were also found to bind at significantly greater levels than CD8+ cells for a selected
range of shear stresses on TNF(x + bFGF treated monolayers. This difference in binding
between the two cell subtypes on the different monolayers implies a critical threshold at
which one or more receptors on CD4+ cells are expressed in higher concentrations or
possibly maintain higher affinities for CAMs that have been down-regulated on the
endothelium by bFGF.
To further analyze the adhesion kinetics of the individual subpopulations, capture
efficiencies were calculated and their plots are shown in Figure 4-2-7. As found for
TNFa-activated monolayers, the cell accumulation curves reproducibly showed a reduction
in binding efficiency that was uniform across the range of shear stresses examined for each
of the lymphocyte subpopulations. A significantly lesser slope (c) was observed for CD4+
cells (1.179 ± 0.072 cm2/dyn) compared to CD8+ cells (1.709 ± 0.298 cm 2/dyn) and
CD56+ cells (1.374 ± 0.097 cm2/dyn), with no statistically significant difference between
the latter two cell subtypes (see Figure 4-2-8a). The lower value of 1c for CD4+ cells on
the TNFa+bFGF activated monolayer indicates that these lymphocytes have a relatively
stronger adhesive force at the time of contact with the endothelium. This results in a
smaller decrease in the capture efficiency with increasing shear stress. Molecules such as
L- and E-selectin have been shown to have dominant effects at high flow rates, especially
when in high concentrations on the cell surface, and significantly affect the value of the
capture coefficient, ic [Melder, et al., 1995]. These findings suggest that L-selectin or a
functionally related receptor, such as sialyl Lewis X, may be elevated in non-activated
CD4+ lymphocytes relative to CD8+ and CD56+ lymphocytes. Since this observation was
evident only on TNFz + bFGF treated monolayers and not on TNFO treated monolayers,
this might only be detectable when the CAM expression is reduced.
Comparison of the capture coefficients between TNFa and TNF(x + bFGF treated
monolayers for the lymphocyte subpopulations, showed significantly greater values for all
three cell subtypes on TNFa + bFGF activated monolayers (p < 0.05). This finding is not
unexpected based on the inhibitory effect which bFGF has on the expression of E-selectin,
a counter-receptor for L-selectin and sialyl Lewis X, on the endothelial cells.
Evaluation of the fitted parameter Eo showed significantly higher values for CD56+
cells (0.937 ± 0.222) and CD8+ cells (0.825 ± 0.198) compared to CD4+ cells (0.495 ±
0.038) (see Figure 4-2-8b). The finding of increased efficiency of CD56+ cells over CD4+
cells is in agreement with that found for TNFxo-activated monolayers, but the increased
efficiency of CD8+ cells over CD4+ cells indicates a possible masking of this difference by
high integrin concentration, which only becomes evident with the reduced CAM expression
on the endothelium by bFGF.
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Figure 4-2-7. Comparison of binding efficiencies between non-activated
CD4+, CD8+, and CD56+ cells on TNFo + bFGF activated HUVEC
monolayers (n = 3).
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Figure 4-2-8. Comparison of the fitted parameters: a) K, capture coefficient,
and b) Eo, efficiency at zero shear generated from the capture efficiency plots
of non-activated lymphocytes on TNFa + bFGF activated monolayers. R2
greater than 0.96 in all cases. * p < 0.05.
-KSE=Ee
......... CD4+
-CD8+
CD56+
i i i N I
2.50
2.00
1.50
1.00
0.50
0.00
4.3 IL-2 Activated Lymphocyte Binding
To determine the binding characteristics of the individual subpopulations of IL-2
activated lymphocytes, cumulative cell binding densities and capture efficiencies were
obtained for each population using identitical conditions to that used for the analysis of the
resting lymphocyte subpopulations in Section 4.2. Positive and negative controls for the
level of adhesion on activated and non-activated endothelium provided an additional means
for directly comparing the results between activated and non-activated lymphocyte
subpopulations for a quantitative assessment of their binding kinetics and mechanisms of
cell adhesion. A margin of error on the order of + 5% was determined based on these
controls.
Experiments using non-activated endothelial cells initially demonstrated a relatively
low, but significant amount of adhesion at the lowest shear stress, 0.56 dyn/cm 2 , by all
three IL-2 activated lymphocyte subpopulations (see Figure 4-3-1 and Table 4-3-1). No
statistical differences of the number of bound cells were noted between the CD4+, CD8+,
and CD56+ cell types at this flow rate. Higher shear stresses resulted in no appreciable
accumulation of any of the lymphocytes, consistant with the previous findings using non-
activated endothelium. This emphasizes the importance of CAM modulation and shear
stress on lymphocyte binding to endothelial substrate.
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Figure 4-3-1. Cumulative binding curves of IL-2-activated CD4+, CD8+,
and CD56+ cells on non-activated HUVEC monolayers. Mean numbers +
SD of bound cells for five adjacent fields are shown for 1 of 3 representative
flow experiments.
Table 4-3-1. Comparison of cell binding densities of IL-2 activated CD4+, CD8+,
and CD56+ cells on non-activated HUVEC monolayers. Mean values ± SD are
shown for n = 3 flow experiments.
Shear stress CD4+ CD8+ CD56+
(dyn/cm2) (bound cells/mm 2) (bound cells/mm 2 ) (bound cells/mm 2)
3.51 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
2.93 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
2.34 0.00 ± 0.00 0.29 ± 0.93 0.00 ± 0.00
1.76 0.00 ± 0.00 0.29 ± 0.93 0.88 ± 1.42
1.17 2.06 ± 2.42 1.59 ± 1.24 3.53 ± 3.34
0.56 10.29 ± 4.65 9.71 ± 4.39 13.82 ± 7.85
Compared to the non-activated cells, each of the L-2 activated lymphocyte subsets
showed significant increases in their cumulative binding densities at the lowest shear stress.
This finding is in agreement with the studies showing increased expression of integrin
molecules on the cell surface of IL-2 activated lymphocytes.
When HUVEC monolayers were activated with TNFa for 24 hrs, significant
increases in activated lymphocyte binding was found for all cell types above baseline levels
for the entire range of flow rates studied. An exception was the activated CD4+ cells which
failed to exhibit adhesion above baseline levels under the highest shear stress only (p <
0.05) (see Figure 4-3-2 and Table 4-3-2). The number of bound cells on the TNFX-
activated monolayer at 0.56 dyn/cm 2 was approximately 10-fold higher than that found on
the non-activated monolayer for all three subpopulations.
In comparing the cell binding densities between the subpopulations, significantly
fewer CD4+ cells consistantly bound to the endothelial monolayer for the complete range of
shear rates examined when compared to both CD8+ and CD56+ cells (p < 0.05). At the
shear stress level of 0.56 dyn/cm 2 , CD4+ cell binding levels were on average 13% and
22% less than the levels obtained by CD8+ and CD56+ cells, respectively.
Differences between CD8+ and CD56+ cells were also observed, but were limited
to only the lowest shear rate, where on average a 10% greater number of CD56+ cells
bound to the endothelial monolayer (p < 0.05). At this level of shear stress, the adhesion
process is dominated by integrin-mediated binding. Therefore, the high levels of CD56+
binding was not suprising, since they are known to possess favorable molecular binding
kinetics via high levels of integrin receptor expression on their cell surface and on their villi
[Allavena, et al., 1991; Melder, et al., 1991]. Likewise, IL-2 activated CD8+ cells may
also exhibit relatively higher levels of integrin expression compared to CD4+ cells,
resulting in their significantly greater binding.
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Figure 4-3-2. Cumulative binding curves of IL-2-activated CD4+, CD8+,
and CD56+ cells on TNFac-activated HUVEC monolayers. Mean numbers +
SD of bound cells for five adjacent fields are shown for 1 of 3 representative
flow experiments. * significant difference between CD4+ and CD8+ or
CD56+ cells, p < 0.05, and t significant difference between CD8+ and
CD56+ cells, p < 0.05.
Table 4-3-2. Comparison of cell binding densities of IL-2 activated CD4+, CD8+,
and CD56+ cells on HUVECs treated with TNFx for 24 hrs. Mean values ± SD are
shown for n = 3 flow experiments.
Shear stress CD4+ CD8+ CD56+
(dyn/cm 2 ) (bound cells/mm2 ) (bound cells/mm 2) (bound cells/mm 2)
3.51 0.59 ± 1.22 1.96 ± 2.13 *,$ 3.53 ± 2.32 *I
2.93 2.35 + 2.28 * 8.04 ± 3.76 *,I 9.41 ± 3.34 *,I
2.34 10.20 + 4.43 * 20.00 + 7.47 * 25.59 ± 7.97 *I:
1.76 27.65 ± 12.42 * 51.08 + 13.65 *,$ 57.94 ± 7.85 *,$
1.17 66.67 + 13.51 * 82.75 + 18.09 *, 87.94 + 11.13 *,
0.56 108.04 ± 16.80 * 124.31 + 19.62 *, 137.65 + 9.78 *
* Significant difference from baseline of the respective cell type, p < 0.05.
$ Significant difference compared to CD4+ cells, p < 0.05.
) Significant difference compared to CD8+ cells, p < 0.05.
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In agreement with these observations are the findings that IL-2 lymphocyte
populations were able to bind at significantly greater levels than the non-activated
populations for the low shear conditions. For instance, at the lowest shear stress of 0.56
dyn/cm 2 , IL-2 activated CD56+, CD8+, and CD4+ cells bound at levels on average 15%,
43%, and 34% greater than the non-activated populations, respectively. Additionally, the
significantly greater levels of activated CD8+ cells which bound compared to activated
CD4+ cells, but which bound at equivalent levels in the non-activated state, suggests a
differential level of integrin upregulation by IL-2 activation on T cell subsets.
To provide further insight into the different binding characteristics between the
lymphocyte subpopulations, capture efficiency plots for each of the cell types were
generated and are shown in Figure 4-3-3.
Binding efficiency plots derived from the cell accumulation curves reproducibly
showed a reduction in binding efficiency that was uniform across the range of shear
stresses examined for each of the lymphocyte subpopulations (see Figure 4-3-3). A
significantly greater slope () of the capture efficiency plot was observed for CD4+ cells
(1.169 ± 0.081 cm 2/dyn) compared to CD8+ cells (0.974 ± 0.089 cm 2/dyn), as well as
CD56+ cells (0.898 ± 0.016 cm 2/dyn) (p < 0.05) (see Figure 4-3-4a). No statistical
difference of the parameter K was evident between CD8+ and CD56+ cells. The increased
value of i for activated CD4+ cells indicates that these lymphocytes have a greater
sensitivity to shear stress by possessing a relatively weaker adhesive force at the time of
contact with the endothelium. As mentioned previously, specific selectin molecules have
been shown to effect capture rates under high flow conditions. To account for the reduced
binding efficiencies observed, these molecules may be significantly reduced in activated
CD4+ lymphocytes relative to activated CD8+ and CD56+ lymphocytes. A comparison
between the activated and non-activated cell subtypes showed no significant differences for
CD56+ and CD8+ cells, but a statistically significant difference between IL-2 activated
CD4+ cells (1.169 ± 0.081 cm 2/dyn) and non-activated cells (0.938 + 0.118 cm 2/dyn) (p <
0.05). The increased value of K observed by CD4+ cells activated by IL-2 was in
accordance with the previously hypothesized state of selectin alteration in these cells.
An analysis of the fitted parameter Eo showed no statistical difference between any
of the activated lymphocyte subpopulations (see Figure 4-3-4b). This result was somewhat
suprising considering the high level of integrin expression on IL-2 activated, as well as the
non-activated, CD56+ cells, which would act to stabilize the adhesion complex and
increase the efficiency of the adhesion process after initial capture. However, upon
activation by IL-2, CD4+ and CD8+ cells may increase their integrin surface expression to
levels approaching that of the activated CD56+ cells. Additionally, cells utilize multiple
molecular species to maintain adhesion which are dependent on specific receptor-ligand
affinities and concentrations. It is conceivable that on TNFct-activated endothelium, the
binding advantages activated CD56+ cells and CD8+ cells have over CD4+ populations
may be over-shadowed by the high level expression of ICAM-1, VCAM-1, and E-selectin.
Modifications to the level of CAM expression on the endothelial surface may provide
further insight to these mechanisms.
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Figure 4-3-3. Comparison of binding efficiencies between IL-2-activated
CD4+, CD8+, and CD56+ cells on TNFa-activated HUVEC monolayers (n
= 3).
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Figure 4-3-4. Comparison of the fitted parameters: a) c, capture coefficient,
and b) Eo, efficiency at zero shear generated from the capture efficiency plots
of activated lymphocytes on TNFa-activated monolayers. R2 greater than
0.96 in all cases. * p < 0.05.
The binding characteristics of the activated lymphocyte populations were also
studied on bFGF and TNFx + bFGF treated HUVEC monolayers, as a means of
providing a negative modulation of CAM expression on endothelial cells. The binding
characteristics of the lymphocyte subpopulations on bFGF (10 ng/ml)-treated HUVEC
monolayers are shown in Figure 4-3-5. A low level of adhesion was evident by all three
cell types at only the lowest shear stress, 0.56 dyn/cm2 , with no statistical difference in the
level of binding between the cells. Higher shear stresses resulted in no appreciable
accumulation of any of the lymphocytes.
Comparison of the binding levels on non-activated and TNFa-activated monolayers
indicated a statistical difference at the shear stress levels between 0.56 to 1.17 dyn/cm 2 for
CD4+ and CD56+ cells, and at 0.56 dyn/cm 2 for CD8+ cells (p < 0.05) (see Table 4-3-3).
The number of lymphocytes binding on the bFGF-treated endotfielium at the lowest shear
rate was, on average, 8- to 15-fold less than that observed for the non-activated
endothelium. This inhibition of binding was found to be directly associated with the level
of CAM expression on the monolayers and is described in further detail in Chapter 5.
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Figure 4-3-5. Cumulative binding curves of IL-2-activated CD4+, CD8+,
and CD56+ cells on bFGF activated HUVEC monolayers. Mean numbers +
SD of bound cells for five adjacent fields are shown for 1 of 3 representative
flow experiments.
Table 4-3-3. Comparison of cell binding densities of IL-2 activated CD4+, CD8+,
and CD56+ cells on HUVECs treated with bFGF for 24 hrs. Mean values ± SD are
shown for n = 3 flow experiments.
Shear stress CD4+ CD8+ CD56+
(dyn/cm2 ) (bound cells/mm 2 ) (bound cells/mm 2 ) (bound cells/mm 2)
3.51 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
2.93 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
2.34 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
1.76 0.00 ± 0.00 0.29 ± 0.93 0.00 ± 0.00
1.17 0.00 ± 0.00 * 0.00 ± 0.00 0.00 ± 0.00 *
0.56 1.18 ± 1.52 * 1.18 ± 1.52 * 0.88 ± 1.42 *
* Significant difference from baseline of the respective cell type, p < 0.05.
To further examine the effects of the negative modulation of CAM expression on
lymphocyte subpopulation binding kinetics, additional experiments were performed
combining TNFu and bFGF treatment, as previously described for the non-activated
lymphocyte subpopulations. These experiments were designed to further examine the
differences in the binding kinetics between activated lymphocyte subpopulations, and to
provide a binding substrate for circulating activated lymphocytes which may effect their
binding efficiencies differently than non-activated lymphocytes.
When HUVEC monolayers were activated with TNFo + bFGF for 24 hrs,
significant increases in activated lymphocyte binding was found for all cell types above
baseline levels for the range of shear stresses between 2.93 to 0.56 dyn/cm 2 (p < 0.05)
(see Figure 4-3-6 and Table 4-3-4). The number of cell which bound on the TNFX +
bFGF activated monolayer at 0.56 dyn/cm 2 shear stress was approximately 6- to 9-fold
higher than that found on the non-activated monolayer for CD4+, CD56+, and CD8+ cells,
respectively. Indicating the importance of CAM modulation on lymphocyte binding
characteristics.
The binding characteristics of the activated lymphocyte subpopulations on TNFc +
bFGF treated monolayers were comparable to those found on TNFca-treated monolayers.
However, key differences were noted in several specific aspects. First, differences in the
binding levels at the lowest shear stress between CD4+ cells and CD8+ cells were
significantly greater on the TNFox + bFGF activated monolayers than on the TNFx
activated monolayers, 33% vs. 13%, respectively. Similar effects were evident between
CD4+ and CD56+ cells on the TNFu + bFGF and TNFc activated monolayers, with
differences in binding levels of 40% vs. 22%, respectively. Second, there was a greater
range of shear stresses over which statistical differences were found between the CD8+ and
CD56+ cells on the TNFu + bFGF activated monolayers. However, at the lowest shear
stress, the difference in the binding levels between these two subpopulations were not
found to be statistically significant between TNFx and TNF( + bFGF treated monolayers.
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Figure 4-3-6. Cumulative binding curves of IL-2-activated CD4+, CD8+,
and CD56+ cells on TNFa + bFGF activated HUVEC monolayers. Mean
numbers ± SD of bound cells for five adjacent fields are shown for 1 of 3
representative flow experiments. * significant difference between CD4+ and
CD8+ or CD56+ cells, p < 0.05, and t significant difference between CD8+
and CD56+ cells, p < 0.05.
Table 4-3-4. Comparison of cell binding densities of IL-2 activated CD4+, CD8+,
and CD56+ cells on HUVECs treated with TNFa+bFGF for 24 hrs. Mean values ±
SD are shown for n = 3 flow experiments.
Shear stress CD4+ CD8+ CD56+
(dyn/cm 2) (bound cells/mm 2 ) (bound cells/mm 2) (bound cells/mm 2 )
3.51 0.00 ± 0.00 0.20 ± 0.76 * 0.78 ± 1.35 *,$
2.93 0.59 + 1.22 * 3.92 + 3.08 "*, 3.14 + 2.07 *,
2.34 2.94 ± 2.49 * 10.39 + 4.43 *,$ 13.53 ± 3.98 *,
1.76 8.82 ± 4.31 * 27.26 + 4.90 *, 33.14 ± 8.79 *,:,t
1.17 30.78 ± 8.23 * 54.90 + 9.35 *,$ 70.59 ± 10.95 *,to
0.56 60.98 ± 8.50 * 90.39 + 13.45 *, 100.00 + 9.37 *t$,
* Significant difference from TNFa-activated monolayers of the respective cell type, p < 0.05.
$ Significant difference compared to CD4+ cells, p < 0.05.
0 Significant difference compared to CD8+ cells, p < 0.05.
These findings are suggestive that the lower CAM expression on TNFO + bFGF
treated monolayers are reaching a threshold in which the favorable molecular binding
kinetics of CD56+ and CD8+ cells are significantly advantageous over CD4+ cells, and
CD56+ cells are advantageous over CD8+ cells.
In comparing the cell binding densities between the subpopulations on TNFa +
bFGF treated monolayers, fewer CD4+ cells consistantly bound to the endothelial
monolayer for the complete range of shear rates examined, compared to both CD8+ and
CD56+ cells (p < 0.05). The only exception occurring at 3.51 dyn/cm 2 shear stress for the
CD8+ cells. At 0.56 dyn/cm 2 shear stress, CD4+ cell binding levels were on average 33%
and 40% less than the levels obtained by CD8+ and CD56+ cells, respectively. Differences
between CD8+ and CD56+ cells were also observed, but were limited to the shear stresses
ranging from 1.76 to 0.56 dyn/cm 2 (p < 0.05). At the lowest shear rate, a 10% greater
number of CD56+ cells than CD8+ cells bound to the endothelial monolayer. These
findings suggest that IL-2 activated CD4+ cells do not increase their integrin expression as
greatly as IL-2 activated CD8+ and CD56+ cells. In addition, the CD4+ cells may also
have a lower selectin expression upon activation compared to CD8+ and CD56+ cells, thus
accounting for their lower binding levels at the higher shear stresses.
These results contrasted with those found for the non-activated cell subtypes.
Activated CD8+ cells dramatically increased their adhesiveness above the levels attained by
activated CD4+ cells for nearly the entire range of shear stresses. However, non-activated
CD4+ cells maintained higher binding levels for the mid-range shear stresses compared to
non-activated CD8+ cells. These findings indicate that the binding advantage which CD4+
cells have over CD8+ cells in the non-activated state can apparently be overcome by the
differential increase in integrin expression in favor of the CD8+ cells in the IL-2 activated
state.
Plots of the capture efficiencies for each of the lymphocyte subpopulations were
generated to further examine the adhesion kinetics on TNFc + bFGF activated monolayers,
and are shown in Figure 4-3-7. The cell accumulation curves reproducibly showed a
reduction in binding efficiency that was uniform across the range of shear stresses
examined for each of the lymphocyte subpopulations. A significantly greater slope (c) of
the capture efficiency plot was observed for CD4+ cells (1.452 ± 0.076 cm 2/dyn)
compared to CD8+ cells (1.079 ± 0.066 cm 2/dyn), as well as CD56+ cells (0.992 ± 0.027
cm 2/dyn) (p < 0.05), and is plotted in Figure 4-3-8a. No statistical difference of the
parameter ic was evident between CD8+ and CD56+ cells. These results are consistent
with those found using TNFa alone, but significant differences in the capture coefficient
values between the two monolayer treatments were found for both CD4+ and CD56+ cells
(p < 0.05). The increased value of Ic on TNFuo + bFGF treated monolayers indicates that
the CD4+ and CD56+ cells experience a relatively weaker initial binding to the
endothelium, which is the result of the decreased expression of selectins on the monolayer
surface. While the K value for CD8+ cells was not found to be significantly different
between the two treatment groups, there was a similar trend towards a larger Kc value on
TNFx + bFGF treated monolayers, and consequently a weaker initial binding force. These
results are in agreement with the findings that monolayers treated with TNFx + bFGF
approach a threshold of CAM expression, whereby variations in the binding kinetics for
each of the activated lymphocyte subpopulations become evident for a relatively broad
range of physiological shear stresses.
In comparison with the non-activated lymphocyte subsets, the activated
lymphocytes showed a differential effect on the value of the capture coefficient. Activated
CD4+ cells demonstrated a significantly increased value for c (1.452 ± 0.076 vs 1.179 +
0.072 cm 2/dyn). As was hypothesized in the comparison between binding characteristics
of CD4+ cells on TNFa-activated endothelium, this may be attributable to a reduced level
of selectin expression maintained by CD4+ cells in the activated state. In contrast, CD8+
and CD56+ cells showed significant decreases in their K values between the activated and
non-activated states. A possible reason for this occurrance may be the increased expression
of a 031 integrin (VLA-4) on the activated lymphocytes, which has been shown to have an
overlapping role in the capture process.
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Figure 4-3-7. Comparison of binding efficiencies between IL-2-activated
CD4+, CD8+, and CD56+ cells on TNFa + bFGF activated HUVEC
monolayers (n = 3).
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Figure 4-3-8. Comparison of the fitted parameters: a) , capture coefficient,and b) Eo, efficiency at zero shear generated from the capture efficiency plots
of activated lymphocytes on TNFa + bFGF activated monolayers. R2greater than 0.96 in all cases. * p < 0.05.
An analysis of the fitted parameter Eo showed no statistically significant difference
between any of the activated lymphocyte subpopulations or between the two monolayer
groups for the respective lymphocytes (see Figure 4-3-8b). Therefore, the differences
found in the binding kinetics and in the capture coefficient between the lymphocyte
subpopulations may be the result of selective molecular interactions. The selectins and 31I
integrins are functionally more dominant at the higher flow rates, and would explain thedifferences observed. The increased binding efficiency found when comparing non-
activated and IL-2 activated CD8+ and CD56+ cells provides additional evidence to the role
of 01 integrins in this process.
4.4 IL-2 Activated Natural Killer Cell Binding Mechanisms
To further elucidate the molecular mechanisms mediating activated CD56+ or A-NK
cell adhesion under a range of physiological shear stress conditions, additional studies were
performed using monoclonal antibodies (mAbs) as blocking agents against selective
CAMs. For these studies, HUVEC monolayers were activated with either TNFoc (50
ng/ml) or tumor interstitial fluid (TIF, 1:50 dilution) for 24 hrs, and unactivated
monolayers were used as baseline controls. Monoclonal antibodies were added in excess
30 min prior to use in the flow assay, as described in Section 3.5. Cumulative cell binding
densities of A-NK cells were determined using the flow chamber under shear stress
conditions ranging from 0.56 to 3.5 dyn/cm2 .
The use of tumor interstitial fluid, a milieu of growth factors and other tumor
products, provided an in vitro model for the potential microenvironmental conditions
experienced by endothelial cells in a tumor. The incubation time of 24 hrs was selected to
reflect prolonged exposure of the endothelium to tumor fluid, and was accordingly
analyzed for its ability to alter CAM expression (see Section 5.2).
Experiments involving TIF-mediated activation demonstrated increased A-NK cell
adhesion to the endothelium, with significant increases in binding between 2.0 and 0.56
dyn/cm 2 (see Figure 4-4-1). The number of bound cells on the TIF-activated monolayer at
0.56 dyn/cm 2 was approximately 10-fold higher than that on the untreated monolayer.
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Figure 4-4-1. Cumulative binding curves of A-NK cells on TIF-activated
and non-activated endothelial cell monolayers. Mean numbers ± SD of
bound cells for five adjacent fields are shown. * p < 0.05.
The relative influence of the receptor-ligand interaction between CD 18, ICAM-1
and ICAM-2 was found to provide a significant contribution to A-NK cell binding, as
demonstrated by mAb blocking (see Figures 4-4-2 and 4-4-3). The effect of independently
blocking ICAM-1 and ICAM-2 produced a 40-50% decrease in the number of cells bound
under a wall shear stress of 0.56 dyn/cm 2 compared to TIF only treated monolayers.
Blocking of the shared receptor, CD18, showed an average decrease of 70-75%. This
reduction was significant between 0.56 to 2.0 dyn/cm 2 for LFA-1 and corresponding
counter-receptor blocking (p < 0.05). When ICAM-1 and ICAM-2 were blocked
simultaneously, the level of binding was reduced further to a total of 65-70% from
controls, and reached levels attained by CD18 blocking. This result was consistent with
the involvement of the two ICAM molecules in interacting with lymphocyte-associated
LFA-1 in forming stable adhesion at low shear stresses.
The 13-integrin, VLA-4 (CD49d), and its corresponding ligand on the endothelium,
VCAM-1, was found to also produce a significant effect on cell binding (see Figure 4-4-4).
Blocking of VCAM-1 produced a 45-55% decrease in the number of cells bound under a
wall shear stress of 0.56 dyn/cm 2 compared to TIF controls, while blocking of VLA-4
produced an average decrease of 70-80%. The reduction in binding was significant up to
shear stresses as high as 2.0 dyn/cm2 (p < 0.05). The discrepancy between the relative
contributions of VLA-4 and VCAM-1 on A-NK adhesion was found to be statistically
significant (p < 0.05). This suggests that an additional ligand may exist on endothelial cells
which interacts with the 1i-integrin, or that the blocking antibodies may have different
affinities or blocking efficiencies.
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Figure 4-4-2. A-NK cell adhesion to TIF-activated HUVEC monolayers
showing the role of CD18:ICAM-1 using monoclonal antibody blocking.
Mean numbers + SD of bound cells for five adjacent fields are shown. * p <
0.05.
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Figure 4-4-3. A-NK cell adhesion to TIF-activated HUVEC monolayers
showing the role of ICAM-1:ICAM-2 using monoclonal antibody blocking.
Mean numbers ± SD of bound cells for five adjacent fields are shown. * p <
0.05.
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Figure 4-4-4. A-NK cell adhesion to TIF-activated HUVEC monolayers
showing the roles of VLA-4:VCAM-1 using monoclonal antibody blocking.
Mean numbers ± SD of bound cells for five adjacent fields are shown. * p <
0.05.
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The relative contribution of the selectin molecules, namely E- and P-selectin, and
their common ligand, sialyl Lewis X, was found to produce modest effects on A-NK cell
adhesion only at the lowest levels of shear stress examined (see Figure 4-4-5 and Figure 4-
4-6). The slight but significant (p < 0.05) reduction in adhesion of A-NK cells at 0.6
dyn/cm2 was by 15%, 7%, and 7% for sialyl-Lewis X, E- and P-selectin mAb treatment,
respectively. As was found with the anti-integrin antibody treatments, stable adhesion of
the flowing cells on the activated endothelium occurred rapidly and displayed no significant
rolling interactions even after prolonged arrest. This provided further evidence of a process
which is largely independent of a selectin-mediated mechanism. However, it is
unprecedented that a modest level of inhibition of A-NK cell binding occurred at the low
shear stress by antibody blocking of the E- and P-selectin, as well as their counter-receptor,
sLeX. These molecules have been characterized as principally mediating the inital phase of
capture, which is most relevant at the higher shear states [von Andrian, et al., 1991].
Additional studies will be needed to further characterize their possible role in A-NK cell
adhesion.
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Figure 4-4-5. A-NK cell adhesion to TIF-activated HUVEC monolayers
showing the role of E-selectin and sialyl-Lewis X using monoclonal
antibody blocking. Mean numbers ± SD of bound cells for five adjacent
fields are shown. * p < 0.05.
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Figure 4-4-6. A-NK cell adhesion to TIF-activated HUVEC monolayers
showing the role of P-selectin using monoclonal antibody blocking. Mean
numbers ± SD of bound cells for five adjacent fields are shown. * p < 0.05.
To define the cooperative function of the 131 and P2 integrins in the adhesion of A-
NK cells to vascular endothelium, A-NK cells were treated with a combination of anti-
CD18 and anti-VLA-4. As shown in Figure 4-4-7a, the combined treatment resulted in
fewer bound cells than either antibody treatment alone (p < 0.05), and the overall number
of bound cells reached baseline levels for all shear stress examined (p > 0.1). Identical
results were obtained by blocking the corresponding ligands on the endothelial cells, i.e.
ICAM-1 and VCAM-1 (see Figure 4-4-7b).
While the results obtained with TIF-activation of HUVEC monolayers conclusively
demonstrated an integrin-dominated cell capture process by A-NK cells, a multiple number
of factors may contribute to the effect produced by TIF, and provide an inherent kinetic
advantage of A-NK cells to utilize a strongly integrin-dominated binding process. To
provide additional support to the findings, binding studies identical to those performed with
TIF were conducted using TNFx to further verify the molecular mechanisms used by A-
NK cells in binding to endothelial cell monolayers.
Results involving TNFa-activation of the endothelium, which causes an uniform
upregulation of ICAM- 1, VCAM- 1 and E-selectin, demonstrated significantly increased A-
NK cell adhesion between 2.0 and 0.56 dyn/cm 2 (see Figure 4-4-8). The number of
bound cells on the TNFa-activated monolayer at 0.56 dyn/cm2 was also approximately 10-
fold higher than that on the non-activated monolayer, a finding similar to that which was
seen with TIF treatment.
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Figure 4-4-7. A-NK cell adhesion to TIF-activated HUVEC monolayers
showing the combined effects of blocking a) CD 18 and VLA-4 on A-NK
cells, and b) ICAM-1 and VCAM-1 on endothelial cells. Mean numbers +
SD of bound cells for five adjacent fields are shown.
Antibody blocking experiments corroborated the findings that A-NK cells adhere to
activated endothelium by an integrin-mediated interaction process involving CD 18/ICAM-1
and VLA-4/VCAM-1 (Figure 4-4-8a and b). Pretreatment of the endothelial cells with anti-
E- or anti-P-selectin showed only a slight, but significant inhibition of A-NK binding at the
low shear stress (p < 0.05). This was in agreement with the previous findings
demonstrating that A-NK cells largely use a selectin-independent binding process. In
addition, as was found with flowing cells on TIF-activated monolayers, rapid arrest
occurred independently of rolling interactions.
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Figure 4-4-8. A-NK cell adhesion to TNFac-activated HUVEC monolayers
showing the roles of a) P1 and P2 integrins, and b) E- and P-selectin using
monoclonal antibody blocking. Mean numbers ± SD of bound cells for five
adjacent fields are shown. * p < 0.05.
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To quantify the level of adhesion receptors available for A-NK cells to bind to
activated endothelial cell monolayers, flow cytometric analysis was periodically performed
to several cultures. Results consistently showed high levels of Pi (VLA-4) and P2 (CD18)
integrin expression, 50-80% and 90-95%, respectively (see Figure 4-4-9). Levels of L-
selectin (35-45%) and sialyl-Lewis X (10-20%), counter-receptors for E- and P-selectin,
were also significantly present but in lower quantities. For the period of time in which the
NK cultures were utilized, between 1.5 to 4 weeks, there was no appreciable shedding or
increase in expression of any of the receptors analyzed.
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Figure 4-4-9. A-NK expression levels of CD18, VLA-4, L-selectin, and
sialyl Lewis X. PBS and IgG isotype staining are provided as controls.
Percentage of positive gated cells ± SD for three separate IL-2 activated NK
cultures are shown. Gates for positive cells were arbitrarily placed based
upon the IgG isotype control fluorescence. See Appendix A for the flow
cytometric histograms.
4.5 Conclusions
The important results obtained from the in vitro studies presented in this chapter can
be generally summarized into the following: a) the lymphocyte subpopulations CD4+,
CD8+, and CD56+, vary in their ability to adhere to activated vascular endothelium, b) IL-
2 activated lymphocytes differ in their ability to bind to vascular endothelium compared to
non-activated populations, with lymphocyte subset variability, and c) IL-2 activated natural
killer cells (CD56+) largely utilize an integrin-dependent (P1 and P2), selectin-independent
adhesion process in binding to activated vascular endothelium.
The lymphocyte subset binding characteristics broadly demonstrated the increased
ability of CD56+ cells, compared CD8+ and CD4+ cells, to adhere to HUVEC monolayers
under a wide range of shear stresses. In the unactivated state, CD4+ and CD8+ cells
bound to the endothelium with relatively equivalent kinetics under high levels of CAM
expression. However, increased binding levels of CD4+ cells were obtained under
reduced levels of counter-receptor expression on the endothelium. Non-activated CD4+
cells may be more dependent on a selectin-mediated mechanism, while non-activated CD8+
cells may utilize a greater integrin-mediated mechanism in binding, as suggested by the
capture efficiency studies.
However, in the IL-2 activated state, CD8+ cells clearly demonstrated an increased
binding level over CD4+ cells, regardless of the extent of counter-receptor expression.
This is consistent with previous studies on tumor-infiltrating lymphocytes containing
proportionally greater levels of CD8+ cells compared to CD4+ 'ells [Takagi, et al., 1989;
Yoo, et al., 1990]. The findings in these experiments are likely to be associated with a
decrease in selectin expression on CD4+ cells and a significantly increased integrin
expression on CD8+ cells following IL-2 mediated activation.
The overall effect of 1L-2 activation was found to increase the binding efficiencies
of each of the lymphocyte subsets. Based on the findings of others demonstrating
increased integrin expression by lymphocytes following IL-2 activation [Roth, 1994;
Melder and Jain, 1992], this may be the major contributor to the increased binding effect.
Additionally, the demonstration of the greater reduction or shedding of L-selectin by
activated CD4+ cells compared to CD8+ cells [Biselli, et al., 1992], may also be
appreciably relevant to the binding characteristics observed.
Further definition of the specific molecular mechanisms used by IL-2 A-NK cells
under dynamic flow conditions complimented previous studies characterizing T cell
(CD3+) capture and adhesion on activated endothelium. While T cells have demonstrated a
significant involvement of selectins in cell capture and the integrins, P1 and 32, in stable
arrest, NK cells were shown in this investigation to largely involve 01 (VLA-4) and 12
(CD18) interactions, with minimal contribution from the selectins. Additionally,
monolayers activated with tumor interstitial fluid were able to retain A-NK cells under
physiological shear stress conditions, providing an in vitro model to the localization of A-
NK cells in tumor vessels.
Several in vivo studies were conducted in collaboration with this work to provide
validation of the in vitro findings [Melder, et al., 1996]. Using LS 174T tumors grown in
the cranial window of SCID mice, human A-NK cells treated with a combination of anti-
CD18 and anti-VLA-4 mAbs were adoptively transfered and shown to significantly
decrease their retention in tumor vessels. These studies also showed rapid binding of the
A-NK cells without rolling interaction in the control mice, providing further support to the
in vitro findings.
Contributions of this work to the field of cell adhesion will have impact on: a)
improving current modeling schemes which attempt to predict the biodistribution of effector
cell populations by providing essential binding kinetic data for each of the subpopulations;
b) providing additional insight into the binding kinetics of helper and effector cell
populations in areas of active immunological response; and c) contributing to a better
understanding of the biophysical and molecular mechanisms used by lymphocytes to
potentially improve or modify current adoptive immunotherapy techniques for cancer
treatment.
Chapter 5
CAM Modulation by Angiogenic
Factors
5.1 Introduction
The adherence of lymphocytes and tumor cells to vascular endothelium is a
necessary step in producing an effective immune response and developing metastases,
respectively. The process requires adhesion receptors found on the lymphocytes or cancer
cells to bind to complementary counter-receptors or ligands on endothelial cells. The cell
adhesion molecules (CAMs) on the endothelium are grouped into two distinct families:
selectins (E- and P-), which primarily mediate the initial capture and rolling of cells; and the
immunoglobulin gene superfamily members, ICAM-1, ICAM-2, and VCAM-1, which
mediate stable adhesion [Springer, 1995; Butcher, 1991]. The expression of the CAMs on
the endothelium can be modulated and regulated by cytokines and growth factors released
by resident tissue cells, infiltrating leukocytes, and/or cancer cells during inflammatory,
immune, and tumor responses [Pober and Cotran, 1990; Freeman, et al., 1995; Jain, et al.,
1996]. Many of these same cytokines and growth factors mediate angiogenesis, and are
conjointly termed angiogenic factors [Folkman, 1995; Fidler and Ellis, 1994]. TNFoa,
VEGF, bFGF, and TGFOJ are four widely documented angiogenic factors which are
present in sites of inflammation, healing wound, and tumor growth [Pober and Cotran,
1990]. The temporal kinetics of CAM modulation by the individual factors alone, or in
combination with each other, have only been explored to a limited extent and are not well
defined.
The expression of both constitutive and inducible CAMs on normal endothelium
has been found to be tissue or organ dependent [Kuzu, et al., 1993]. Specifically, the
expression of CAMs in the tumor vasculature has been shown to be heterogeneous, both
intra-tumorally and inter-tumorally [Jain, et al., 1996]. A positive correlation between the
accumulation of inflammatory cells and the expression of specific CAMs in tumor vessels
have been demonstrated [Suzuki, et al., 1995]. These observations are suggestive of the
tumor microenvironment providing a significant contribution to modulating CAM
expression and, thereby, regulating the infiltration of leukocytes. Insight into the
regulation of adhesion molecule expression and leukocyte-endothelial interactions by
angiogenic factors found in tumor has been significantly limited.
In this chapter, results are presented from several experiments using targeted
sampling fluorometry, flow cytometry, and the parallel-plate flow chamber to address the
following essential issues: a) what effect does the interstitial fluid from tumors (TIF), a
model of the tumor microenvironment, have on CAM expression in endothelial cells; b)
what are the levels of angiogenic factors in the tumor fluid, which may establish a
mechanism for its ability to modulate CAM expression; c) what are the kinetics of CAM
expression in endothelial cells treated independently, or in combination, with the known
angiogenic factors TNFuo, VEGF, bFGF, and TGFI; and d) what is the functional
significance of the effects of TIF and angiogenic factors on lymphocyte binding to treated
endothelial cells under dynamic flow conditions?
The findings from these studies provide additional understanding of the role of
angiogenic factors in regulating the host response to sites of tumor growth and
inflammation, as well as in modifying the metastatic potential of tumors.
5.2 Surface Expression and Activation Kinetics
The first objective of this investigation was to determine the level and kinetics of
cell surface adhesion molecule expression on endothelial cells activated by TIF and various
angiogenic factors. Two expression assays were used to perform this task: a) flow
cytometric analysis (FACScan), and b) targeted sampling fluorometry (TSF). The results
are presented as intensity histograms with the number of counts or percentage of cells
compared to the fluorescence intensity measured. The temporal kinetics of activation or
inhibition, whichever the case may be, were analyzed at 6 and 24 hr time points. These
time points were selected based on preliminary experiments demonstrating that 6 and 24 hrs
were representative of early and long-term responses, respectively.
5.2.1 Tumor Interstitial Fluid (TIF)
The use of tumor interstitial fluid to activate the endothelial monolayer was initially
performed to determine whether the expression of CAMs on the endothelium could be
modulated by the modeled tumor microenvironment. An incubation time of 24 hrs was
selected to reflect prolonged or chronic exposure of the endothelium to tumor fluid.
The resulting expression profiles of ICAM-1, VCAM-1, E-selectin and P-selectin
are shown in Figure 5-2-1a-d. In response to TIF activation, surface expression of ICAM-
1 and VCAM-1 was significantly upregulated compared to untreated cells. E-selectin also
showed a slight increase in expression, but P-selectin expression was not altered by the
TIF. These findings provide distinct evidence that within and locally around a tumor,
CAM expression on endothelial cells can be altered by factors existing in the tumor
microenvironment.
Various agents may exist in the tumor microenvironment that could potentially
mediate the increased CAM expression on endothelial cells, including inflammatory
cytokines and angiogenic factors. To ascertain the possible constituents present in the TIF,
an enzyme-linked immunosorbent assay was utilized to determine the levels of VEGF,
bFGF, and TNFa in the fluid. These cytokines or angiogenic factors were selected based
on previous findings of their expression within tumors [Senger, et al., 1993; Rodeck, et
al., 1991; Bebok, et al., 1994; Dalal, et al., 1993; Folkman, 1995].
As shown in Figure 5-2-2, the level of VEGF, bFGF, and TNFU was found to be
14.23 ± 2.55 ng/ml, < 0.40 ng/ml, and < 0.10 ng/ml, respectively. Due to the relatively
small quantities of fluid available with each collection, which is estimated at less than 50 gl
per mouse, and the heterogeneity which exists between samples, the lower limit of accurate
detection was obtained for the latter two samples. However, functional analysis using the
adhesion assay, as well as published results using various angiogenic assays [Frater-
Schroder, et al., 1987; Montesano, et al., 1986], have shown these levels to be at the lower
limit of biological responsiveness for endothelial cells. Additionally, the concentration of
the TIF used in the expression experiments was at a dilution of 1:50, further lowering the
relative dosage of growth factor experienced by the endothelial cells. Therefore, the TIF
sampled can be cautiously interpreted as having significant levels of VEGF, but
significantly low concentrations of bFGF and TNFu. Additional studies using Northern
blot analysis to determine the RNA levels of VEGF and bFGF in LS 174T tumors have
shown a strong correlation with these protein expression results3
3 Communicated by Dr. Kyungran Park, Department of Radiation Oncology, Massachusetts General
Hospital.
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Figure 5-2-1. Kinetics of CAM expression on HUVEC monolayers treated
with LS 174T TIF for 24 hrs using targeted sampling fluorometry: a) ICAM-
1, b) VCAM-1, c) E-selectin, and d) P-selectin. - = TIF treatment (1:50),
- - = no treatment (baseline), -.. = IgG isotype control.
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However, relative caution should be considered in interpreting these results due to
several limitations in the overall analysis. Firstly, the viability of the protein within the
fluid has not been determined, only the overall level of protein expression. Significant
levels of proteases within the tumor may modulate the effectiveness of the growth factor at
its receptor binding site, but not at the epitope site for antibody binding. Secondly, cross-
reactivity issues may be a factor since the fluid is extracted from xenotransplanted tumors.
There may be sufficient amounts of growth factor produced by the host cells of the mouse
that are influencing the tumor microenvironment, and thus the responsiveness of the
endothelial cells to the TIF in culture. Thirdly, other potent factors, such as IL- 10, IFN-y,
and TGFi, may exist in the tumor fluid and provide a major regulatory mechanism to the
CAM expression observed. Additionally, the fluid collected using the Gullino chamber
represents the minimum level of protein present in the tumor interstitial compartment. The
absence of growth factor in the TIF collected does not negate its presence in the tumor, but
rather may be a limitation of the collection technique. Lastly, the tumor fluid extracted is an
average, global representation of the environment within a tumor, rather than a local
microenvironmental representation. Given the fact that tumors are exceptionally
heterogeneous and that CAM expression has been shown to vary from one region to the
other, local variation in the level of growth factor may not be representative of the global
milieu. To this end, there was also found a general lack of correlation between the level of
VEGF produced by these tumors and their ability to regulate lymphocyte-endothelial
interaction, as indexed in Figure 5-2-2a.
Considering these limitations and the finding that of the growth factors analyzed,
only significant levels of VEGF, and not bFGF or TNFa, were produced by the LS 174T
tumor line, a detailed analysis was performed on the kinetics of CAM expression on
endothelial cells activated with the individual angiogenic factors TNFa, VEGF, bFGF and
TGFP. Other tumors, such as mammary carcinomas and melanomas, have been shown to
express high levels of these angiogenic factors, and thus warrant their investigation.
5.2.2 TNFa
Tumor necrosis factor-a, a pro-inflammatory cytokine, at a concentration of 50
ng/ml was placed on HUVEC monolayers. The temporal kinetics were determined for
ICAM-1, VCAM-1, E-selectin, and P-selectin. Although the kinetics of this endogenous
stimulator have been well characterized, differences in culture medium conditions (serum-
free), endothelial cell phenotype (HUVEC), and confluency level (greater than 90%) may
have altered the responsiveness of the endothelial cells to the cytokines and growth factors
examined. These variables were utilized as controls.
As shown in Figure 5-2-3 using flow cytometric analysis, the expression of ICAM-
1, VCAM-1 and E-selectin were all substantially increased above baseline levels by 6 hrs,
while P-selectin showed no significant difference from controls. By 24 hrs, ICAM-1,
VCAM-1 and E-selectin levels for the TNFa-activated monolayer continued to be
significantly above the non-treated controls, and P-selectin remained at baseline levels.
These results are in agreement with those previously documented [Osborn, 1990;
Munn, et al., 1995], and indicate that TNFa is a rapid and potent inducer of CAMs on the
endothelium.
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Figure 5-2-3. Kinetics of CAM expression on HUVEC monolayers treated
with TNFa for 6 and 24 hrs using flow cytometry: a) ICAM-1 (6 hr), b)
ICAM-1 (24 hr), c) VCAM-1 (6 hr), d) VCAM-1 (24 hr), e) E-selectin (6
hr), f) E-selectin (24 hr), g) P-selectin (6 hr), and h) P-selectin (24 hr). - =
TNFa treatment (50 ng/ml), - - = no treatment (baseline), ... = IgG isotype
control.
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5.2.3 VEGF
Vascular endothelial growth factor was the next angiogenic factor considered in this
investigation. While VEGF is widely known for its mitogenic and permeability enhancing
activity, its capability for altering CAM expression has largely been ignored. Using a
concentration of 35 ng/ml, as conjectured from studies on its angiogenic activity, the
temporal kinetics were determined for each of the CAMs and the results are shown in
Figure 5-2-4.
As was found for the TNFxo experiments, VEGF induced increased levels of
ICAM-1, VCAM-1 and E-selectin by 6 hrs of incubation on endothelial cells. P-selectin
was found to be unchanged from control levels. By 24 hrs of treatment, ICAM-1 remained
at substantially higher levels above controls, while P-selectin remained at baseline levels.
The expression of VCAM-1 and E-selectin, while reduced compared to their respective
levels at 6 hrs, remained significantly above the non-treated levels at 24 hrs.
Since a) VEGF can induce increased ICAM-1, VCAM-1 and E-selectin expression
on endothelial cells, similar to TIF, and that b) VEGF was found in substantial quantities in
the tumor fluid, suggests that VEGF may be a mediator TIF modulation of CAM
expression in tumors. However, the concentration of VEGF in the TIF was found not to
correlate with the ability of TIF to modify CAM expression. This suggests that another
mediator may be involved which either inhibits the action of VEGF or is a co-activator of
VEGF in altering CAM expression on endothelial cells. Basic FGF and TGF were
studied next as possible inhibitory agents of CAM expression.
5.2.4 bFGF
Basic fibroblast growth factor, another potent mitogenic and angiogenic factor, has
been shown to increase the expression of several alpha and beta integrins [Klein, et al.,
1993], but its effect on CAM modulation is poorly understood [Kitayama, et al., 1994;
Griffioen, et al., 1996]. Using a concentration of 10 ng/ml, as determined from several
angiogenic studies, the temporal kinetics were determined for each of the CAMs and the
results are shown in Figure 5-2-5.
Basic FGF was found to produce a biphasic effect on ICAM-1 expression. After 6
hrs of activation with bFGF, endothelial cells expressed a slight, but significant increase in
ICAM-1 expression. However, after 24 hrs of treatment, the endothelial cells showed a
slight, but significant decrease in the basal expression of ICAM-1 compared to non-treated
controls. The levels of VCAM-1, E-selectin and P-selectin were unaffected by bFGF
treatment at 6 and 24 hrs compared to baseline expression.
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Figure 5-2-4. Kinetics of CAM expression on HUVEC monolayers treated
with VEGF for 6 and 24 hrs using TSF: a) ICAM-1 (6 hr), b) ICAM-1 (24
hr), c) VCAM-1 (6 hr), d) VCAM-1 (24 hr), e) E-selectin (6 hr), f) E-
selectin (24 hr), g) P-selectin (6 hr), and h) P-selectin (24 hr). - = VEGF
treatment (35 ng/ml), - - = no treatment (baseline), ... = IgG isotype
control.
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Figure 5-2-5. Kinetics of CAM expression on HUVEC monolayers treated
with bFGF for 6 and 24 hrs using flow cytometry: a) ICAM-1 (6 hr), b)
ICAM-1 (24 hr), c) VCAM-1 (6 hr), d) VCAM-1 (24 hr), e) E-selectin (6
hr), f) E-selectin (24 hr), g) P-selectin (6 hr), and h) P-selectin (24 hr). - =
bFGF treatment (10 ng/ml), - - = no treatment (baseline), ... = IgG isotype
control.
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The unique biphasic regulation of ICAM-1 expression by bFGF has been
simultaneously verified by others [Griffioen, et al., 1996], but the kinetics of the response
profile have been shown to lag that found in this investigation. One explanation for this
discrepancy is that under serum-free conditions, as was used in the studies presented here,
endothelial cells showed an accelerated response to bFGF compared to endothelial cells in
the continued presence of serum. Since serum contains significant levels of various growth
factors, including bFGF, exogenous stimulation by additional growth factor may result in a
longer response time by the endothelial cells.
While the modulation of ICAM-1 by bFGF alone may be used to explain the minor
variability observed in ICAM-1 expression within various tumors, bFGF appears not to
play a significant role in the expression characteristics found using the LS 174T tumor
interstitial fluid, as suggested by the ELISA results (see Section 5.2.1).
5.2.5 TGFP
Transforming growth factor-n (TGF3), a multifunctional agent eliciting a broad
range of pleiotropic responses, was examined as a final possible mediator of CAM
expression in angiogenic tissue. TGF3 has been previously shown to inhibit the adhesion
of T lymphocytes and neutrophils to untreated and TNFa-treated human endothelium,
respectively, through an E-selectin-mediated mechanism [Gamble and Vadas, 1988;
Gamble and Vadas, 1991]. However, the kinetics of the CAM regulation in this system
have not been explored in detail.
To this end, the temporal kinetics of CAM expression on HUVEC monolayers
treated with TGFP (10 ng/ml) were studied and the results are shown in Figure 5-2-6.
Compared to baseline levels of non-treated controls, monolayers treated for 6 hrs with
TGF demonstrated no significant differences in the expression of ICAM- 1, VCAM- 1, E-
selectin and P-selectin. Similarly, no significant differences were observed at 24 hrs.
While the absence of a change in ICAM-1, VCAM-1 and P-selectin expression was
in agreement with previous findings, the ability of TGFI to reduce E-selectin expression
was not evident in this investigation. The baseline level of E-selectin expression was also
sufficiently low that an accurate comparative analysis could not be performed and may
explain this discrepancy. Differences in culture conditions, including the addition of serum
to the culture medium, did not produce any significant changes to baseline levels and the
results remained indifferent.
These findings suggest that TGFP is not one of the major mediators which may be
acting to regulate the CAM expression on endothelial cells by TIF, even in lieu of its
reported E-selectin modulation.
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Figure 5-2-6. Kinetics of CAM expression on HUVEC monolayers treated
with TGFP for 6 and 24 hrs using flow cytometry: a) ICAM-1 (6 hr), b)
ICAM-1 (24 hr), c) VCAM-1 (6 hr), d) VCAM-1 (24 hr), e) E-selectin (6
hr), f) E-selectin (24 hr), g) P-selectin (6 hr), and h) P-selectin (24 hr). - =
TGFp treatment (10 ng/ml), - - = no treatment (baseline), ... = IgG isotype
control.
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5.2.6 Combination of Angiogenic Factors
While the characterization of the kinetics of cell surface adhesion molecule
expression by the individual cytokines and growth factors is essential for their fundamental
understanding, several growth factors and cytokines may be acting simultaneously to
influence the microenvironment in tumor or inflammation [Cotran and Pober, 1990]. The
individual angiogenic factors may synergize, augment or inhibit the responsiveness of
endothelial cells to other factors, and thus influence the expression of CAMs on the cell
surface [Jain, et al., 1996]. To further study the responsiveness of endothelial cells to
positive modulators of CAM expression, namely TNFx and VEGF, the angiogenic factor
basic FGF was simultaneously applied to the monolayers. The levels of ICAM-1, VCAM-
1, E-selectin, and ICAM-2 (a constitutively expressed adhesion molecule [Stauton, et al.,
1989]) were measured. The analysis also provided a means for overcoming the limitation
of observing the effect of bFGF on CAMs expressed at low baseline levels.
The expression kinetics of HUVEC monolayers activated with TNFx (50 ng/ml),
bFGF (10 ng/ml), and the combination of TNFa + bFGF are shown in Figures 5-2-7 and
5-2-8. Following 6 hrs of incubation, there was no significant difference in the levels of
ICAM-1 or VCAM-1 induced by TNFx in the presence of bFGF. The slight increase in
ICAM-1 expression produced by bFGF alone compared to controls, did not augment the
level produced by TNFa. The exceptionally potent effects of TNFa on ICAM-1
expression may provide an overwhelming stimulus to the endothelial cells and limit their
sensitivity to a far less potent stimulus.
However, slight differences were observed in the levels of E-selectin expressed by
the endothelial cells when exposed to TNFz alone and TNFx + bFGF. The significant
inhibition of TNFa-induced E-selectin by bFGF was not observed when HUVECs were
treated with bFGF alone. However, as observed for TGFO, this may have been the result
of low baseline levels of E-selectin expression.
No differences were found in the alteration of the constitutively expressed ICAM-2
molecule by TNFa, bFGF, or the combination of the two angiogenic factors. Therefore, a
selective modulation of the CAMs is imposed by bFGF at 6 hrs post-treatment on activated
endothelium.
Following 24 hrs of co-incubation, significant differences were observed in several
of the CAMs studied (Figure 5-2-8). The levels of TNFa-induced ICAM-1, VCAM- 1 and
E-selectin expression were significantly reduced on monolayers treated with bFGF. No
differences in the level of ICAM-2 expression for the co-incubated monolayers compared to
controls were observed at 24 hrs post-treatment.
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Figure 5-2-7. Kinetics of CAM expression on HUVEC monolayers treated
with a combination of TNFa (50 ng/ml) and bFGF (10 ng/ml) for 6 hrs
using TSF: a) ICAM-1, b) VCAM-1, c) E-selectin, and d) ICAM-2.
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As was found for the individual treatments, bFGF acts to inhibit or decrease the
sensitivity of endothelial cells to the expression of ICAM-1 by 24 hrs. Also, the slight
suppressive effect which bFGF elicited on E-selectin at 6 hrs, continued through the 24 hr
period. The additional finding that VCAM-1 expression is inhibited by bFGF at 24 hrs,
and not at 6 hrs post-treatment, suggests a possible difference in the response kinetics of
selectives CAMs to bFGF.
Combined studies with VEGF and bFGF were also performed and demonstrated
similar results to those found for TNFa and bFGF. Considering the similar temporal
kinetics of CAM expression by VEGF and TNFa, and the potential use of similar down-
stream secondary messengers in regulating CAM expression, these results seemed
reasonable. However, the results were especially interesting since VEGF and bFGF are
known to synergistically cause endothelial cell proliferation and act via similar receptor
tyrosine kinase signaling pathways [Goto, et al., 1993; Carpenter, 1987]. Further
elucidation of the signaling pathways used by the two molecules is needed to explain these
results and is described in Chapter 6.
5.3 Functional Correlation
The expression studies described above demonstrated differential regulation of the
CAMs on the endothelial cells by the angiogenic factors and are suggestive of the induction
of functional changes in lymphocyte-endothelial cell adhesion. To provide functional
relevance of the expression findings, the adhesion assay involving the parallel-plate flow
chamber was utilized. Activated natural killer cells, whose specific molecular mechanisms
of cell adhesion have been defined in Chapter 4, served as the lymphocyte effector
population.
5.3.1 TIF
As demonstrated in Chapter 4, activation of HUVEC monolayers with TIF (diluted
1:50) for 24 hrs resulted in significant accumulation of A-NK cells under physiological
flow conditions (see Figure 5-3-1). The greatest increase in binding was observed for the
low shear rate ranges, the kinetics of which are suggestive of integrin-mediated binding.
Antibody blocking experiments demonstrated that ICAM-1 and VCAM-1 were the major
adhesion molecules involved in the adhesion process, which strongly correlated with
significant increases in ICAM-1 and VCAM-1 expression induced by TIF on the
endothelial cells.
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5.3.2 Individual Angiogenic Factors
To determine the functional relevance of the expression results for the individual
angiogenic factors TNFa, VEGF, bFGF and TGFP, adhesion studies were performed.
Dose response curves were initially determined for each of the factors and are shown in
Figures 5-3-2 (TNFa, TGFP) and 5-3-3 (VEGF, bFGF). Non-activated monolayers
served as the baseline control, and A-NK adhesion was measured under flow conditions
producing a wall shear stress of 1 dyn/cm2 . Total incubation time for all of the cytokines
and growth factors was kept constant at 24 hr.
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Figure 5-3-1. Cumulative binding curves of A-NK cells on TIF-activated
(24 hr) and non-activated endothelial cell monolayers. Monoclonal antibody
blocking of ICAM- 1 and VCAM- 1 are additionally shown. Mean numbers +
SD of bound cells for five adjacent fields are shown.
The dose response of TNFa-activated monolayers showed significantly elevated
levels of A-NK binding for concentrations as low as 1 ng/ml, with optimal levels between
20 and 40 ng/ml. The concentration of 50 ng/ml used in the expression assay correlated
well with the functional response at this dosage. The elevated levels of ICAM-1 and
VCAM-1 induced by TNFx following 24 hr of incubation could readily explain these
functional results, and additional antibody blocking experiments confirmed this hypothesis.
Titrations of the growth factor TGFO, ranging from 100 pg/ml to 50 ng/ml, showed
no statistically significant differences from baseline controls (Figure 5-3-2). This finding
correlated well with the expression results showing no changes in the baseline expression
of ICAM- 1, VCAM- 1 and E-selectin following 24 hrs of TGFP treatment.
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Figure 5-3-2. TNFa and TGF3 dose response curves of activated NK cell
binding to HUVEC monolayers treated with the cytokines for 24 hr. A flow
rate corresponding to 1 dyn/cm 2 wall shear stress was imposed. Mean
numbers ± SD of bound cells for eight adjacent fields are shown for 1 of 3
representative flow experiments.
HUVEC monolayers treated with a broad range of dosages of VEGF for 24 hrs
demonstrated significant levels of A-NK binding (Figure 5-3-3). The optimal
concentration was found to be approximately 35 ng/ml, similar to that used for the
expression analysis. The VEGF-induced upregulation of ICAM-1 and VCAM-1 correlated
well with the lymphocyte binding levels found using the adhesion assay.
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Figure 5-3-3. VEGF and bFGF dose response curves of activated NK cell
binding to HUVEC monolayers treated with the angiogenic factors for 24 hr.
A flow rate corresponding to 1 dyn/cm2 wall shear stress was imposed.
Mean numbers ± SD of bound cells for eight adjacent fields are shown for 1
of 3 representative flow experiments.
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The dose response curve showing the effect of bFGF was found to produce slight,
but statistically significant decreases in the level of A-NK binding to the activated
endothelium (Figure 5-3-3). Concentrations as low as 1 ng/ml were able to elicit a
reduction in the binding, and correlated with the slightly decreased level of ICAM-1
induced by bFGF.
Using the information obtained from the dose response analysis, the time course of
activation was then studied for each of the individual angiogenic factors and correlated with
the results on the CAM expression kinetics.
The time course of activation of TNF on A-NK cell binding was initially
performed and the results are shown in Figure 5-3-4. TNFx was found to rapidly activate
the monolayer over a 4 to 6 hr period resulting in significant A-NK cell binding. The
continued presence of TNFa maintained the level of cell adhesion for up to 24 hrs. These
results are in agreement with the findings of increased ICAM-1, VCAM-1, and E-selectin
on the TNFa-activated monolayer occurring within the initial 6 hrs and sustained over the
24 hr period.
The temporal kinetics of bFGF activation on A-NK cell binding was studied next
and the results are also shown in Figure 5-3-4. Correlating with the slightly increased
levels of ICAM-1 expression demonstrated in the expression assay, A-NK cells showed
small, but significant levels of increased adhesion to monolayers activated with bFGF for 6
hrs. This level of binding was found to be approximately 10% of that found for
monolayers activated with TNFa-activated monolayers for an equivalent period of time.
The prolonged exposure of endothelial cells to bFGF resulted in a rapid decrease in the
level of adhesion by 16 hrs and lasting for up to 24 hrs. As demonstrated in the expression
assays (see Section 5.2.4), these results corresponded to the decrease in ICAM-1
expression on the monolayers treated with bFGF for 24 hrs.
The ability of A-NK cells to adhere to endothelial cells as a function of VEGF
exposure time is shown in Figure 5-3-5. Following 6 hrs of VEGF treatment, lymphocyte
adhesion to the monolayer was significantly above baseline levels, and comparable to the
kinetics of TNFz activation. These results agree with the expression studies showing
increased ICAM-1, VCAM-1, and modestly E-selectin expression on the monolayers after
6 hrs of exposure. Cell binding levels remained elevated up to 24 hrs of VEGF
stimulation, correlating with the continued elevated expression of the CAMs. The overall
binding level of A-NK cells on VEGF-activated monolayers was found to be less than that
on TNFa-activated monolayers, and correlated with lower levels of CAM expression (see
Section 5.2).
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The temporal kinetics of TGF3 on lymphocyte adhesion was performed and the
results are shown in Figure 5-3-5. Monolayers exposed to 10 ng/ml of TGFP for up to 24
hrs showed no significant differences from baseline levels of A-NK adhesion. This
directly correlated with a lack of detectable CAM modulation by TGF3 treatment shown in
the expression experiments (see Section 5.2.5).
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Figure 5-3-4. Temporal kinetics of 50 ng/ml TNFa and 10 ng/ml bFGF on
A-NK cell binding to activated HUVEC monolayers. A flow rate
corresponding to 1 dyn/cm 2 wall shear stress was imposed. Mean numbers
± SD of bound cells for eight adjacent fields are shown.
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Figure 5-3-5. Temporal kinetics of 35 ng/ml VEGF and 10 ng/ml TGF on
A-NK cell binding to activated HUVEC monolayers. A flow rate
corresponding to 1 dyn/cm2 wall shear stress was imposed. Mean numbers
± SD of bound cells for eight adjacent fields are shown.
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5.3.3 Combined Angiogenic Factors
To further determine the biological significance of bFGF and TGFP inhibition on
cytokine and growth factor enhanced leukocyte-endothelial interaction, functional adhesion
studies were designed to simulate these conditions. Dose requirements and kinetics of the
response were analyzed to further define the responsiveness of endothelial cells to
scenarios involving multiple stimuli. The results were then correlated with the regulatory
effects of the angiogenic factors on CAM expression. To limit the range of possible
considerations, a specific focus was placed on the interaction between TNFo and bFGF.
Combinations of the other angiogenic factors are noted for their influences in specific
cases.
The dose response profiles of A-NK cell binding to endothelial cells activated for
24 hrs with broadly varying concentrations of TNF(x and bFGF combinations were
determined under flow conditions (1 dyn/cm 2) and the results are shown in Figure 5-3-6.
Basic FGF was shown to produce a dose-dependent inhibitory effect on TNFca-mediated
A-NK cell adhesion. The inhibitory response consistently showed similar profiles for the
full range of concentrations analyzed, which were between 0 and 50 ng/ml of bFGF and
between 0 and 200 ng/ml of TNFa. A concentration of 10 ng/ml of bFGF was found to
produce optimal levels of inhibition (46.0 + 10.6%, p < 0.05) for TNFo concentrations 2
50 ng/ml.
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Figure 5-3-6. Dose response curve of activated NK cell binding to HUVEC
monolayers treated simultaneously with TNFa and bFGF for 24 hr. A flow
rate corresponding to 1 dyn/cm 2 wall shear stress was imposed. Mean
numbers ± SD of bound cells for eight adjacent fields are shown.
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Similar inhibitory dose responses were obtained on HUVECs treated with VEGF
(35 ng/ml) and bFGF (Figure 5-3-7). At a concentration of 10 ng/ml of bFGF, optimal
levels of inhibition (52.5 ± 12.6%, p < 0.05) were obtained, indicating that the sensitivity
of endothelial cells to the inhibitory effect of bFGF is constant despite different positive
modulators of CAM expression.
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The influence of TGFI on endothelial cell monolayers treated with TNFa was also
documented and found to inhibit the binding level of A-NK cells under flow conditions
(Figure 5-3-8). A concentration of 1 ng/ml of TGF3 caused a 15.7 ± 4.2% inhibition of
A-NK binding to HUVECs treated with 50 ng/ml TNFx. This level of inhibition is close
to the level obtained by antibody blocking of E-selectin on TNFa-activated monolayers,
and provides support to its effect being limited to the regulation of E-selectin expression
[Gamble and Khew-Goodall, 1993].
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Figure 5-3-8. Dose response
curve of activated NK cell binding
to HUVEC monolayers treated
simultaneously with TNFa (50
ng/ml) and TGFP for 24 hr. A
flow rate corresponding to 1
dyn/cm 2 wall shear stress was
imposed. Mean numbers ± SD of
bound cells for eight adjacent
fields are shown.
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Using the information obtained from the dose response analysis, the time course of
inhibition was then specifically studied for bFGF on TNFa-activated endothelial cell
monolayers and correlated with the results on the CAM expression kinetics.
Upon simultaneous application of bFGF and TNFa, a decrease in the level of A-
NK binding became evident after 6 hrs of treatment, with significant levels occurring after
12 hrs (p < 0.05) (Figure 5-3-9). The total inhibition obtained was accomplished after 24
to 48 hrs of initial exposure. The time course of A-NK cell binding inhibition directly
correlated with the expression assay results, which showed that ICAM-1 and VCAM-1
levels were not reduced until 6 hrs following bFGF exposure.
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Figure 5-3-9. Inhibition kinetics of A-NK cell binding to HUVEC
monolayers treated simultaneously with 50 ng/ml TNFa and 10 ng/ml
bFGF. A flow rate corresponding to 1 dyn/cm 2 wall shear stress was
imposed. Mean numbers ± SD of bound cells for eight adjacent fields are
shown.
To provide additional evidence for a direct correlation between CAM expression
and lymphocyte binding inhibition by bFGF on TNFa-treated monolayers, antibody
blocking experiments were performed. As shown in Figure 5-3-10, addition of anti-
ICAM-1 mAb or anti-VCAM-1 mAb to TNFx and TNFa + bFGF treated monolayers
showed significant differences between the two treatment groups (p < 0.05). This directly
indicated that both molecules were essential in the reduced level of binding of A-NK cells
to bFGF-treated monolayers. Also, a combination of both blocking antibodies effectively
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eliminated differences in the TNFx and TNFx + bFGF treated monolayers, demonstrating
that ICAM- and VCAM-1 were the principal molecules involved in the functional adhesion
process for both treatment groups.
To test whether previous exposure of the endothelial cells to either of the factors
influenced the kinetics of the response, experiments were conducted where either TNFa
was applied prior to bFGF exposure or bFGF was applied at various times prior to TNF(X
activation for 5 hrs. The results of these two sets of experiments are shown in Figure 5-3-
11. Regardless of prior sensitization of the endothelial cells to cytokine or growth factor
exposure, the kinetics of bFGF inhibition on TNFa-induced CAM expression required
greater than 6 hrs of exposure of the endothelial cells to bFGF. This indicates that
signaling induced by bFGF on endothelial cells defines the time course of CAM
expression, and that exposure to other angiogenic factors or inflammatory cytokines does
not dramatically influence it.
anti-ICAM-1
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Figure 5-3-10. Antibody blocking experiments demonstrating a direct
correlation between ICAM-1 and VCAM-1 expression and A-NK cell
binding to HUVEC monolayers treated simultaneously with 50 ng/ml TNFa
and 10 ng/ml bFGF. A flow rate corresponding to 1 dyn/cm 2 wall shear
stress was imposed. Mean numbers ± SD of bound cells for eight adjacent
fields are shown. * p < 0.05. Treatment and antibody controls showed no
significant effect on A-NK cell binding.
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Figure 5-3-11. Inhibition kinetics of A-NK cell binding to activated
HUVEC monolayers pretreated with either a) 50 ng/ml TNFa (24 hr total
exposure time) and then 10 ng/ml bFGF for the time indicated, or b) 10
ng/ml bFGF for the time indicated and then 50 ng/ml TNFa for 5 hrs. A
flow rate corresponding to 1 dyn/cm 2 wall shear stress was imposed. Mean
numbers ± SD of bound cells for eight adjacent fields are shown. * p <
0.05.
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5.4 Conclusions
The key findings obtained from the in vitro investigations presented in this chapter
can be generally summarized as follows: a) the interstitial fluid (TIF) from xenotransplanted
adenocarcinomas provides a model of the tumor microenvironment which increases the
expression of specific CAMs in endothelial cells; b) the TIF used in these studies contains
significant levels of the angiogenic factor VEGF, but low or absent levels of bFGF and
TNFa, and level of VEGF in the TIF does not directly correlate with its ability to modulate
CAM expression; c) the angiogenic factors TNFx and VEGF are able to upregulate the
expression of specific CAMs in endothelial cells in a dose-dependent manner, while bFGF
has a biphasic effect on ICAM-1 expression only, and TGFP has no observable effect on
CAM expression; d) combined treatment of bFGF and TNFa or VEGF show significantly
reduced levels of CAM expression in a time-dependent process which is independent of
prior sensitization; and e) the biological modulation of CAM expression by the TIF and
angiogenic factors has functional relevance as determined by lymphocyte binding
characteristics under physiological flow conditions.
The ability of the TIF to simulate the microenvironment experienced by endothelial
cells in a tumor and for selected samples to significantly increase ICAM-1, VCAM-1, and
E-selectin expression provided invaluable information to the mechanisms used by
leukocytes to adhere to the tumor vasculature. The presence of various angiogenic factors
within the tumor for the development of an increased vascular blood supply, may be the
primary response elements responsible for the alteration in CAM expression by the TIF.
The finding that VEGF was expressed in significant levels in the tumor fluid and that it
induced the upregulation of ICAM-1, VCAM-1 and E-selectin, with kinetics similar to that
of TNFa, was suggestive of it being an essential mediator. However, while significant
variability existed in the ability of TIF samples to influence lymphocyte adhesion, VEGF
levels remained consistently elevated. Co-activators or inhibitory factors present in the TIF
may explain the discrepancy.
Along those lines, basic FGF, another angiogenic factor produced by various
neoplastic cells [Moscatelli, et al., 1986], was found to significantly decrease the
expression of ICAM-1, VCAM-1, and E-selectin in a time-dependent manner, and to also
functionally reduce the level of lymphocyte adhesion to TNFa and VEGF stimulated
endothelium. The decrease in the counter-receptor expression by bFGF has been shown in
Chapter 4 to differentially affect the ability of lymphocyte subpopulations to bind to
activated endothelial cells. Infiltrating lymphocytes and macrophages in the tumor
vasculature, in addition to the angiogenic factors produced by the cancer cells and
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surrounding normal tissue, may further influence the tissue microenvironment and the
products of the immune response to a tumor or inflammatory site. While bFGF was found
not to be present in sufficient levels in the TIF sampled, the aforementioned underscores
the influence the growth factor may have in the protective mechanisms found in other
tumors and angiogenic tissue towards reducing exposure to leukocytes by downregulation
of CAM expression and decreasing the response to inflammatory cytokines.
TGF3 may also be influential in mediating the immunological response to tumors.
While its concentration within the TIF was not examined, it was demonstrated that it can
produce a modest decrease in the ability of lymphocytes to adhere to cytokine-stimulated
endothelial cells. However, its mediating effects has been shown by others to be limited to
E-selectin expression and cannot explain the global variance experienced by the TIF
samples.
Several in vivo studies were also conducted in collaboration with this work to
provide validation of the in vitro findings [Melder, et al., 1996; Detmar, et al., 1998]. One
set of in vivo studies used LS174T tumors grown in the cranial window of SCID mice.
Human A-NK cells were adoptively transferred and shown to preferentially adhere to the
tumor vasculature, providing validation to the TIF findings. In addition, bFGF was
exogenously perfused onto the tumors and a significant reduction in the number of bound
cells to the tumor vasculature was observed, providing supporting evidence that bFGF can
inhibit lymphocyte adhesion in vivo.
In another set of in vivo experiments, transgenic mice were generated which
selectively overexpressed VEGF in the epidermis. Dramatic increases were found in
leukocyte rolling and adhesion to the postcapillary skin venules, which were significantly
inhibited by antibody combinations of anti-E-/P-selectin and anti-ICAM-1N/VCAM-1,
respectively. These studies provided supporting evidence that VEGF can promote
leukocyte rolling and adhesion in vivo, in accordance with the in vitro findings provided in
this thesis.
Implications for the results presented in this chapter include the following: a)
providing insight into the regulatory and protective mechanisms potentially found in
tumors, as well as in inflammation and wound healing, by the action of the various
angiogenic factors present; b) contributing to the better understanding of metastasis and the
role of angiogenic factors in the process; c) providing additional information towards
formulating a comprehensive paradigm of the microenvironmental effects on tumor growth
and evasiveness; and d) offering potential possibilities towards improving current anti-
tumor immunotherapies and treatments for inflammatory diseases.
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Chapter 6
Molecular Mechanisms of bFGF in
CAM Modulation
6.1 Introduction
The adhesion of circulating lymphocytes to the endothelium is mediated by the
expression of adhesion molecules on the lymphocyte surface and their interaction with
counter-receptors expressed on the endothelial cell surface [Butcher, 1991]. The cell
adhesion molecules on the endothelium include ICAM-1, VCAM-1, and E-selectin, with
each performing distinct functions [Oppenheimer-Marks, et al., 1991]. As was
demonstrated in Chapter 5 of this thesis, TNFa induces the protein expression of all three
of these adhesion molecules in endothelial cells, while bFGF inhibits their expression and
biological function. In general, the surface expression of these CAMs is known to
correlate with the transcriptional activation of their genes and corresponding increases in
their mRNA levels when activated by TNFa. However, the particular molecular
mechanisms used by bFGF in altering TNFa-induced CAM expression has not been
studied.
Previous studies examining the signaling pathways used by bFGF in modifying
other cellular responses, such as cell proliferation and angiogenesis in endothelial cells,
have shown it to involve a specific interaction with its high affinity, transmembrane
receptor and low affinity, membrane-bound heparin sulfate polysaccharides [Jaye, et al.,
1992]. The ternary complex causes autophosphorylation of its receptor tyrosine kinases,
leading to the direct phosphorylation of phospholipase C-yl (PLC-yl) and subsequent
breakdown of phosphatidylinositol bisphosphate (PIP2 ) to generate inositol 1,4,5-
triphosphate (IP 3) and diacylglycerol (DAG) [Mohammadi, et al., 1992; Ullrich and
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Schlessinger, 1990]. IP 3 causes the mobilization of Ca2+ from intracellular stores, which
combines with DAG to activate protein kinase C (PKC). The secondary messengers
generated in this cascade have been implicated in controlling many of the physiological
responses produced by bFGF. However, the specific role of each messenger in mediating
the cellular functions of bFGF are strongly cell-type dependent and function-dependent
[Jaye, et al., 1992; Peters, et al., 1992].
To date, the intracellular signals by which TNFx regulates adhesion molecule gene
transcription in endothelial cells have been studied to a modest extent. Investigations have
shown that it interacts with two distinct receptors, TR55 and TR75, and that the complex
triggers PLC-phosphatidylcholine (PC) to produce DAG, and subsequently the activation
of PKC and acidic sphingomyelinase (SMase) [Schtitze, et al., 1991; Schitze, et al.,
1992]. These two secondary messengers then go on to induce NF-KB activity, which may
be involved with the transcriptional regulation of ICAM-1, VCAM-1, and E-selectin by
TNFc [Read, et al., 1994]. However, the actions of the two enzymes are cell-type
dependent and differ in the kinetics and in subunit composition and function of NF-KB
activation.
In this chapter, results are presented from several experiments using Northern blot
analysis, fluorescence immunoassay, and the parallel-plate flow chamber to address the
following essential issues regarding the molecular mechanisms used by bFGF to inhibit
CAM expression and function: a) does bFGF act directly or indirectly through an
extracellular or paracrine mechanism to modify CAM expression and function; b) what
effect does bFGF have on CAM mRNA levels and expression kinetics; c) does bFGF alter
CAM mRNA expression at the transcriptional or translational levels; d) what are the
proximal signaling pathways used by bFGF in producing its inhibitory effect on CAM
function; and e) what are the broader implications of the inhibitory effect of FGF?
Investigation into these specific questions and the importance of knowing the
kinetics and molecular mechanisms of the action of bFGF may prove to be essential for
improved disease treatment and cancer therapy.
6.2 Characterization of bFGF-Mediated Inhibition
6.2.1 Protein and Functional Level
In the studies carried out in Chapter 5, it was demonstrated that with TNFc as the
stimulus, bFGF inhibits the surface protein expression of ICAM-1, VCAM-1, and E-
selectin. The constitutively expressed ICAM-2 molecule was not shown to be effected by
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the presence of bFGF nor TNFa. In addition, kinetic analysis showed that bFGF inhibited
surface CAM expression and biological function only after 8-12 hrs of exposure, and
reached optimal inhibitory levels after 24 hrs. Therefore, bFGF acts to selectively inhibit
specific CAMs on the surface of endothelial cells after a sufficiently latent period of
exposure. The question that now remains to be answered is how bFGF actually acts to
reduce CAM expression?
For one possible explanation of these findings it can be suggested that bFGF acts
indirectly and induces the production of a second substance, possibly another growth factor
or cytokine, which is the actual mediator of the observed effects on CAM expression. This
would be consistent with the latency of the bFGF-mediated effect observed in this
investigation, and concordant with its known ability to induce the production of urokinase-
type plasminogen activator and release of arachidonate from endothelial cells to elicit
multiple physiological and pathophysiological responses [Sa and Fox, 1994; Gualandris
and Presta, 1995].
To investigate a possible paracrine mechanism for the inhibitory action of bFGF,
conditioned medium transferred from HUVEC monolayers treated for 6 hrs with 10 ng/ml
bFGF was placed on a second monolayer and treated with TNFct for several time periods
ranging from 5 to 24 hrs. As a negative control, the supernatant from sham-treated
HUVEC monolayers, where bFGF was added just prior to collection, was transferred to a
second monolayer and subsequently treated with TNFoa. Additionally, another set of
monolayers were exposed to medium collected from non-treated HUVEC monolayers for 6
hrs and subsequently treated with or without TNFx. These served as positive and baseline
controls, respectively. The treated monolayers were then placed in the parallel-plate flow
chamber and assessed for their ability to bind A-NK cells under flow conditions, which has
already been shown to directly correlate to the expression of CAMs on the endothelial cells.
The results of this experiment are shown in Figure 6-2-1.
Monolayers treated with bFGF-conditioned medium were found to produce similar
temporal binding kinetics of A-NK cells as sham-treated controls, and both showed
significant differences from the positive control group. The inability of the conditioned
medium to elicit a kinetically faster inhibitory response compared to the sham controls is
strongly suggestive that bFGF does not produce a secondary product which is inhibitory to
CAM expression and the functional binding of lymphocytes. However, these results must
be interpreted cautiously and are not absolutely conclusive of bFGF eliciting a direct
inhibitory effect on the endothelial cells.
The cells may be responsive to only high, local concentrations of a secondary
substance produced by bFGF treatment, and may be insufficiently sensitive to the global
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concentrations present in the conditioned medium. Also, the cells may be producing an
intracellular protein which effectively elicits the inhibitory response and, thus, would not be
present in the conditioned medium.
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Figure 6-2-1. Kinetics of A-NK cell binding to HUVEC monolayers treated
with bFGF-conditioned medium and 50 ng/ml TNFa. A flow rate
corresponding to 1 dyn/cm2 wall shear stress was imposed. - = TNFa
positive control, - - - = TNFa+bFGF-conditioned medium, ... =
TNFa+bFGF sham, - - = no treatment (baseline). Mean numbers ± SD of
bound cells for eight adjacent fields are shown for n = 3 experiments.
As another possible mechanism for the inhibitory action mediated by bFGF,
specific interaction between bFGF and one of its receptors may cause a downregulation of
the expression of TNFao receptors on the cell. This would also be consistent with the
latency of the bFGF-mediated effect observed, and in agreement with its known ability to
attenuate the in vitro growth inhibitory effect of TGFP by downregulating the 85 kDa
TGF3 receptor subtype in a dose-dependent manner [Fafeur, et al., 1990]. However,
preliminary experiments have found no alteration in the levels of TNFp55R and TNFp75R
expressed on endothelial cells treated with bFGF for extended periods [Griffioen, et al.,
1996].
Basic FGF has also been found to decrease the level of ICAM- 1 expression on non-
activated endothelial cells (Chapter 5), thus not requiring specific cytokine activation of the
CAMs to produce its response. Additionally, bFGF inhibits lymphocyte binding to
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monolayers activated by other inflammatory cytokines (IL-1 ; Section 6.5) as well, which
utilize distinct receptors. Therefore, bFGF does not appear to affect cytokine receptor
levels as a mechanism for its CAM regulation.
Experiments were conducted to examine the effect bFGF has on the protein
synthesis, as well as on the degradation rate, of the CAMs. Since the level of protein
expressed in a cell is a function of the continuously opposing processes of protein
degradation and synthesis, an effect on either process could elicit the response seen for
bFGF. Also, the cell surface adhesion molecules are inducible proteins dependent on the
translation of their mRNA and, consequently, the transcription of their genes. Alteration in
the transcriptional or translational process effectively influences the level of protein
expressed and provides a potential pathway through which bFGF acts.
To study whether bFGF effects the rate of degradation of the CAMs, HUVEC
monolayers initially treated with TNFa for 6 hrs were washed with serum-free medium to
remove the TNFa and then exposed to either the presence or absence of bFGF. Initial
exposure of the endothelial cells to TNFx results in the transcriptional activation of the
genes for ICAM-1, VCAM-1 and E-selectin, and upregulation of their protein expression.
The subsequent removal of TNFa effectively prevents additional CAM gene transcription,
and by 24 hrs, results in the downregulation of the CAM proteins to baseline levels [Read,
et al., 1994].
Using the functional adhesion assay as an indirect gauge of the CAM expression
conducive to lymphocyte binding, the kinetics of A-NK adhesion to the treated monolayers
were analyzed. As shown in Figure 6-2-2, removal of TNFx from the activated
monolayers resulted in a dramatic decrease in the ability of lymphocytes to bind, which
reached baseline levels by 24 hrs. This finding directly correlated with the CAM
downregulation pattern observed under similar treatment conditions [Read, et al., 1994].
The addition of bFGF to the monolayers demonstrated no significant difference in the rate
of decrease of lymphocyte binding compared to the appropriate controls (p > 0.1),
suggestive that bFGF does not act to increase the rate of degradation of CAM proteins on
the cell surface.
6.2.2 mRNA Level
To confirm that the specific effect of bFGF was to inhibit protein synthesis and to
determine whether the effect on synthesis occurred before translation, Northern blot
analysis was performed to directly measure the mRNA levels and kinetics of expression of
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ICAM-1, VCAM-1, E-selectin and ICAM-2 in endothelial cells treated with TNF(, bFGF,
and the simultaneous combination of TNFa and bFGF.
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Figure 6-2-2. Kinetics of A-NK cell binding to HUVEC monolayers
initially treated with 50 ng/ml TNFa for 6 hrs (t = 0) and then subsequently
washed and treated with ± 10 ng/ml bFGF. A flow rate corresponding to 1
dyn/cm2 wall shear stress was imposed. ... = presence of bFGF, - - - =
absence of bFGF. Mean numbers ± SD of bound cells for eight adjacent
fields are shown for 1 of 3 representative experiments.
As shown in Figure 6-2-3 and 6-2-4a, treatment of HUVEC monolayers with
TNFa resulted in an initial rapid induction of ICAM-1 mRNA expression that peaked
around 4 hrs of treatment, followed by a steady and gradual decrease over 24 hrs.
Treatment with bFGF produced a rapid, but transient increase in ICAM-1 mRNA in the
first 4 hrs that reduced to baseline levels by 8 hrs. The HUVEC response to combined
treatment generally showed similar kinetics as that of TNF( treated monolayers, but with
lower levels of ICAM-1 expression consistently occurring after 8 hrs of treatment. In two
sets of experiments, significant differences were noted only after 8 hrs of bFGF exposure,
while a third showed differences occurring as early as 4 hrs (shown in Figure 6-2-4a). The
results obtained for the individual treatment groups were consistent with the responses
observed at the protein and functional levels for the CAMs. The combined treatment of the
cells with TNF( and bFGF generally demonstrated a reduction in the level of ICAM-1
mRNA expression which was sufficiently delayed to explain the kinetics of the decreased
protein levels observed.
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Figure 6-2-3. Northern blot analysis showing the kinetics of bFGF (10
ng/ml)-induced inhibition of ICAM-1, VCAM-1, and E-selectin mRNA
levels in HUVECs simultaneously activated by TNFa (50 ng/ml). Northern
blots are shown for (a) 24 hr treatment, and (b) 2 to 12 hrs of treatment. Data
are representative of 1 of at least 2 similar experiments.
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Figure 6-2-4. Graphic representation of the kinetics of bFGF (10 ng/ml)-
induced inhibition of (a) ICAM-1, (b) VCAM-1, (c) E-selectin, and (d)
ICAM-2 mRNA levels in HUVECs simultaneously activated by TNFa (50
ng/ml). CAM RNA levels are shown with respect to f3-actin RNA levels as
determined by densitometric measurement of Northern blots. Data are
representative of 1 of at least 2 similar experiments.
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The effects of TNFa on both VCAM-1 and E-selectin mRNA expression showed
characteristically similar kinetics, with a rapid initial increase peaking between 4 and 8 hrs
and then decreasing to a steady-state level after 12 hrs. Treatment with bFGF resulted in
no significant change in the mRNA levels of both CAMs even 24 hrs after initial exposure.
The combination of both TNFx and bFGF produced rather similar kinetics as that of
TNF( treated monolayers, but with significantly lower levels of expression occurring even
prior to 2 hrs of treatment and lasting for the complete 24 hrs. The results of the E-selectin
expression correlated well with the kinetics observed at the protein level for all of the
treatment groups. However, while TNFct and bFGF induction kinetics of VCAM-1
mRNA expression were consistent with those observed at the protein level, the combined
treatment using TNFa and bFGF demonstrated reductions in the level of VCAM-1 mRNA
expression which significantly preceded any changes on the protein level. As a possible
explanation for this finding, the combined treatment may produce a sufficient threshold of
VCAM-1 expression at the protein level, such that initial differences relative to TNFx
controls are not apparent at the mRNA level until a longer exposure duration.
The effect of the treatment groups on the constitutively expressed molecule ICAM-2
produced profound differences compared to the inducible CAMs. While treatment with
either TNFa or TNFa combined with bFGF did not alter the level of ICAM-2 mRNA
expression, treatment with bFGF alone resulted in a slight increase in ICAM-2 expression
after 4 hrs and remained for up to 24 hrs. This effect of bFGF on ICAM-2 mRNA levels
was not evident at the protein level, which showed no significant differences between the
treatment groups.
Possible reasons for the discrepancy between the protein and mRNA levels are: a)
ICAM-2 may have a sufficient half-life that increases in its mRNA expression do not
become evident within 24 hrs, b) there may be a threshold of ICAM-2 which is continually
present on the cell surface and do not reflect changes in its mRNA expression, or c) the
sensitivity of the protein expression assay may have been insufficient to detect the small
differences in ICAM-2 levels which possibly were produced.
6.3 mRNA Regulation
The suppression of the TNFa-inducible CAM mRNAs by bFGF indicates that its
effect does not occur on the post-translational level, but rather on the pre-translational or
transcriptional level. In an effort to further understand the molecular regulation of the
selected CAM mRNA, a set of experiments were conducted to determine whether bFGF
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affects the stability, a post-transcriptional event, of ICAM-1, VCAM-1, E-selectin, and
ICAM-2 mRNA.
To this end, HUVECs were initially treated with TNFa (50 ng/ml) for 4 hrs, to
increase the level of the inducible CAM mRNA within the cell, as determined by the
previous kinetic analysis. Actinomycin D (10 gg/ml) was then added to block
transcriptional activity, in the presence or absence of bFGF (10 ng/ml). Total RNA was
isolated at various times (2, 4, 8, 12, and 24 hrs) after addition of the actinomycin D and
subjected to Northern blot analysis.
As shown in Figure 6-3-1, when transcriptional activity was blocked, the
suppressive effect of bFGF on ICAM-1, VCAM-1, and E-selectin was effectively
inhibited. Additionally, the expression of ICAM-2 mRNA was unaffected relative to the
TNFa treated cells, demonstrating that the addition of actinomycin D does not alter overall
constitutive protein expression.
The control groups for these experiments are shown in Figure 6-3-2, and represent
the endothelial cells that were treated with TNFa for 4 hrs prior to the exposure to bFGF
and without the addition of actinomycin D. As was found with the kinetic analysis using
simultaneous treatments, significant differences in all three of the inducible CAMs were
evident after 2 to 4 hrs of treatment with bFGF, and maintained over a 24 hr duration.
Also, the mRNA levels of ICAM-2 remained unaltered by the continued exposure to TNFx
or TNFa combined with bFGF.
The findings of this study are suggestive that the stability of TNFa-induced ICAM-
1, VCAM-1, and E-selectin mRNA are not affected by the presence of bFGF. Therefore,
the inhibition of the protein and mRNA levels of these CAMs may likely be regulated by
bFGF at the transcriptional level, and not significantly at the translational or post-
translational levels. Additional investigation using transcription run-on assays to examine
the changes in promoter activity of the CAM genes by bFGF are needed to determine
whether the rate of transcription is actually affected [Neish, et al., 1992].
It has also been previously shown that TNFx activates NF-icB transcriptional
regulatory proteins, which are capable of inducing the transcription of ICAM- 1, VCAM- 1,
and E-selectin genes via NF-icB binding sites located on their promoter regions [Collins, et
al., 1995]. NF-icB is a heterodimer of two proteins, p50 and p65, which upon activation
translocates from the cytoplasm to the nucleus. Basic FGF may suppress the activation of
this transcription factor through second or third messengers activated by one of its
intracellular signaling pathways. Electrophoretic mobility shift assays using nuclear
extracts from TNFa induced HUVECs are needed in defining this as a possible mechanism
[Marui, et al., 1993].
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Figure 6-3-1. Graphic representation of the effects of bFGF (10 ng/ml) on
the stability of (a) ICAM-1, (b) VCAM-1, (c) E-selectin, and (d) ICAM-2
mRNA in HUVECs initially activated with TNFa (50 ng/ml) for 4 hrs. The
CAM RNA levels are shown with respect to P-actin RNA levels as
determined by densitometric measurement of Northern blots. Data are
representative of 1 of 3 similar experiments.
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Figure 6-3-2. Graphic representation of the effects of bFGF (10 ng/ml) on
(a) ICAM-1, (b) VCAM-1, (c) E-selectin, and (d) ICAM-2 mRNA in
HUVECs initially activated with TNFax (50 ng/ml) for 4 hrs. These served
as control groups for the stability analysis study, and the CAM RNA levels
are shown with respect to p-actin RNA levels as determined by densitometric
measurement of Northern blots. Data are representative of 1 of 3 similar
experiments.
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6.4 Signaling Pathways
In an effort to further define the mechanisms employed by bFGF in its regulation of
the transcriptional activity of the inducible CAM genes, studies were conducted to
investigate the specific early signaling pathways used by bFGF in modulating CAM
expression and function. Utilizing information obtained from previous studies examining
the signaling pathways used by bFGF in modifying other physiological responses, an axis
was established to narrow the focus of the investigation. Sufficient scope was maintained
to provide essential understanding of the specific signal transmission pathway(s) linking
bFGF to several intracellular mediators, as well as its potential interaction with the
signaling pathways used by TNFx in activating CAM expression.
An illustration of the bFGF-mediated pathways considered and the plausible
interaction with TNFa signaling is shown in Figure 6-4-1. The paradigm to be considered
involves the following specific interactions: a) bFGF with its high affinity receptors
(bFGF:FGFR), b) bFGF with the low affinity heparin sulfate polysaccharide, c) receptor
tyrosine kinase activation, d) protein tyrosine phosphatase function, e) phospholipase C-yl
activation, f) phospholipase D activation, and g) protein kinase C activation. Selective,
commercially available blocking agents and antibodies were used to determine the role of
each of these interactions and are listed in Table 6-1 along with their specific modes of
action. Dose response curves were conducted for the blocking agents using the functional
adhesion assay to determine the effective concentrations for use in the expression and
functional analysis, and are shown in Appendix C for reference.
6.4.1 Surface Protein Expression
To study the influence of each of the various signaling components on TNFa- and
bFGF-induced modulation of adhesion molecule expression on endothelial cells, the
fluorescence immunoassay (FIA) method was used in conjunction with the appropriate
signal transduction blockers.
Experiments were first conducted to determine the role of the high-affinity receptor-
ligand interaction of bFGF:FGFR. HUVEC monolayers were initially treated with a
solution consisting of 1 gg/ml bFGF neutralizing antibody and 10 ng/ml of bFGF and/or
TNFu for 24 hrs and then assessed for the level of CAM expression. As shown in Figure
6-4-2, the neutralizing antibody showed no significant effect on TNFx activated ICAM-1,
VCAM-1 or E-selectin expression, as well as no effect on non-treated baseline controls.
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Simplified schematic of the TNFa and bFGF signaling
Table 6-1. Specific signal transduction inhibitors and their modes of action.
Agent Selectivity Mode of action
anti-bFGF mAb bFGF:FGFR bFGF-specific neutralizing antibody
Methyl 2,5-dihydroxycinnamate Tyrosine kinase Erbstatin analog, a competitive
(MDHC) inhibitor of FGF receptor-associated
tyrosine kinase
Sodium orthovanadate (Na3VO4) Protein tyrosine Broad-spectrum potent inhibitor of
phosphatase protein tyrosine phosphatases
2-nitro-4-carboxyphenyl N,N- Phospholipase C Blocks hydrolysis of PPI to IP3
diphenylcarbamate (NCDC)
l-[isopropylamino]-3-[1- Phospholipase D Blocks phospholipase D-derived DAG
naphthyloxy]-2-propanol by inhibiting phosphatidate
(propranolol) phosphohydrolase
Calphostin C Protein kinase C Highly specific inhibitor of PKC,
competes at the binding site of DAG
and phorbol esters
Bisindolylmaleimide Protein kinase C Highly selective inhibitor of PKC,
(GF109203X) competes at the ATP-binding site
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Due to the relative insensitivity of the assay system for low levels of expression, small
differences in CAM expression on monolayers treated with bFGF were not evident, nor
were the effects of the neutralizing antibody on the response of bFGF. However, in
comparison with TNFa( treatment, monolayers treated with both TNFxc and bFGF showed
significant reversal of CAM inhibition by the addition of the bFGF antibody. Therefore,
the results demonstrate that bFGF acts through its receptor in mediating the inhibitory
action on ICAM-1, VCAM-1 and E-selectin protein expression induced by TNFax.
Fluorescence Units
0 200 400 600 800 1000 1200 1400
no bGFAb
Z control
TNF
bFGF
TNF+bFGF.. A
Fluorescence Units
0 100 200 300 400
Fluorescence Units
0 5 0 100 150
500
nor
TNF
bFGF
TNF+bFGF
200 250
[ bFGF: Ab
[] control
Fluorescence Units
0 5 0 100 150 200 250
[ control
D
Figure 6-4-2. Effect of bFGF neutralizing antibody on TNFa and bFGF
induced HUVEC protein expression of a) ICAM-1, b) VCAM-1, c) E-
selectin, and d) IgG isotype control. Data represent means ± SEM from
triplicate wells.
In addition to the high-affinity interaction which bFGF has with its receptor, low-
affinity receptors for bFGF exist that are predominantly proteoglycans carrying heparan
sulphate side chains [Klagsburn, 1990]. While unable to activate a signal transduction by
themselves, heparin and heparan sulphates sequester and present bFGF to its high-affinity
receptors and facilitate efficient binding. To explore the potential of heparin to modulate the
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inhibitory effect of bFGF, experiments were conducted in which supplemental heparin (10
gg/ml) was added to endothelial cell monolayers along with cytokine and growth factor
treatment for 24 hrs. As shown in Figure 6-4-3, heparin treatment did not alter the level of
ICAM-1, VCAM-1, or E-selectin induced by TNF(, nor did it significantly affect the
ability of bFGF to inhibit their expression. Baseline levels for each of the CAMs were also
unaffected by the exogenous addition of heparin. These results indicate that, under the
conditions used in this investigation, supplemental heparin does not change the
effectiveness of bFGF to alter CAM expression on TNFa treated monolayers.
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Figure 6-4-3. Effect of supplemental heparin on TNFa and bFGF induced
HUVEC protein expression of a) ICAM-1, b) VCAM-1, c) E-selectin, and
d) IgG isotype control. Data represent means ± SEM from triplicate wells.
As the next step in the signaling cascade, autophosphorylation of the tyrosine
kinase domain on the cytoplasmic portion of the FGF receptor is known to occur, which,
in turn, leads to the tyrosine phosphorylation of a number of intracellular proteins. The
ability of the receptor tyrosine kinase to transduce the inhibitory signal of bFGF was
studied using MDHC as the blocking agent. Following a 2 hr pretreatment with 5 giM of
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MDHC, TNFcc and/or bFGF was applied to HUVEC monolayers for a 24 hr period in the
continued presence of the inhibitor. Their ability to alter endothelial cell surface expression
of all three CAMs was then assessed. As shown in Figure 6-4-4, the blockage of receptor
tyrosine kinase (RTK) phosphorylation resulted in a significant decrease in the ability of
TNFu to induce the expression of ICAM-1, VCAM-1, and E-selectin. Although
cytoplasmic amino acid sequences of TNF receptors demonstrate a lack of intrinsic
protein tyrosine kinase activity [Loetscher, et al., 1990], TNF(o has been shown to induce
rapid protein tyrosine phosphorylation in PMN [Fuortes, et al., 1993], and be required for
NF-icB mobilization and induction of VCAM-1 and E-selectin by TNFX [Weber, et al.,
1995]. The attenuation of ICAM-1 induction may be attributed to a distinct inhibitory
mechanism of the particular blocking agent used in this investigation.
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Figure 6-4-4. Effect of the receptor tyrosine kinase inhibitor MDHC on
TNFa and bFGF induced HUVEC protein expression of a) ICAM-1, b)
VCAM-1, c) E-selectin, and d) IgG isotype control. Data represent means ±
SEM from triplicate wells.
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The RTK inhibitor did not elicit a significant effect on the CAM expression of
bFGF treated monolayers, as well as the baseline controls, except for a modest decrease in
the baseline level of ICAM-1. However, there was observed a significant inability of
bFGF to inhibit all three of the CAMs induced by TNFa, suggesting that bFGF acts via the
specific phosphorylation of its receptor tyrosine kinase in producing its effect on inducible
CAM expression. This specific activity has been demonstrated to be essential for bFGF to
initiate DNA synthesis and mitogenic signaling in endothelial cells [Hawker and Granger,
1994].
To further assess the role of tyrosine phosphorylation in the induction of adhesion
molecules by TNFa and in the inhibitory effect elicited by bFGF, expression studies were
performed on monolayers treated with sodium orthovanadate, a protein tyrosine
phosphatase (PTP) inhibitor. HUVEC monolayers were treated for 2 hrs with 30 M of
sodium orthovanadate and then incubated with TNFa and/or bF-F for a further 24 hrs in
the continued presence of the PTP-inhibiting agent. The results obtained showed a
significant decrease in TNFa-induced VCAM-1 expression by vanadate, while exhibiting
no significant effect on ICAM-1 or E-selectin (Figure 6-4-5). In addition, vanadate
produced slightly increased basal levels of VCAM- 1 and E-selectin expression, correlating
with previous studies using HUVECs [May, et al., 1996].
Blockage of tyrosine phosphatase activity elicited only a small effect on the ability
of bFGF to inhibit the expression of VCAM-1 by TNFa, and did not produce differences
in the inhibition of ICAM-1 or E-selectin. Most likely this was due to the significant
reduction in the control levels of TNFa-induced VCAM-1 expression, which was evident
in the presence of sodium orthovanadate. No significant differences were also observed
for the CAMs on monolayers treated with bFGF alone. Therefore, in agreement with the
studies blocking the receptor tyrosine kinase function, further evidence is provided in favor
of bFGF mediating its CAM inhibition through the tyrosine phosphorylation activity of its
receptor.
Phospholipase C-y (PLC-y) is a RTK substrate (SH2 domain) possessing catalytic
activity and regulated by tyrosine phosphorylation [Burgess, et al., 1990]. As a potential
next step in the signal transduction cascade leading to CAM inhibition by bFGF, the role of
PLC-y was studied. Using the known PLC inhibitor, NCDC, HUVEC monolayers were
treated with 50M of the blocking agent and exposed to TNFa and/or bFGF for 24 hrs.
As shown in Figure 6-4-6, inhibition of PLC activity was shown to produce a decrease in
the levels of ICAM-1 and E-selectin induced by TNFa, with no significant change in
VCAM-1 expression. While NCDC acts to inhibit the action of PI-PLC in producing
DAG, a PLC-y-mediated mechanism used by bFGF, it may non-specifically interfere with
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the action of PC-PLC in producing DAG, which is used by TNF( in mediating CAM
expression.
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Figure 6-4-5. Effect of the protein tyrosine phosphatase inhibitor sodium
orthovanadate on TNFa and bFGF induced HUVEC protein expression of
a) ICAM-1, b) VCAM-1, c) E-selectin, and d) IgG isotype control. Data
represent means ± SEM from triplicate wells.
Blockage of PLC-y was also demonstrated to effectively prevent the inhibition of all
three CAMs by bFGF. No significant differences were noted in the baseline controls or in
the monolayers treated with bFGF alone. Therefore, these findings are suggestive that
bFGF acts, in part, through a PLC-y-mediated mechanism in eliciting its inhibitory
response to CAM expression.
Another possible pathway which bFGF may incorporate is one involving
phospholipase D (PLD). Activation of PLD by bFGF is known to catalyze the hydrolysis
of phosphatidylcholine (PC) to produce a precursor of diacylglycerol in either a PKC-
dependent or an inositol-lipid hydrolysis-independent mechanism [Billah and Anthes,
1990; Ahmed, et al., 1994]. PC is also hydrolyzed by a TNFa-responsive PLC to
produce the second messenger DAG, a known activator of PKC and acidic
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sphingomyelinase, and signifies one of the early signaling interactions between bFGF and
TNFa. To further elucidate the role of PLD in CAM regulation by bFGF, propranolol was
used as the specific PLD antagonist.
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Figure 6-4-6. Effect of the phospholipase C inhibitor NCDC on TNFa and
bFGF induced HUVEC protein expression of a) ICAM-1, b) VCAM-1, c)
E-selectin, and d) IgG isotype control. Data represent means ± SEM from
triplicate wells.
HUVEC monolayers treated with 50 [tM of propranolol were found to show no
difference in their ability to upregulate the expression of ICAM- 1, VCAM- 1 or E-selectin
induced by TNFR (Figure 6-4-7). Baseline and bFGF controls also remained unaltered by
the treatment with propranolol. However, significant reduction in the bFGF-mediated
suppression of all three inducible CAMs was evident.
These results demonstrate that PLD is a significant contributor to the bFGF
response. In conjunction with the finding that PLC-y also provides a significant
contribution, it would appear that bFGF acts to hydrolyze phosphoinositides by PLC-y to
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form DAG and the eventual activation of PKC. PKC may, in turn, activate PLD to
contribute to the inhibitory signaling by bFGF and directly compete with TNF(x signaling.
To determine the specific role of PKC in mediating the bFGF response to CAM
regulation, experiments were conducted using the specific PKC inhibitors, calphostin C
and bisindolylmaleimide (BIM). The two independent blocking agents were separately
utilized in order to provide a better perspective on the influence of PKC, which consists of
seven isoforms that differ in their dependence on calcium and phospholipid cofactor
activity.
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Figure 6-4-7. Effect of the phospholipase D inhibitor propranolol on TNFa
and bFGF induced HUVEC protein expression of a) ICAM-1, b) VCAM-1,
c) E-selectin, and d) IgG isotype control. Data represent means + SEM from
triplicate wells.
The results of the blocking experiments are shown in Figure 6-4-8. Both agents
reduced TNFa-induced surface expression of VCAM-1, 38% by calphostin C and 63% by
BIM. However, neither agent was influential in modifying ICAM-1 or E-selectin
expression, consistent with the known effects using other PKC inhibitors on TNFox
signaling [Ritchie, et al., 1991; Deisher, et al., 1993]. The inhibitory effect elicited by
bFGF on TNFa-induced VCAM-1 expression was also effectively reduced by BIM
140
--- -- ~cl-- rl -- IC-~~------ -- ~-
MINIM=
~7777~7~
i - ... A
(30%), but less so by calphostin C (10%). Moreover, the ability of bFGF to inhibit
induced ICAM-1 and E-selectin expression was essentially unaltered by both agents.
Baseline controls were found to be unaffected by blocking PKC activity with either
compound. The differences found between the two agents may partly be the result of their
specific inhibitory action on PKC, with BIM acting as a competitive inhibitor for the ATP-
binding site, and calphostin C competing at the binding site of diacylglycerol and phorbol
esters. Additionally, the selectivity for the various PKC isozymes may vary between the
two compounds.
Based on the results obtained it would appear that bFGF may act through PKC to
mediate its inhibitory action on TNFa-induced VCAM-1 expression only, and not ICAM-1
or E-selectin. The fact that TNFa utilizes a PKC-dependent mechanism only for the
selective upregulation of VCAM-1, and a PKC-independent mechanism for the induction of
ICAM-1 and E-selectin on endothelial cells, is suggestive that bFGF uses a diverse scheme
in modulating the CAMs induced by TNFu.
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Figure 6-4-8. Effects of the protein kinase C inhibitors calphostin C and
bisindolylmaleimide (BIM) on TNFa and bFGF induced HUVEC protein
expression of a) ICAM-1, b) VCAM-1, c) E-selectin, and d) IgG isotype
control. Data represent means ± SEM from triplicate wells.
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However, it does leave unanswered the possibility that bFGF may still utilize PKC
for reducing ICAM-1 and E-selectin expression by cytokines using the PKC pathway for
their induction. To address this possible mechanism, the phorbol ester, PMA, a known
activator of PKC and inducer of ICAM-1, VCAM-1 and E-selectin expression, was utilized
and the effect of bFGF on suppressing its ability to activate the CAMs via PKC was
examined. Calphostin C was used as the blocking agent, as it interacts with the regulatory
domain of PKC by competing directly at the binding site for the phorbol ester. As shown
in Figure 6-4-9, PMA induces the expression ICAM-1, VCAM-1, and E-selectin, and that
addition of calphostin C effectively reduces the expression of all three CAMs by 32%,
35%, and 25%, respectively. Addition of bFGF to PMA-treated endothelial cells also
caused a reduction in the level of the inducible CAMs, which was effectively blocked by
using calphostin C. Therefore, it would appear evident that bFGF can act through both a
PKC-dependent and independent means to reduce the expression of adhesion molecules by
positive modulators, depending on the pathway used by the specific inducer. This may be
the result of a competitive effect by bFGF in its activation of second messengers for
eliciting other cellular processes, such as cell proliferation and migration.
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Figure 6-4-9. Effects of the protein kinase C inhibitor calphostin C on PMA and
bFGF induced HUVEC protein expression of a) ICAM-1, b) VCAM-1, c) E-selectin,
and d) IgG isotype control. Data represent means ± SEM from triplicate wells.
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6.4.2 Functional Correlation
Having established a set of early signaling pathway mediators used by bFGF in
inhibiting the expression of selective CAM proteins, adhesion assay studies using the
parallel-plate flow chamber were conducted to demonstrate the functional relevance of the
biological findings. IL-2 activated natural killers cells served as the lymphocyte model and
were analyzed for their ability to bind to HUVEC monolayers treated with TNFo and/or
bFGF in combination with the signal transduction blocking agents under dynamic flow
conditions (1.0 dyn/cm2 ).
Initial studies performed examined the interaction of bFGF with its receptor using
identical conditions as that for the expression assay. The results obtained showed no effect
by the neutralizing bFGF Ab on A-NK binding to TNFa-activated or non-treated
monolayers (Figure 6-4-10). However, the antibody did significantly suppress the ability
of bFGF to inhibit ANK binding to the activated monolayers compared to the control group
(p < 0.05). These findings directly correlate with the expression assay results showing
significant reversal of CAM inhibition by addition of the bFGF antibody, and thus further
demonstrate that bFGF acts through its high-affinity receptor to modulate A-NK adhesion.
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To determine a possible functional influence of a low affinity interaction of bFGF
with heparin, a facilitator of increased bFGF binding to its receptor, on the ability of bFGF
to inhibit A-NK binding, flow experiments were performed on monolayers treated with
supplemental heparin under conditions matching those used in the expression assay.
As shown in Figure 6-4-11, the addition of exogenous heparin did not increase the
level of inhibition produced by bFGF on A-NK adhesion to TNFa-activated monolayers,
as might be expected if the bFGF signal was particularly sensitive to low affinity
complementation. In fact, there was a slight, but statistically insignificant, increase in A-
NK binding, which most likely was attributable to the soluble binding of bFGF. This
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overall effect of heparin was evident for a broad range of heparin dosages, varying from 1
to 200 gg/ml, and did not influence the level of binding to the treatment control groups.
These results are strongly supportive of the expression assay findings that CAM inhibition
by bFGF was unaltered by the presence of supplemental heparin.
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The activation of the bFGF receptor tyrosine kinase, the third stage in the signal
transduction cascade analyzed using the expression assay, was next explored for its
functional significance on A-NK binding. In agreement with the reduced levels of ICAM-
1, VCAM- 1, and E-selectin found upon blockage of the RTK by MDHC on TNFoa-treated
monolayers, decreased A-NK cell binding was demonstrated to occur at significant levels,
with approximately a 30% reduction compared to controls (Figure 6-4-12). While changes
in baseline levels were found to be insignificant, the ability of bFGF to inhibit lymphocyte
binding to TNFx-treated monolayers was abrogated by blocking RTK activation.
Therefore, specific phosphorylation of its receptor tyrosine kinase is essential for both the
inhibition of CAM expression and function under physiological flow conditions.
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Figure 6-4-12. Effect of
MDHC (5 gM) on A-NK cell
binding to HUVEC
monolayers treated with
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In an effort to place further emphasis on the role of tyrosine kinase phosphorylation
by both bFGF, in mediating its inhibitory response, and TNFa, in mediating its excitatory
response, sodium orthovanadate was used as the particular blocking compound against
tyrosine phosphatase activity and studied under flow conditions. The results obtained,
which are shown in Figure 6-4-13, were found to correlate reasonably well with the
expression data. Namely, the reduction in TNFa-induced VCAM-1 expression by
vanadate (40%) was associated with a corresponding decrease (18%) in the A-NK cell
binding to the monolayer, emphasizing the importance of tyrosine phosphorylation on
TNFa-mediated VCAM-1 expression and function. Also, by blocking the phosphatase
action, the inhibitory action of bFGF was not only found to remain active, but was even
enhanced. However, this enhancement was more likely the result of decreased VCAM-1
induction by TNFa on PTP inhibited monolayers, as demonstrated by FIA analysis, than
an actual increase in the proficiency of bFGF-mediated reduction in lymphocyte binding.
Lastly, the slight increase in baseline VCAM-1 and E-selectin expression that was found to
occur by PTP inhibition did not contribute significantly to A-NK cell binding. This was
likely due to the increased CAM levels being below kinetically favorable concentrations for
cell binding. Therefore, it can be concluded that the phosphorylation of tyrosine kinases is
necessary for the bFGF-mediated inhibitory process, as well as being contributory to
TNFa-induced VCAM-1 expression and function.
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With the role of the receptor tyrosine kinase having been found to be essential for
bFGF-mediated regulation of both protein expression and lymphocyte adhesion, the
functional relevance of the biologically effective PLC activation, a RTK substrate, was
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subsequently studied. HUVEC monolayers treated with TNFa and exposed to the PLC
blocking agent, NCDC, demonstrated no difference in their ability to bind A-NK cells
(Figure 6-4-14). Although in contrast to the finding that ICAM-1 and E-selectin were
suppressed by PLC blockage, the relative level of downregulation may not have been
sufficient to elicit a functional response to lymphocyte binding, thereby accounting for the
indifferent cell binding densities on the monolayers. As for the bFGF response, blocking
the action of PLC resulted in significant suppression of the inhibitory effect of bFGF on
both TNFa-treated and non-treated monolayers, with A-NK binding reaching levels nearly
equivalent to TNFa and baseline controls. These findings were in direct correlation with
the expression results, and provides additional support to the contributory role of this
mediator in bFGF signaling.
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As found for phospholipase C, phospholipase D was also demonstrated to provide
a significant role in the bFGF-mediated reduction in A-NK cell binding and CAM
expression. As shown in Figure 6-4-15, when HUVEC monolayers were exposed to the
phospholipase D inhibitor, propranolol, the inhibitory action of bFGF on lymphocyte
binding was abolished and effectively reached the levels obtained by the TNFa control
group. Results obtained from FIA analysis were in close agreement with these functional
findings.
As for the effect of the blocking agent on TNFa signaling, it was also found to be
modestly inhibitory. A-NK cell binding to TNFa-treated monolayers were reduced by
15% compared to unblocked TNFo controls. This was in agreement with the decreased
levels of VCAM- 1 demonstrated in the expression analysis.
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With the involvement of both PLC and PLD in the bFGF response, and partly to
the TNF(x response, it becomes circumspect as to the scope of the downstream second
messenger PKC in contributing to the response. Functional studies were conducted to
provide additional insight, as well as biological relevance, to the expression results
obtained earlier. As shown in Figure 6-4-16, monolayers treated with TNFa were found
to be slightly less conducive to A-NK cell binding when PKC activity was blocked by
calphostin C. This effect could be attributed to the decreased VCAM-1 expression which
was found to occur when PKC activity was blocked.
As for the bFGF response, blocking of PKC actually further decreased the level of
A-NK binding to the endothelial cell monolayers. Although the inhibition of TNFa-
induced VCAM-1 expression by bFGF is slightly reduced by blocking PKC activity, the
overall effect of calphostin C causes a significant reduction in the level of VCAM-1
expression. When compounded by the PKC-independent decrease of ICAM-1 and E-
selectin by bFGF, the overall decrease in the binding levels observed can be explained by
the expression results.
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For additional insight into the involvement of PKC in mediating the inhibitory
response of bFGF at the functional level, the phorbol ester PMA was utilized for its ability
to increase CAM expression largely through PKC. As shown in Figure 6-4-17, a 3 hr,
low dose PMA treatment effectively enhanced the ability of A-NK cells to bind to the
monolayers, producing a near 15-fold increase. Additionally, monolayers pretreated with
bFGF for 24 hrs showed significant reduction in the ability of PMA to elicit cell binding.
These findings directly correlated with the expression results, which demonstrated
increased levels of ICAM-1, VCAM-1 and E-selectin following short term PMA treatment,
and their effective suppression upon pretreatment with bFGF.
When calphostin C was added 2 hrs prior to PMA treatment, the resultant level of
A-NK adhesion was effectively reduced, in agreement with the expression results showing
decreased levels of expression of all three CAMs. Moreover, monolayers treated with
calphostin C obviated the ability of bFGF to inhibit PMA-induced cell adhesion. In
concordance with the expression results involving PMA, it would appear evident that
bFGF acts at least partly through PKC signaling in mediating its inhibitory response.
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To provide an additional means for assessing bFGF and TNFx signaling, a long
term (48 hrs), high dose (200 nM) PMA treatment was also given to the HUVEC
monolayers to effectively deplete the cells of intracellular PKC. Monolayers subsequently
given TNFx treatment for 24 hrs showed reduced, but significant levels of A-NK cell
binding (Figure 6-4-18). Presumably, the increase in cell binding was the result of TNFa
utilizing its PKC-indpendent mechanism to upregulate ICAM-1 and E-selectin expression.
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Addition of bFGF to these monolayers demonstrated significant reduction in A-NK cell
binding, providing additional evidence that bFGF also utilizes a PKC-independent pathway
in its functional inhibition of lymphocyte binding.
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6.5 Generalization of Findings
The findings above provide significant insight into the particular mechanisms by
which bFGF is able to regulate CAM expression and function on TNFca- and PMA-treated
monolayers. While this provides invaluable information to the potential role of bFGF in
normal physiology, as well as pathological disease, the scope of the work presented in this
chapter has been rather limited to specific cell-types and CAM excitatory/inhibitory agents.
To provide an increased breadth to the work, four specific questions were addressed: a)
does bFGF act to inhibit lymphocyte binding to HUVECs treated with a cytokine or growth
factor other than TNFa; b) do other members of the FGF family exhibit similar inhibition
responses in endothelial cells; c) are other endothelial cell-types responsive to the inhibitory
action of bFGF; and d) are other lymphocyte subpopulations inhibited from binding to
activated endothelial cells?
Preliminary studies were first conducted using the proinflammatory cytokine IL- 3
as an alternative positive modulator of CAM expression. HUVEC monolayers treated with
50 ng/ml of the cytokine for 24 hrs were able to increase A-NK cell binding by 10-fold
compared to baseline levels (Figure 6-5-la). Moreover, the addition of 10 ng/ml of bFGF
resulted in a significant decrease (45%) compared to positive controls. This inhibitory
effect was not only associated with proinflammatory cytokines, but also shown to exist on
HUVEC monolayers treated with the angiogenic factor VEGF (see Chapter 5). Therefore,
the inhibitory influence which bFGF partakes on the cells is not dependent on the specific
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positive modulator utilized, but rather by the competitive inhibition of converging
downstream intracellular signals or the regulation of transcriptional activity of the CAM
genes.
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As one of the prototypical members of the FGF family, bFGF (FGF-2) may utilize
similar signal transduction pathways as other members in eliciting its response on
endothelial cells. To explore this possibility, HUVEC monolayers were treated with acidic
FGF (FGF-1) for a 24 hr period and tested for their ability to inhibit TNFa-induced A-NK
cell binding. As shown in Figure 6-5-1b, acidic FGF at a concentration of 10 ng/ml was
able to significantly suppress the level of A-NK binding to the monolayers treated with
TNFa, and the reduction was equivalent to that obtained by basic FGF. Also, treatment
schemes combining both aFGF and bFGF showed no additional influence on cell binding,
suggestive of similar signaling pathways being utilized. These results imply that FGF-
family proteins may globally produce inhibitory regulation of CAM expression and
function. Additional experiments are needed to explore this potential using other, non-
prototypical, members of the family.
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Also critical to the understanding of FGF-mediated inhibition is the cell-type in
which it is studied. The specific role of each messenger in mediating the cellular functions
of bFGF, as well as TNFa and other cytokines, are strongly cell-type dependent [Jaye, et
al., 1992; Schiitze, et al., 1992]. In keeping with the endothelial cell model, human dermal
microvascular endothelial cells (HDMECs) were utilized to examine whether bFGF is able
to elicit similar inhibitory characteristics on A-NK cell binding. As shown in Figure 6-5-
Ic, monolayers treated with bFGF were found to significantly reduce the level of binding
on TNFca-activated HDMEC monolayers. Therefore, similar signaling characteristics and
responses may exist in the two venular endothelial cells with respect to bFGF, which may,
in turn, imply similar potential in other endothelial cell subtypes.
Lastly, the biological relevance of the CAM modulation by bFGF on endothelial
cells has largely been studied using A-NK cells. While t his lymphocyte subpopulation
possess distinct binding kinetics compared to others, the general binding characteristics are
similar and there is universal inhibition in binding under modified counter-receptor levels.
A more complete and detailed analysis is provided in Chapter 4.
6.6 Conclusions
The important results obtained from the studies performed in this chapter on the
molecular mechanisms of bFGF inhibition of CAM expression and function can be
generally summarized as follows: a) bFGF does not appear to act through a paracrine
mechanism to inhibit the functional binding of lymphocytes to activated endothelium; b)
bFGF acts to inhibit protein synthesis, as opposed to increasing the rate of protein
degradation, by suppressing TNFa-induced mRNA expression of ICAM-1, VCAM-1, and
E-selectin; c) the decrease in mRNA expression by bFGF is not due to changes in mRNA
stability, but rather a reduction in the rate of transcription of the CAM genes; d) bFGF
utilizes a signal transduction pathway which involves the activation of its receptor,
phospholipase C-y, phospholipase D, and partially protein kinase C; and e) the inhibitory
effect on A-NK cell binding can be extended to other members of the FGF family, and the
response is effective on other endothelial cell types, lymphocyte subpopulations, and
inflammatory cytokines.
Results obtained from the previous chapter demonstrated a significant delay in the
ability of bFGF to inhibit ICAM-1 and VCAM-1 protein expression induced by TNFa,
which was directly correlated with functional studies using the parallel-plate flow chamber.
The significant time delay raised speculation on the mechanism used by bFGF in regulating
the response.
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When bFGF binds to its receptor, the bFGF-FGFR complex is internalized and the
surface receptors are downregulated. Unlike other growth factors, bFGF is not degraded
through the lysosomal pathway, but is taken up in the nucleus [Baldin, et al., 1990;
Moscatelli, 1988]. While it remains to be elucidated as to how the nuclear translocation of
bFGF affects signal transduction, the delayed inhibitory response of bFGF on the protein
level found in the previous chapter was suggestive of a ligand/receptor complex being a
rate-limiting step, as hypothesized for the long-term exposure required for bFGF to induce
proliferation in endothelial cells [Hawker and Granger, 1994]. However, the mRNA
expression kinetics analyzed in this investigation using Northern blot analysis were shown
not to be in agreement with such a limitation. For instance, VCAM-1 mRNA was found to
be reduced within 2 to 4 hrs of exposure to monolayers treated with both TNFa and
bFGF, compared to monolayers just treated with TNFa, which is comparatively faster than
the time suggested by the protein studies. This may be hypothesized as a result of a
threshold limitation being evident on the protein level, and would not appear to be the result
of a transport limitation of the receptor complex.
As another source of the latency observed at the protein level, bFGF was suggested
as possibly inducing the production of a second substance which actually mediated the
observed effects in a paracrine-type mechanism. However, functional studies performed in
this investigation using conditioned medium from bFGF-treated monolayers demonstrated
no discernible increase in the kinetic response. Additionally, the mRNA kinetics were
more suggestive of a direct response by the endothelial cells than to a secondary effect.
The direct evidence of the regulation of inducible CAM expression at the mRNA
level by bFGF additionally raised the question of whether it acted at the transcriptional or
translational level. Specific experiments using a transcriptional blocking agent found that
the decrease in the ICAM-1, VCAM-1 and E-selectin mRNA levels were due to a reduction
in the rate of transcription of the CAM genes and not from changes in the stability of the
mRNA. A possible mechanism may involve the inhibition of the activation of the
transcriptional factor NF--iB, which has been shown to be used by TNFa in its induction
of ICAM-1, VCAM-1 and E-selectin expression [Collins, et al., 1995]. Additional studies
are needed using nuclear run-on assays and electrophoretic mobility shift assays to
specifically characterize the transcriptional regulation by bFGF and the potential
involvement of a NF-icB-dependent mechanism.
A portion of the early signaling pathways used by bFGF in regulating the surface
protein expression and function of the TNFa-inducible CAMs was also uncovered in this
investigation. It was demonstrated that bFGF specifically interacts with its high affinity
tyrosine kinase receptor and does not require additional low affinity interaction with
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supplemental heparin in effectively transducing its signal. Based on studies using the
specific blocking agents MDHC and sodium orthovanadate, the autophosphorylation of the
receptor and its activation of tyrosine residues was found to be essential in further
transduction of the signal. In addition, it was shown that NCDC and propranolol,
inhibitors of phospholipase C-y and phospholipase D, respectively, effectively inhibited the
bFGF-induced suppression of CAM protein expression and function. These two
molecules have been shown to be interconnected in their signaling activity. PLD catalyzes
the hydrolysis of phosphatidylcholine, producing a precursor to the formation of
diacylglycerol, which activates PKC to further activate PC-PLD. PLC-y, activated by
tyrosine phosphorylation, catalyzes the hydrolysis of phosphoinositides to produce
diacylglycerol and inositol phosphates, which activate PKC and potentially PC-PLD.
Subsequent analyses using two specific inhibitors of PKC, calphostin C and
bisindolylmaleimide, were shown to produce a partial inhibition of the bFGF-mediated
suppression of TNFa-induced CAM expression, but complete inhibition of the bFGF-
mediated suppression of PMA-induced CAM expression.
Implications for the results presented in this chapter include the following: a)
contributing to a better understanding of the signaling pathways used by bFGF to modify
cell adhesion molecule expression, and the relation to its other physiological functions,
such as cell proliferation, migration, and angiogenesis; b) providing insight into angiogenic
processes and the kinetic responses elicited by specific growth factors in the
microenvironment; c) improving current cancer therapies by providing potential
mechanisms for drug intervention to control CAM expression in tumors, regulate metastatic
potential, and increase immune cell localization; and d) improving current therapies for
immunologically-based complications, such as auto-immune diseases, graft and transplant
rejection, and even atherosclerotic plaque formation.
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Chapter 7
Conclusions
7.1 Summary
The investigations carried out in this thesis used a combination of engineering and
biological principles to provide an improved understanding of the in vitro binding
mechanisms of lymphocyte subpopulations, regulation of cell adhesion molecule (CAM)
expression by angiogenic factors, and the intracellular signaling mechanisms used by
bFGF to modulate CAM expression on vascular endothelial cells.
The following conclusions were formulated from the studies performed in this
thesis:
(i) Lymphocyte binding kinetics.
Using the parallel-plate flow chamber, it was determined that IL-2 activated and
non-activated lymphocyte subpopulations (CD4+, CD8+, and CD56+ cells) vary in their
ability to adhere to activated vascular endothelial cells. More specifically, CD56+ cells
demonstrate an increased binding avidity over the other cell subtypes for a wide-range of
physiological flow rates. Also, activated lymphocytes are able to bind to endothelial cell
monolayers at increased levels of efficiency over the non-activated populations. The
lymphocyte subset binding kinetics were found to depend on the level of counter-ligand
expression on the endothelium and the state of activation of the lymphocytes. Additional
studies demonstrated that IL-2 activated natural killer cells (CD56+) principally utilize an
integrin-dependent (P1 and P2), selectin-independent adhesion process in binding to
activated vascular endothelium.
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(ii) CAM modulation by angiogenic factors.
Using targeted sampling fluorometry and flow cytometry, it was determined that
fluid extracted from the tumor interstitium (TIF) increases specific CAMs on endothelial
cells in vitro, which is conducive to lymphocyte binding. These results correlate with the
in vivo findings demonstrating increased adhesion of activated natural killer cells to certain
regions of the tumor vasculature, and thus provides an in vitro model of the tumor
microenvironment. Analysis of the TIF contents revealed it contains significant levels of
VEGF, but low or absent levels of bFGF and TNFa. Expression studies on these
individual angiogenic factors, as well as TGFO, showed that TNFa and VEGF are able to
upregulate specific cell surface CAMs in a dose-dependent manner with similar temporal
kinetics. However, bFGF produces a biphasic effect on ICAM-1 regulation fails to
produce an observable effect on the expression of other CAMs. Monolayers treated with
TGF showed no significant change in the level of CAM expression. Treatment regimens
combining bFGF with TNFa or VEGF showed reduced levels of induced CAM
expression in a time-dependent process, independent of prior treatment. Also, the
biological regulation of surface CAM expression by the angiogenic factors is functionally
relevant to lymphocyte binding.
(iii) Molecular mechanisms of CAM modulation by bFGF.
The inhibitory effect of bFGF does not appear to act through a paracrine-type
mechanism or a rate-limited degradation of the surface proteins. Rather it acts to inhibit
new protein synthesis by suppressing the mRNA expression of ICAM- 1, VCAM- 1, and E-
selectin induced by TNFa. The decrease in mRNA levels by bFGF is due to a reduction in
the rate of transcription of the CAM genes, and not the result of changes in mRNA
stability. The early signaling events involved in this regulation consist of receptor tyrosine
kinase activation, followed by the activation of phospholipase C-y, phospholipase D, and
protein kinase C. Additionally, the effects of bFGF can be extended to other members of
the FGF family, and are similarly effective on other endothelial cell types, lymphocyte
subsets, and proinflammatory cytokines.
7.2 Future Work
The studies presented in this thesis provide important advances in the fields of
angiogenesis, vascular biology, tumor physiology and immunology. However, a good
deal more remains to be elucidated and understood. Firstly, several of the studies
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conducted and the underlying assumptions used are distinctly limited and serve as avenues
for further study. Secondly, the results presented provide directive for future studies to
expand upon the work and offer new insights to the respective fields. The discussion
which follows briefly addresses these possibilities and future directions.
The diversity of the lymphocyte binding kinetics was hypothesized to be the result
of differences in the expression of adhesion receptors on the lymphocytes. This was based
on the characteristics of the capture efficiencies and the fitted parameters 1c and E0 .
Additionally, the hypothesis was consistent with findings on P2 integrin surface density
variation between lymphocyte subsets [Pardi, et al., 1989]. To provide a definitive
answer, studies are needed using flow cytometry to characterize the surface expression of
the adhesion receptors on both IL-2 activated and non-activated lymphocyte
subpopulations. Also, antibody blocking experiments would provide functional relevance
to the expression data and cast additional insight to receptor-ligand interaction.
As a possible extension to this work, alteration of the receptor expression on
specific lymphocyte subsets could be performed using gene transfection or biochemical
modification. The former could be done by either directly altering the genetic production of
the receptors or incorporating genetic stimulators, such as IL-2, to induce receptor gene
expression. This may provide a means for improving the responsiveness and localization
of these cells to sites requiring an immunological response.
The results presented in this thesis also showed that the TIF extracted from LS 174T
tumors contain substantial levels of VEGF, but no detectable levels of bFGF or TNFa.
While VEGF was shown to be a positive modulator of CAM expression and function,
variability between the TIF samples to promote lymphocyte adhesion did not correlate with
VEGF concentration. Further experiments are needed to determine whether other cytokines
or growth factors exist within the TIF that can modulate the response. As a possible factor,
TGFP was shown in this study to be a significant inhibitory agent to A-NK cell adhesion,
although less than bFGF (46.0 ± 10.6% for bFGF vs. 15.7 ± 4.2% for TGFi). Others
have demonstrated that TGFP suppresses the expression of basal and TNFa-induced E-
selectin, but with no observable effects on ICAM-1 or VCAM-1 [Gamble and Khew-
Goodall, 1993]. Consequently, TGFi cannot independently explain the results obtained
with the TIF. Further study may reveal that it may either synergize with bFGF or act to
suppress VEGF receptor expression in eliciting its response.
As another possible explanation for the TIF effect, additional experiments
measuring the viability of the VEGF in the TIF may provide valuable insight. Since a
variety of proteases are essential for tumor angiogenesis and migration of tumor cells,
VEGF may have a variable susceptibility to these proteases and their heterogeneous
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presence. Therefore, the alteration in CAM expression may not be a function of the level of
inhibitors or correlate with the level of positive stimulators. This may prove to be a
remarkable feature of tumors which has important ramifications for cancer therapies.
To further expand upon the present work, tumors normally lacking the ability to
produce bFGF, or another angiogenic factor, may be genetically-engineered to express the
specific growth factor. Interstitial fluid collected from these tumors could be compared to
unaltered tumors for their specific lymphocyte binding capacities. Addition of high
concentrations of exogenous bFGF has already been shown to elicit a suppressive effect on
A-NK binding in vivo [Melder, et al., 1996], and is suggestive that inherent bFGF
production may produce similar results.
The analysis performed on the molecular mechanisms of bFGF-mediated CAM
inhibition is also open to further study. The present work has suggested that bFGF acts at
the transcriptional level to regulate CAM expression. This was concluded after having
shown no significant effect by bFGF on CAM mRNA stability. To provide definitive
evidence of the ability of bFGF to alter the rate of CAM gene transcription, nuclear run-on
assays are needed to measure the promoter activities of each CAM gene. These studies
would preclude additional experiments exploring the potential of bFGF to inhibit NF-KiB-
dependent transactivation of the CAM genes. This has been proposed as a possible
mechanism based on the central role which NF-icB maintains in cytokine-mediated
upregulation of CAMs [Collins, et al., 1995]. To address this possibility and provide a
conclusive result, electrophoretic mobility shift assays are needed to be performed.
The early signaling pathways used by bFGF in modulating CAM expression may
also be studied in further detail. While specific transmembrane molecules and second
messengers have been shown to be necessary for the inhibition of CAM expression and
function, these studies were limited to using selective inhibitors. These results must be
cautiously interpreted due to non-specific effects occurring with other pathways and
mediators. Other techniques are available which permit direct measurement of the
activation of these messengers, and thus better define their role. Additionally, specific
second messenger agonists may be used to provide further validation of the results.
Nevertheless, in vivo experiments using similar blocking agents as presented in this
thesis need to be conducted in the future. Although many of these agents have already been
used in cancer studies, their application has largely been directed towards altering tumor
cell growth and proliferation. By specifically focusing their action to the vascular
endothelium, it may increase the localization of host immune cells, as well as adoptively
transferred lymphocytes. Also, the alteration in counter-receptor expression on the
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endothelium may be sufficient to improve lymphocyte subset diversity, as found in the in
vitro cell binding studies presented.
Similar studies may be performed in analyzing the effect of CAM alteration on
metastatic potential. Since the same CAMs are potentially used by metastasizing tumor
cells as immune cells, increasing CAM expression may increase the metastatic potential of
tumors. To date, this important question has not been specifically addressed and remains
essential for future cancer therapies incorporating this strategy.
Another possible extension of this thesis work would be to further define the
differences between the VEGF and bFGF signaling pathways. Both growth factors act
through similar receptors having intrinsic tyrosine kinase activity. Consequently, many of
the same early signaling events are used by both factors and have been shown to mediate
their proliferative responses in vascular cells. However, it has been demonstrated in this
thesis that the two growth factors have quite different effects on CAM regulation.
Additional pathways may exist which have not been well explored that may explain the
differences. Kinetic analysis of their signaling activation may also be useful in revealing
specific sequencing patterns that are unique to each factor and prove essential for eliciting
its response. Clearly, distinct differences exist in the intracellular signaling pathways
utilized, and their elucidation would provide an invaluable contribution to tumor
physiology, as well as to basic vascular biology.
7.3 Clinical Significance and Implications
For the first time the American Cancer Society has reported a decline in the total
number of new cancer cases, with a decrease of more than 11% compared to 1997, and a
reduction in the cancer death rates among many cancers [Landis, et al., 1998]. While a
significant trend, it has largely been attributed to new early detection and prevention
techniques. This fact provides greater incentive for continued research in the treatment of
cancer and its effective implementation into the clinic, so that future trends continue on this
path. As a contribution to this undertaking, several findings presented in this thesis
provide important implications for new insights and strategies.
The strategy of immune-based therapies, or adoptive immunotherapy, continues to
hold promise as a systemic-based strategy against cancer. Clinical trials using lymphokine-
activated killer cell- and tumor infiltrating lymphocyte-based adoptive immunotherapy have
found limited success in treating patients with malignant melanoma and renal cell carcinoma
[Rosenberg, 1990]. However, it has been largely unsuccessful in treating other cancers,
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and the mechanisms remain to be elucidated. The results obtained in this thesis contribute
to a better understanding of the biophysical and molecular mechanisms used by
lymphocytes in localizing to the tumor vasculature. Additional insight is also provided to
the regulatory and protective mechanisms potentially found in specific tumors by the action
of the various angiogenic factors present. This information augments current paradigms of
the microenvironmental effects on the evasiveness of tumors, and provides potential
mechanisms for drug intervention to increase immune cell localization. These may
ultimately improve or modify current adoptive immunotherapy techniques.
Another exciting new area of cancer therapy involves altering the vasculature in a
growing tumor. The genomic stability and homogeneity of the endothelial cells make them
particularly alluring targets compared to the high genetic instability and heterogeneity of
tumor cells. Two primary methods have arisen using this strategy. One uses anti-
angiogenic compounds directed against a tumor's endothelial cells [Boehm, et al., 1997],
and the other genetically alters endothelial cells to increase the immune response. Several
findings presented in this thesis have direct relation to the latter therapeutic option. Firstly,
specific intracellular signaling agonists or antagonists may be used to alter the level of CAM
expression induced on the endothelium, thereby enhancing the capture rates of circulating
immune cells. Additionally, induction of specific counter-ligands on the endothelium may
further enhance selective lymphocyte localization and kinetics of binding. These therapies
have the benefit of being relatively non-cytotoxic, and may be combined with other tumor-
specific agents to enhance their selectivity for the tumor vasculature. However, a potential
limitation of this technique is that many of the same CAMs used by immune cells are also
used by tumor cells which are metastasizing.
In terms of clinical treatment planning options, physiologically-based
pharmacokinetic models continue to be improved and offer invaluable use for optimization
and efficacy potential [Zhu, et al., 1996]. Essential to the effectiveness of these models is
the accurate prediction or assessment of the kinetic parameters. The studies performed in
this thesis on the lymphocyte binding kinetics may serve to enhance the ability of these
models to accurately predict the biodistribution of the effector cell populations used in
adoptive immunotherapy schemes. Additionally, the new treatment strategies proposed
may be applied to the models and assessed for their potential efficacy in vivo.
Of even greater potential significance of this thesis are the ramifications of its
findings beyond the field of cancer. Numerous other pathophysiological conditions, as
well as normal physiological processes, may benefit from its findings. For instance, heart
disease continues to have the highest overall mortality rate in the U.S. (32% of all yearly
deaths), and is associated with an inflammatory process involving the progressive
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formation of atherosclerotic plaques. The plaques eventually lead to the blockage of
coronary arteries and formation of ischemic myocardial tissue, and/or the production of
emboli resulting in stroke. Consistent with the early events of the disease is the expression
of adhesion molecules on the endothelium and the local production of a variety of
cytokines. Early therapeutic interventions may serve to prevent destructive downstream
consequences.
As a possible therapeutic intervention, stents incorporating the controlled-release of
a negative CAM modulator, such as bFGF or similar analogue, may be used to regulate the
local CAM expression. Additionally, the angiogenic factor would support the re-
endothelialization of the stent by providing a mitogenic stimulus to the cells.
Another therapy which has recently received acclaim is the use of VEGF in
enhancing collateral circulation and improving regional perfusion in patients with
obstructed coronary arteries. However, a potential drawback to this therapy may be the
increased ability of leukocytes to adhere to the local vasculature and eventually lead to the
occlusion of the collateral circulation. This may occur by either directly obstructing the
blood flow or by initiating the subsequent plaque formation. Use of specific signaling
antagonists uncovered in this thesis or by combining treatment with bFGF may serve to
provide adequate CAM regulation, while still maintaining angiogenic potential.
Additional implications of this thesis are:
a) providing additional understanding of the binding kinetics of helper and effector cell
populations in areas of active immunological response;
b) providing insight to the regulatory and protective mechanisms potentially found in
inflammation, ischemic-reperfusion injury and wound healing, by the action of the
various angiogenic factors present;
c) providing insight into the angiogenic process and the kinetic responses elicited by
specific growth factors in the microenvironment;
d) potentially improving current therapies for immunologically-based complications, such
as autoimmune diseases, graft vs. host disease, and transplant rejection.
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Appendix A
Binding Kinetics Data
The following supplemental sections present the experimental plots of the IL-2 and
non-activated lymphocyte subpopulation binding kinetics. Each set was performed in
triplicate under identical flow conditions using the parallel-plate flow chamber. Four
treatment groups were analyzed: TNFx, bFGF, TNFx+bFGF and non-treatment. Total
activation time for all runs was 24 hr.
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A.1 Non-Activated Lymphocyte Binding Data
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Figure A-1-1. Non-activated lymphocyte binding kinetics
HUVEC monolayers: (a) CD4+, (b) CD8+, and (c) CD56+.
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Figure A-1-2. Non-activated lymphocyte binding kinetics on TNFa-treated
HUVEC monolayers: (a) CD4+, (b) CD8+, and (c) CD56+.
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Figure A-1-3. Non-activated lymphocyte binding kinetics on bFGF-treated
HUVEC monolayers: (a) CD4+, (b) CD8+, and (c) CD56+.
164
---*--- CD4+.1
-- CD4+.2
-- CD4+.3
1 0
1 0
1 0
100
80
6 0
40
20
1 2 3 4
Wall Shear Stress (dyn/cm2 )
100
0 1 2 3 4 5
Wall Shear Stress (dyn/cm 2)
100,
80
60
40
2 0
1 2 3 4 5
Wall Shear Stress (dyn/cm2)
Figure A-1-4. Non-activated lymphocyte binding kinetics on TNFa+bFGF-
treated HUVEC monolayers: (a) CD4+, (b) CD8+, and (c) CD56+.
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A.2 IL-2 Activated Lymphocyte Binding Data
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Figure A-2-1. IL-2 activated lymphocyte binding kinetics on non-treated
HUVEC monolayers: (a) CD4+, (b) CD8+, and (c) CD56+.
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Figure A-2-2. IL-2 activated lymphocyte binding kinetics on TNFa-treated
HUVEC monolayers: (a) CD4+, (b) CD8+, and (c) CD56+.
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Figure A-2-3. IL-2 activated lymphocyte binding kinetics on bFGF-treated
HUVEC monolayers: (a) CD4+, (b) CD8+, and (c) CD56+.
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Figure A-2-4. IL-2 activated lymphocyte binding kinetics
treated HUVEC monolayers: (a) CD4+, (b) CD8+, and (c)
on TNFao+bFGF-
CD56+.
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A.3 A-NK Receptor Expression Data
Figure A-3-1. IL-2 activated NK cell expression of CD18. Data sets from
three separate experiments shown. IgG istoype control staining represented
as dotted lines.
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Figure A-3-2. IL-2 activated NK cell expression of VLA-4. Data sets from
three separate experiments shown. IgG istoype control staining represented
as dotted lines.
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Figure A-3-3. IL-2 activated NK cell expression of sLeX. Data sets from
three separate experiments shown. IgG istoype control staining represented
as dotted lines.
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Figure A-3-4. IL-2 activated NK cell expression of L-selectin. Data sets
from three separate experiments shown. IgG istoype control staining
represented as dotted lines.
173
C
r
'~
..
: r .. T~
..
i .
, *Tcr~rwlr~
w
I
- ---------- .._____~_~__ _~~c~___ __ _______
Appendix B
CAM Expression Data
The following sections provide supplemental data to the CAM surface expression
analyses for HUVEC monolayers treated with tumor interstitial fluid (TIF), TNFa, VEGF,
bFGF, TGF[, and TNFa+bFGF. In addition, the computer algorithm written and used in
this research for processing the TSF images using the NIH Image software4 is provided.
B.1 TSF Algorithm for NIH Image
Macro algorithm for targeted sampling fluorometry (TSF)
By: G.C. Koenig and L.L. Munn
Copyright 1995
This macro is used to retrieve a series of files for obtaining an optimal regional thresholding
of nuclear stained images. In addition, this macro features an automatic ROI sizing routine
to accomodate varying cell diameters. It was developed for 20x objective. All images must
be located in the same folder and the directory path to this folder must be entered in lines 2
and 3 of the macro (after 'begin'). Images should be labeled with Slide # as the first digit,
well# as the second digit, and field# as the third digit (SWF; for example 352 would be the
2nd field from the 5th well of the third slide analyzed). There should be both an image (in
our case, green) of the stained surface proteins, and a corresponding image of the nuclear
stain (in our case, red), labeled SWFg.tif and SWFr.tif, respectively. The macro was
written to analyze images from experiments done in 8 well chamber slides, and it therefore
keeps track of the slide, well and field#s. You can change the loop indices for these
4 The NIH Image software and all supporting information are available by anonymous ftp from
zippy.nimh.nih.gov.
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parameters to suit your application. The "process images" option will do basic noise
reduction and background subtraction of the immunostained images. To use this, include a
background image labeled "calib" in the image folder. The macro can save a number of the
intermediate images as well as the resulting data. If you want, you can supress some of the
save commands by enclosing them in brackets. Results for each field are stored in files
labeled .data. They include the ROI area (nPix), the average intensity for each ROI
(cmean), the modal intensity (cmode), the minimum pixel value (cmin), and the maximum
pixel value (cmax). In addition, a running summary file (sum data) is kept that records the
filename, the mean pixel value for the entire image ( tmean), the average of the ROI means
for the field (avg), the associated sstandard deviation (sd), the total area covered by the
ROIs (totalarea), and the mean ROI diameter (avgdiam). The parameters listed above are in
column order as stated: no headings are supplied }
var
filered, fileg, outfileb,filed:string;
infileg, infilered,infiler,
filename2,infilename2,outfilename2,outname 1 :string;
outfiled, outfiler, outfileg,test,outfilepg,filepgname:string;
indirect,indirect2,outdirect,calfilename,file,filegreen,
filegname,prcalfn:string;
i,j,c,f,k,mm,opt,temp,image 1 ,tpix,tmax,tmin,totalmean,cal,grnimg,nPixels:
integer;
pp,ppp,nfields,process,image2,count,icount,cmode,cmin,cmax,mode,regions:
integer;
kkk,m,n,width,height,x,y,w,h,Tlow,Tup,nPix,total,ihigh,ilow,kk,jj,fact,tick,p:
integer;
cPix, calibmean, cmode, cmin, cmax: integer;
dx,dy,tmean,tmode,diameter,max,min,min2,dtotal,tarea,totalarea:real;
sd,variance,avg,total,cmean,mean,totalmeansqr,con,tdiam,avgdiam:real;
begin
{ **** Input file and folder location **** }
indirect:=concat('STORAGE:test:');
outdirect:=concat('Storage:Output files:');
test:=concat(outdirect,'greet');
NewTextWindow(test,330,50);
writeln('Begin Program');
Wait(1.8);
SaveAs(test);
Dispose;
process:=GetNumber('shading correction? (1=yes, O=no)', 1);
nfields:=GetNumber('number of fields per well?', 3);
NewTextWindow('sum data');
for m:= 1 to 1 do begin {4= number of slides}
if (process= 1) then begin
calfilename:=concat(indirect,'calib');
Import(calfilename);
Smooth;
SelectAll;
Measure;
GetResults(cPix, calibmean, cmode, cmin, cmax);
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prcalfn:=concat(outdirect,'prcal. 1 ');
SetPicName(prcalfn);
{ SaveAs(prcalfn); }
cal:=PicNumber;
end; {process shading }
for n:= 1 to 1 do begin {# of wells }
for k:= 1 to nfields do begin {#of fields per well }
file:=concat( m: 1, n: 1, k: 1);
filered:=concat(file, 'r.tif);
filegreen:=concat(file, 'g.tif);
filegname:=concat(file, 'g');
filepgname:=concat(file, 'pg');
infiler:=concat(indirect, filered);
infileg:=concat(indirect, filegreen);
outfileg:=concat(outdirect, file,'g');
outfilepg:=concat(outdirect, file,'pg');
outfiler:=concat(outdirect, file,'r');
outfiled:=concat(outdirect, file,'.data');
outfileb:=concat(outdirect, file,'.bin');
Import(infileg);
SetPicName(outfileg);
SaveAs(outfileg);
gmimg:=PicNumber;
{ ********* Processing Image Files ********* }
if (process= 1) then begin
SelectAll;
f:=calibmean;
ImageMath('div', grnimg, cal, f, 0, 'Result');
ReduceNoise;
Smooth;
SelectWindow('Result');
SaveAs(outfilepg);
SelectWindow(filegname);
Dispose;
end; {process}
Import(infiler);
SetPicName(outfiler);
SaveAs(outfiler);
GetPicSize(width,height);
image 1:=PicNumber;
SetNewSize(width,height);
MakeNewWindow('Temporary');
temp:=PicNumber;
MakeNewWindow('Optimum');
opt:=PicNumber;
{ **** Optimal Grid Code **** I
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regions:=5;
dx:=width/regions;
dy:=height/regions;
for x:=O to (regions-1) do begin
for y:=0 to (regions-1) do begin
ChoosePic(imagel);
SelectAll;
copy;
ChoosePic(temp);
paste;
MakeRoi(x*dx,y*dy,dx,dy);
AutoThreshold;
GetThreshold(Tlow,Tup);
Tlow:=Tlow-0.05*Tlow;
if Tlow<O then Tlow:=O;
if Tlow>255 then Tlow:=255;
SetThreshold(Tlow);
MakeBinary;
copy;
SelectAll;
SetThreshold(- 1);
Clear;
ChoosePic(opt);
MakeRoi(x*dx,y*dy,dx,dy);
paste;
end;
end;
SelectPic(temp);
Dispose;
SelectPic(image 1);
Dispose;
SelectWindow('Optimum');
SelectAll;
Invert;
SetBinaryCount(4);
Erode;
SaveAs(outfileb);
{ ***** Setting up Particle Analysis of Binary PI Image ***
SetOptions('X-Y Center');
LabelParticles(false);
OutlineParticles(true);
IgnoreParticlesTouchingEdge(true);
IncludelnteriorHoles(false);
SetParticleSize(50,900);
SelectAll;
AnalyzeParticles;
count:=rCount;
Dispose;
{**** Input fluorescent stained image and folder location **** }
image2:=gmimg;
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if (process =1) then SelectWindow(filepgname) else
SelectWindow(filegname);
Measure;
GetResults(tPix, tmean, tmode, tmin, tmax);
Undo;
SetUser lLabel('ROI intensity.');
SetUser2Label('ROI area');
diameter:=40;
max:=diameter/2;
total:=0; tdiam:=0;
totalarea:=0;
fact:=0.5;
totalmean:=0; totalmeansqr:=0;
for i:=1 to count do begin
min:=max;
min2:=max;
ilow:= i - 100;
ihigh:= i + 100;
if ilow < 1 then ilow:=1;
if ihigh > count then ihigh:=count;
for j:= ilow to ihigh do begin
dx:= abs(rX[i] - rX[j]);
dy:= abs(rY[i] - rY[j]);
if i = j then dx:=30;
if i = j then dy:=30;
dtotal:= fact*sqrt(dx*dx + dy*dy);
if dtotal < min then begin
min2:=min;
min:=dtotal;
end; {if}
end; {j }
diameter:=min+min2;
if diameter < 30 then diameter:=30.0;
SetOptions('X-YCenter;Area;Mean;Std.Dev. ;Userl 1;User2');
if ((rX[i] - diameter/2) > 0) and ((rY[i] - diameter/2) > 0) and
((rX[i] + diameter/2) < width) and ((rY[i] +
diameter/2) < height) then begin
MakeOvalRoi(rX[i]-diameter/2,rY[i]
diameter/2,diameter,diameter);
Measure;
GetResults(nPix,cmean,cmode,cmin,cmax);
rUserl [i]:=cmean;
rUser2[i]:=npix;
Undo;
tdiam:=tdiam + diameter;
total:=total + 1;
totalarea:=totalarea +npix;
totalmean:=totalmean + cmean;
totalmeansqr:=totalmeansqr + cmean*cmean;
end else begin
rUserl [i]:=0;
rUser2[i]:=0;
end; {if}
end; { i }
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SetExport('measurements');
SetOptions('X-Y Center;Userl ;User2');
Export(outfiled);
avg:=totalmean/total;
avgdiam:=tdiam/total;
variance:=(total*totalmeansqr-(totalmean*totalmean))/
((total 1l)*total);
sd:=sqrt(variance);
SelectWindow('sum data');
Writeln(file, tmean:9:2, avg:9:2, sd:9:2, totalarea: 14:2,
avgdiam:9:2);
SetText('centered');
Import(outfileb);
for i:= 1 to count do begin
MoveTo(rX[i],rY[i]);
SetForegroundColor(80);
Write(i);
end;
SaveAs(outfileb);
Dispose;
Beep;
SelectPic(image2);
ResetCounter;
Dispose;
end; { k }
end; { n }
if (process=1) then begin
SelectWindow(prcalfn);
Dispose;
end; {if)
end; { m}
end; {begin)
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B.2 CAM Expression Kinetics by TIF and Angiogenic Factors
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Figure B-2-1. CAM expression on HUVECs treated with TIF for 24 hrs.
Two sets of each group representing: a) ICAM-1, b) VCAM-1, c) E-
selectin, and d) P-selectin. - = TIF, - - = non, ... = IgG control.
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Figure B-2-2. CAM expression on HUVECs treated with TNFa for 6 and
24 hrs. Each time period shown for: a) ICAM-1, b) VCAM-1, c) E-
selectin, and d) P-selectin. - = TNFa, - - = non, ... = IgG control.
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Figure B-2-3. CAM expression on HUVECs treated with VEGF for 6 and
24 hrs. Each time period shown for: a) ICAM-1, b) VCAM-1, c) E-
selectin, and d) P-selectin. - = VEGF, - - = non, - = IgG control.
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Figure B-2-4. CAM expression on HUVECs treated with bFGF for 6 and
24 hrs. Each time period shown for: a) ICAM-1, b) VCAM-1, c) E-
selectin, and d) P-selectin. - = bFGF, - - = non, ... = IgG control.
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Figure B-2-5. CAM expression on HUVECs treated with TGFP for 6 and
24 hrs. Each time period shown for: a) ICAM-1, b) VCAM-1, c) E-
selectin, and d) P-selectin. - = TGFP, - - = non, ... = IgG control.
184
2
B (6 hr)
0
5
0
0 5 0 100
0 L
0
2 5 r
2 0
1 5
1 0
5
150 200
D (24 hr)
0 L
0
0 5 0 100
0 5 0 100 150 200
2
1
5
0 5 0 100 150
Fluorescence Intensity
200 5 0 100
Fluorescence
150
Intensity
Figure B-2-6. CAM expression on HUVECs treated with TNFa+bFGF
for 6 and 24 hrs. Each time period shown for: a) ICAM-1, b) VCAM-1,
c) E-selectin, and d) P-selectin. - = TNFa, ... = TNFa+bFGF,
bFGF, - - = non.
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Figure B-2-7. CAM expression on HUVECs treated with VEGF+bFGF
for 6 and 24 hrs. Each time period shown for: a) ICAM-1, b) VCAM-1,
c) E-selectin, and d) P-selectin. - = VEGF, -- = VEGF+bFGF, --
= bFGF, - - = non.
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Figure B-2-8. Effect of angiogenic factors on ICAM-2 expression in
HUVECs treated for 6 and 24 hrs. Factors presented are: a) TNFz, b)
VEGF, c) bFGF, and d) TGFP. - = angiogenic factor, - - = non, =
IgG control.
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Figure B-2-9. Combined effect of angiogenic factors on ICAM-2
expression in HUVECs treated for 6 and 24 hrs. Factors presented are: a)
TNFa+bFGF, and b) VEGF+bFGF. - = TNFa/VEGF, ... =
TNFa/VEGF+bFGF, - bFGF, - - = non.
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B.3 Functional Kinetics of Angiogenic Factors
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Figure B-3-1. Dose response curve of A-NK cell binding to HUVEC
monolayers treated with VEGF or bFGF. A flow rate corresponding to 1
dyn/cm2 wall shear stress was imposed. Mean numbers ± SD of bound
cells for eight adjacent fields are shown for two sets of experiments.
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Figure B-3-2. Dose response curve of A-NK cell binding to HUVEC
monolayers treated with VEGF or bFGF. A flow rate corresponding to 1
dyn/cm2 wall shear stress was imposed. Mean numbers ± SD of bound
cells for eight adjacent fields are shown for two sets of experiments.
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Figure B-3-3. Temporal kinetics of TNFa and bFGF treatment on A-NK
cell binding. A flow rate corresponding to 1 dyn/cm 2 wall shear stress
was imposed. Mean numbers ± SD of bound cells for eight adjacent
fields are shown for two sets, (a) and (b), of two separate experiments.
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Figure B-3-4. Inhibition kinetics of A-NK cell binding to HUVEC
monolayers treated with TNFa (total exposure time of 24 hr) and bFGF
(time shown). A flow rate corresponding to 1 dyn/cm2 wall shear stress
was imposed. Mean numbers ± SD of bound cells for eight adjacent
fields are shown for two separate experiments. * p < 0.05.
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Figure B-3-5. Extended inhibition kinetics of A-NK cell binding to
HUVEC monolayers treated with TNFa (total exposure time of 24 hr) and
bFGF (time shown). A flow rate corresponding to 1 dyn/cm2 wall shear
stress was imposed. Mean numbers ± SD of bound cells for eight
adjacent fields are shown.
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T N Fa activation time = 24 hrs (total)
Appendix C
Northern Blot and Signal
Transduction Analyses
The following sections provide additional information on the experiments pertaining
to: a) the kinetics of CAM mRNA regulation by bFGF on TNFza-activated HUVEC
monolayers (Northern blot analysis), b) the effect of bFGF on CAM mRNA stability
(Northern blot analysis), c) the dose response curves and adhesion assays for A-NK
binding to HUVECs treated independently with the various signal blocking agents, and d)
the FIA analysis on CAM expression following addition of the blocking agents.
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C.1 Kinetics of CAM mRNA Expression
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Figure C-1-1. Graphic representation of ICAM-1 mRNA
expression following 4 hr treatment with TNFa.
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Figure C-1-2. Graphic representation of VCAM-1 mRNA
expression following 4 hr treatment with TNFa.
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Figure C-1-3. Graphic representation of E-selectin mRNA
expression following 4 hr treatment with TNFa.
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Figure C-1-4. Graphic representation of ICAM-2 mRNA kinetics of
expression following 4 hr treatment with TNFa.
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Figure C-1-5. Northern blots of mRNA kinetics of expression following
4 hr treatment with TNFa. Blots shown are from three separate
experiments.
197
..... T.. N F
--- E3--- TNF + bFGF
-
- bFGF
" .
- .& ------ - -------
6 8 10 12
time (hrs)
1 .2
1.0
0.8
0.6
0.4
0.2
1.2
1.0
0.8
0.6
0.4
0.2
0 2 4 6
time (hrs)
-- - TNF
---- E3--- TNF + bFGF
-- - bFGF
-A-------A
8 10 12
U---TNF
--- E--- TNF + bFGF
-- t -bFGF
- - A- - -- ----------- A
0 2 4 6 8 1 0 1 2
time (hrs)
Figure C-1-6. Graphic representation of CAM mRNA kinetics of
expression following simultaneous addition of TNFa and bFGF. Plots
shown are: a) ICAM-1, b) VCAM-1, and c) E-selectin expression from 0
to 12 hrs of activation.
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Figure C-1-7. Graphic representation of CAM mRNA levels following 24
hr co-incubation of TNFa and bFGF.
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Figure C-1-8. Northern blots of CAM mRNA levels following co-
activation with TNFa and bFGF from 0 to 24 hrs.
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Figure C-2-1. Graphic representation of ICAM-1 mRNA stability analysis
following 4 hr treatment with TNFa.
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Figure C-2-2. Graphic representation of VCAM-1 mRNA stability analysis
following 4 hr treatment with TNFoa.
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Figure C-2-3. Graphic representation of E-selectin mRNA stability
analysis following 4 hr treatment with TNFa.
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Figure C-2-4. Graphic representation of ICAM-2 mRNA stability analysis
following 4 hr treatment with TNFa.
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Figure C-2-5. Northern blots of mRNA stability analysis following 4 hr
treatment with TNFa. Blots shown are from three separate experiments.
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C.3 Signaling Inhibition Data
C.3.1 Dose Response Curves
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Figure C-3-1. Heparin dose response curve on A-NK cell binding.
Heparin applied on monolayer for 24 hrs. Flow rate of 0.085 mlm
was utilized.
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Figure C-3-2. MDHC dose response curve on A-NK cell binding.
MDHC applied on monolayer for 24 hrs. Flow rate of 0.085 mlm
was utilized.
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Figure C-3-3. Sodium orthovanadate dose response curve on A-
NK cell binding. Vanadate applied on monolayer for 24 hrs. Flow
rate of 0.085 mlm was utilized.
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Figure C-3-4. NCDC dose response curve on A-NK cell binding.
NCDC applied on monolayer for 24 hrs. Flow rate of 0.085 mlm
was utilized.
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Figure C-3-5. Propranolol dose response curve on A-NK cell
binding. Propranolol applied on monolayer for 24 hrs. Flow rate
of 0.085 mlm was utilized.
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Figure C-3-6. Calphostin C dose response curve on A-NK cell
binding. Calphostin C applied on monolayer for 24 hrs. Flow rate
of 0.085 mlm was utilized.
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C.3.2 Adhesion Assay
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Figure C-3-7. Effect of neutralizing mAb for bFGF on A-NK cell binding
to HUVEC monolayers treated with TNFa and bFGF.
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Figure C-3-8. Effect of heparin (10 gg/ml) on A-NK cell
HUVEC monolayers treated with TNFx and bFGF.
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Figure C-3-9. Effect of MDHC (5 gM) on A-NK cell binding to HUVEC
monolayers treated with TNFa and bFGF.
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Figure C-3-10. Effect of sodium orthovanadate (30 gM) on A-NK cell
binding to HUVEC monolayers treated with TNFa and bFGF.
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Figure C-3-11. Effect of NCDC (50 gM) on A-NK cell binding to
HUVEC monolayers treated with TNFa and bFGF.
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Figure C-3-12. Effect of propranolol (50 gtM) on A-NK cell binding to
HUVEC monolayers treated with TNFa and bFGF.
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Figure C-3-13. Effect of calphostin C (50 nM) on A-NK cell binding to
HUVEC monolayers treated with TNFa and bFGF.
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Figure C-3-14. Effect of bisindolylmaleimide (50 nM) on A-NK cell
binding to HUVEC monolayers treated with TNFa and bFGF.
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C.3.3 FIA Analysis
Table C-1. Surface CAM expression following treatment with MDHC, an
inhibitor of receptor tyrosine kinases (RTK-i), and NCDC, an inhibitor of
phospholipase C (PLC-i).
IgG ICAM-1 VCAM-1 E-selectin
1. control
non 16.927 ± 15.930 77.593 ± 22.981 28.593 + 10.477 10.927 + 12.468
TNF 1.593 ± 6.173 648.590 + 59.600 152.930 + 30.234 112.930 ± 19.675
bFGF 5.927 ± 9.208 43.260 + 16.442 8.593 + 3.844 7.593 + 6.741
TNF+bFGF 22.593 ± 11.921 397.590 + 39.014 87.593 + 23.730 51.593 + 19.599
2. RTK-i
non 15.593 ± 12.601 24.593 + 6.984 13.927 + 15.015 10.927 + 12.548
TNF 10.260 ± 16.371 304.930 + 37.905 92.260 + 30.790 65.927 + 13.569
bFGF 18.593 ± 7.219 26.927 + 3.480 19.927 + 7.055 12.593 + 8.090
TNF+bFGF 17.927 ± 8.762 331.590 + 54.192 83.927 + 18.206 69.927 + 15.026
3. PLC-i
non 13.593 ± 9.387 29.260 + 6.807 17.927 ± 1.856 8.593 + 14.903
TNF 9.593 ± 6.360 471.260 + 29.513 132.590 + 17.458 71.260 + 16.197
bFGF 7.593 ± 6.489 37.593 + 6.489 19.260 ± 9.238 9.260 ± 6.245
TNF+bFGF 7.593 ± 8.413 453.930 ± 21.987 128.930 + 22.578 61.260 ± 22.502
Table C-2. Surface CAM expression following treatment with sodium
orthovanadate, an inhibitor of phosphotyrosine phosphatase (PTP-i), and
propranolol, an inhibitor of phospholipase D (PLD-i).
IgG ICAM- 1 VCAM-1 E-selectin
1. control
non 6.877 + 5.239 34.877 ± 13.220 11.877 ± 4.410 6.880 + 2.906
TNF 13.210 ± 6.658 612.880 ± 29.475 216.880 + 35.834 108.880 + 34.187
bFGF 3.210 ± 6.083 20.210 + 15.144 4.877 ± 8.951 3.210 + 4.619
TNF+bFGF 8.877 ± 16.045 381.210 + 45.654 83.877 ± 43.191 58.877 + 14.438
2. PTP-i
non 6.543 ± 14.530 40.540 + 10.414 24.880 ± 7.881 14.210 + 4.509
TNF 7.210 ± 13.503 546.880 + 57.074 119.210 ± 17.578 104.210 + 9.238
bFGF 5.877 ± 13.776 16.877 + 7.753 12.540 ± 6.692 6.543 + 6.489
TNF+bFGF 7.210 ± 9.452 327.540 + 26.872 79.543 ± 23.596 36.543 + 9.262
3. PLD-i
non 1.543 ± 7.881 9.210 ± 14.503 5.877 ± 5.608 2.877 + 4.978
TNF 8.543 ± 6.119 521.540 + 67.432 167.880 ± 27.847 94.877 + 11.260
bFGF 4.210 ± 4.583 11.877 ± 8.192 6.543 ± 4.978 2.543 ± 4.807
TNF+bFGF 4.543 ± 4.978 492.880 ± 65.170 163.540 + 45.042 88.543 ± 11.260
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Table C-3. Surface CAM expression following treatment with a neutralizing
monoclonal antibody selective for bFGF, and heparin, a low affinity, bFGF
binding molecule.
Table C-4. Surface CAM
kinase C inhibitors (PKC-i),
expression following treatment with the protein
calphostin C and bisindolylmaleimide (BIM).
1. control
non
TNF
bFGF
TNF+bFGF
2. PKC-i
(calphostin C)
non
TNF
bFGF
TNF+bFGF
3. PKC-i
(BIM)
non
TNF
bFGF
TNF+bFGF
IgG
6.933 ± 9.405
21.600 + 7.000
12.933 + 7.860
18.933 ± 9.528
12.933 + 5.608
19.600 ± 10.504
20.933 ± 13.776
21.267 + 11.289
1.600 + 13.614
14.267 ± 10.088
12.933 ± 9.244
21.933 ± 7.881
ICAM-1
50.933 ± 8.951
564.600 + 86.170
27.933 ± 5.044
360.930 ± 40.275
43.267 ± 9.208
549.930 ± 65.859
8.933 + 5.548
348.270 + 81.538
41.600 + 8.505
527.600 + 45.299
18.933 ± 9.262
334.930 ± 68.494
VCAM-1
15.933 ± 10.745
261.270 ± 78.257
19.600 + 7.550
135.600 + 31.193
14.267 ± 13.618
161.270 + 36.112
19.933 ± 11.200
113.930 + 37.560
4.267 + 6.173
96.267 + 40.193
17.600 + 15.885
86.933 + 24.781
E-selectin
10.267 ± 2.404
94.600 ± 13.454
16.933 + 9.280
59.267 ± 17.629
13.933 ± 6.333
89.267 + 14.970
15.933 + 3.180
49.933 ± 17.704
13.267 ± 7.535
83.267 + 17.420
13.933 + 9.563
46.933 + 6.839
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Table C-5. Surface CAM expression following treatment with
kinase C inhibitor calphostin C on PMA-activated monolayers.
IgG ICAM-1 VCAM-1
the protein
E-selectin
1. control
non
PMA
bFGF
PMA+bFGF
2. PKC-i
(calphostin C)
non
PMA
bFGF
PMA+bFGF
29.567 ±
27.233 ±
38.567 ±
34.900 ±
28.900 ±
29.567 ±
27.567 ±
26.900 ±
6.359
8.647
3.383
2.082
3.786
4.333
6.333
8.888
43.233
892.900
24.233
591.230
± 14.655
± 119.620
± 5.897
± 66.996
38.233 ± 10.914
610.570 ± 82.321
33.567 ± 9.135
601.230 ± 74.414
33.233 ±
528.570 ±
31.233 ±
352.570 ±
27.233 ±
341.900 ±
32.233 ±
324.900 ±
3.712
79.434
5.175
38.490
5.841
62.746
5.812
62.429
27.233 ± 4.978
111.570 ± 8.413
26.233 ± 6.333
73.233 ± 26.359
27.233 ± 7.965
83.233 ± 11.215
25.233 ± 6.489
75.567 ± 20.301
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